<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE PubmedArticleSet SYSTEM "http://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_170101.dtd">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">10014320</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0556-2821</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>45</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>1992</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Physical review. D, Particles and fields</Title>
          <ISOAbbreviation>Phys Rev D Part Fields</ISOAbbreviation>
        </Journal>
        <ArticleTitle>T- and P-odd electron-nucleon interactions and the electric dipole moments of large atoms.</ArticleTitle>
        <Pagination>
          <MedlinePgn>4148-4155</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Barr</LastName>
            <Initials>SM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Phys Rev D Part Fields</MedlineTA>
        <NlmUniqueID>0242621</NlmUniqueID>
        <ISSNLinking>0556-2821</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1002115</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0301-0163</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>7</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1976</Year>
            </PubDate>
          </JournalIssue>
          <Title>Hormone research</Title>
          <ISOAbbreviation>Horm Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Changes in the concentration of LH, FSH and estrogen in the immature female rat during precocious sexual maturation induced by electrochemical stimulation of the brain.</ArticleTitle>
        <Pagination>
          <MedlinePgn>34-42</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Electrochemical stimulation of the hypothalamus of 23-day-old female rats induced precocious puberty as judged by occurrence of vaginal opening, the degree of uterine hypertrophy, changes in ovarian steroid content and incidence of first ovulation. Three types of responses were observed: (I) pubertal ovulation within 96 h; (II) pubertal ovulation within 120 h, and (III) vaginal opening at 120 h not followed by ovulation. All treated animals showed a sustained increase in the LH/FSH ratio in both pituitary and plasma. Plasma estrogen was also increased 1 h after stimulation. A preovulatory rise in plasma estrogen and gonadotropins was noted in type I and type II animals. These data lend further support to the suggestion that brain stimulation causes a release of gonadotrophins which induced ovarian steroidogenesis leading to an ovulatory gonadotropin surge via a positive feedback effect.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>YoungLai</LastName>
            <ForeName>E V</ForeName>
            <Initials>EV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holmes</LastName>
            <ForeName>M J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruf</LastName>
            <ForeName>K B</ForeName>
            <Initials>KB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Horm Res</MedlineTA>
        <NlmUniqueID>0366126</NlmUniqueID>
        <ISSNLinking>0301-0163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004967">Estrogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-67-9</RegistryNumber>
          <NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-68-0</RegistryNumber>
          <NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>J</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010060" MajorTopicYN="N">Ovulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012741" MajorTopicYN="Y">Sexual Maturation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014621" MajorTopicYN="N">Vagina</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="PIP">764688</OtherID>
      <OtherID Source="POP">00038457</OtherID>
      <OtherAbstract Type="PIP" Language="eng">
        <AbstractText>Changes in pituitary and plasma gonadotropins and plasma estrogen following a unilaeral basic hypothalamic lesion in immature (21-day-old) Sprague-Dawley female rats are described.  On Day 23 of life, unilateral electrochemical stimulation of the basal hypothalmus was done.  Precocious puberty was thus induced.  Pubertal ovulation occurred in 96 or 120 hours or the vaginal opening was noted at 120 hours without ovulation.  All treated animals showed a sustained increase in the luteinizing hormone:follicle stimulating hormone (LH:FSH) ratio in both pituitary tissue and plasma.  Pituitary FSH remained the same in all 3 groups.  Plasma LH and plasma estrogen were increased 1 hour after stimulation and maintained over the next 2 days.  A preovulatory rise in plasma estrogen and gonadotropins was noted only when ovulation followed.  Hormonal profiles observed suggest that LH-releasing hormone initially discharged from the lesion site activated ovarian estrogenic production which modulated pituitary function.  During spontaneous sexual maturation it is thought that other hormones also are factors in the gonadotropin output.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="PIP">
        <Keyword MajorTopicYN="Y">Age Factors</Keyword>
        <Keyword MajorTopicYN="Y">Animals, Laboratory</Keyword>
        <Keyword MajorTopicYN="N">Biology</Keyword>
        <Keyword MajorTopicYN="N">Central Nervous System</Keyword>
        <Keyword MajorTopicYN="N">Clinical Research</Keyword>
        <Keyword MajorTopicYN="N">Demographic Factors</Keyword>
        <Keyword MajorTopicYN="N">Endocrine System</Keyword>
        <Keyword MajorTopicYN="Y">Estrogens--analysis</Keyword>
        <Keyword MajorTopicYN="N">Feedback</Keyword>
        <Keyword MajorTopicYN="Y">Follicle Stimulating Hormone--analysis</Keyword>
        <Keyword MajorTopicYN="N">Gonadotropins</Keyword>
        <Keyword MajorTopicYN="N">Gonadotropins, Pituitary</Keyword>
        <Keyword MajorTopicYN="Y">Hematological Effects</Keyword>
        <Keyword MajorTopicYN="N">Hemic System</Keyword>
        <Keyword MajorTopicYN="N">Hormones</Keyword>
        <Keyword MajorTopicYN="Y">Hypothalamus</Keyword>
        <Keyword MajorTopicYN="Y">Luteinizing Hormone--analysis</Keyword>
        <Keyword MajorTopicYN="Y">Ovulation</Keyword>
        <Keyword MajorTopicYN="N">Physiology</Keyword>
        <Keyword MajorTopicYN="N">Population</Keyword>
        <Keyword MajorTopicYN="N">Population Characteristics</Keyword>
        <Keyword MajorTopicYN="N">Reproduction</Keyword>
        <Keyword MajorTopicYN="N">Research Methodology</Keyword>
      </KeywordList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022381</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-1759</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>222</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunological methods</Title>
          <ISOAbbreviation>J Immunol Methods</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>145-53</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>As a simple method for field studies to assess the cytokine-status of patients with tuberculosis (TB), the use of whole blood instead of isolated cells has advantages, especially since the risk of contamination is minimal. Therefore, cytokine production in whole blood cultures was determined using non-specific and disease-specific stimuli. Heparinized blood from healthy volunteers was either incubated in closed vacutainer tubes or in tissue culture wells after dilution in culture medium. Dose-response and kinetics were investigated for the production of TNFalpha, IL-1beta, IL-1ra, IL-10 and IFNgamma. Patients with TB and healthy individuals were examined for IFN-gamma production in whole blood. In the absence of a stimulus, the production of cytokines is negligible in whole blood cultures. LPS induces the production of TNFalpha, IL-1beta, IL-1ra and IL-10; PHA induces the production of IFNgamma and IL-10. Live BCG induces the production of proinflammatory cytokines, irrespective of tuberculin skin status. In contrast, PPD and MTB-culture filtrate induce production of IFNgamma in skin-test positive and not in skin-test negative healthy subjects. Five out of 13 patients with TB had a low antigen-specific IFNgamma production, suggestive of a minimal or absent specific T-cell response. For most purposes, cultures in closed vacutainer tubes are optimal. If one wishes to focus on T-cell cytokines or if only small volumes of blood are available, dilution of whole blood in culture medium before incubation in tissue culture wells may be preferable.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Crevel</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine 541 University Hospital Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Ven-Jongekrijg</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Netea</LastName>
            <ForeName>M G</ForeName>
            <Initials>MG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Lange</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kullberg</LastName>
            <ForeName>B J</ForeName>
            <Initials>BJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Meer</LastName>
            <ForeName>J W</ForeName>
            <Initials>JW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>J Immunol Methods</MedlineTA>
        <NlmUniqueID>1305440</NlmUniqueID>
        <ISSNLinking>0022-1759</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010835">Phytohemagglutinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014373">Tuberculin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001772" MajorTopicYN="N">Blood Cell Count</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007206" MajorTopicYN="N">Individuality</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009163" MajorTopicYN="N">Mycobacterium bovis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010835" MajorTopicYN="N">Phytohemagglutinins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014373" MajorTopicYN="N">Tuberculin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014374" MajorTopicYN="N">Tuberculin Test</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022246</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0378-4274</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>102-103</Volume>
            <PubDate>
              <Year>1998</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxicology letters</Title>
          <ISOAbbreviation>Toxicol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes.</ArticleTitle>
        <Pagination>
          <MedlinePgn>143-7</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The cytochrome P450 superfamily is known to exhibit a high degree of genetic polymorphism and polymorphisms associated with absent or low enzyme activity in CYP2D6, CYP2C19 and CYP2C9 are particularly well studied. However, despite early reports of strong disease associations for particular CYP2D6 phenotypes, these have not been confirmed in recent, more detailed studies and it now appears that analysis of CYP2D6, CYP2C19 and CYP2C9 genotype is of most value in predicting metabolism of specific drugs. Polymorphisms in other cytochrome P450 genes are less well studied and appear not to be associated with complete absence of enzyme activity. We have recently carried out studies of polymorphism in both CYP1A1 and CYP2E1. The molecular basis of the apparent CYP1A1 'high inducibility' polymorphism was investigated by studying CYP1A1 and Ah receptor polymorphisms in a group of phenotyped individuals who were genotyped both for known and novel CYP1A1 and Ah receptor polymorphisms. Three novel polymorphisms in CYP1A1 (C(-459)T, G(-469)A and C(4151)T) and one in the Ah receptor (G(1768)A; V(570)I) were detected by single strand conformational polymorphism analysis and DNA sequencing. Among both novel and previously known polymorphisms, only the Ah receptor G(1721)A polymorphism, which has an allele frequency of 0.12 in Caucasians and was detected previously in a Japanese population, was significantly associated with high induced CYP1A1 activity. In the case of CYP2E1, we have detected three polymorphisms in the promoter region (A(-316)G, T(-297)A and G(-35)T) and one in the coding sequence (G(4804)A; V(179)I) by screening Caucasian DNA samples. The significance of these alleles has been investigated but only G(-35)T combined with T(-297)A, which has an allele frequency of 0.05, appears to be of functional significance, with an apparent 1.8-fold increase in levels of transcriptional activity compared with the wild-type.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Daly</LastName>
            <ForeName>A K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacological Sciences, Medical School, University of Newcastle upon Tyne, UK. a.k.daly@newcastle.ac.uk</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fairbrother</LastName>
            <ForeName>K S</ForeName>
            <Initials>KS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smart</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Toxicol Lett</MedlineTA>
        <NlmUniqueID>7709027</NlmUniqueID>
        <ISSNLinking>0378-4274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 1.14.13.-</RegistryNumber>
          <NameOfSubstance UI="D019392">Cytochrome P-450 CYP2E1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.1</RegistryNumber>
          <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019363" MajorTopicYN="N">Cytochrome P-450 CYP1A1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019392" MajorTopicYN="N">Cytochrome P-450 CYP2E1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>24</NumberOfReferences>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023744</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0032-5791</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Poultry science</Title>
          <ISOAbbreviation>Poult. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sex differences in the resistance of turkeys to Escherichia coli challenge after immunosuppression with dexamethasone.</ArticleTitle>
        <Pagination>
          <MedlinePgn>38-44</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Five-week-old male and female commercial turkeys were immunosuppressed with two levels of dexamethasone (DEX) and challenged by airsac inoculation with 100 cfu of Escherichia coli. Mortality and airsacculitis (AS) scores were significantly higher in challenged birds treated with DEX and marginally higher in males than in females. Male mortalities had significantly higher AS scores than females. Recovery of E. coli from blood and tissues was significantly higher in challenged birds treated with DEX, marginally higher in males (P = 0.09), and significantly higher in male mortalities than in female mortalities. The low level of DEX seemed to have a protective effect against bacterial challenge in males, whereas the high level of DEX had a more adverse effect in males than in females. Body weights 2 wk postchallenge were significantly decreased by both DEX and E. coli, challenge. Relative liver and heart weights were increased by both DEX and E. coli, challenge, whereas bursal:spleen ratios were decreased by both treatments. Total leukocyte counts and relative heterophil counts from blood samples taken 24 h postinfection were significantly higher in DEX-treated birds and in unchallenged DEX-treated females than in males. The DEX treatment resulted in significantly higher heterophil:lymphocyte ratios, but there was no difference between sexes. Males had significantly lower serum levels of uric acid, total protein, albumin, aspartate aminotransferase, and lactate dehydrogenase than did females. Dexamethasone treatment also resulted in lower levels of total protein, albumin, and aspartate aminotransferase. These data suggest that male turkeys may be more susceptible to colisepticemia than female turkeys, especially when under severe stress.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huff</LastName>
            <ForeName>G R</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>USDA Agricultural Research Service, Poultry Production and Product Safety Research, Poultry Science Center, University of Arkansas, Fayetteville 72701, USA. grhuff@comp.uark.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huff</LastName>
            <ForeName>W E</ForeName>
            <Initials>WE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balog</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rath</LastName>
            <ForeName>N C</ForeName>
            <Initials>NC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Poult Sci</MedlineTA>
        <NlmUniqueID>0401150</NlmUniqueID>
        <ISSNLinking>0032-5791</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7S5I7G3JQL</RegistryNumber>
          <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002060" MajorTopicYN="N">Bursa of Fabricius</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004927" MajorTopicYN="N">Escherichia coli Infections</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="Y">Immunosuppression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011201" MajorTopicYN="N">Poultry Diseases</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014422" MajorTopicYN="N">Turkeys</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022847</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0261-4189</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>The EMBO journal</Title>
          <ISOAbbreviation>EMBO J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans-Golgi network to secretory granules.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1059-70</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The disulfide-bonded loop of chromogranin B (CgB), a regulated secretory protein with widespread distribution in neuroendocrine cells, is known to be essential for the sorting of CgB from the trans-Golgi network (TGN) to immature secretory granules. Here we show that this loop, when fused to the constitutively secreted protein alpha1-antitrypsin (AT), is sufficient to direct the fusion protein to secretory granules. Importantly, the sorting efficiency of the AT reporter protein bearing two loops (E2/3-AT-E2/3) is much higher compared with that of AT with a single disulfide-bonded loop. In contrast to endogenous CgB, E2/3-AT-E2/3 does not undergo Ca2+/pH-dependent aggregation in the TGN. Furthermore, the disulfide-bonded loop of CgB mediates membrane binding in the TGN and does so with 5-fold higher efficiency if two loops are present on the reporter protein. The latter finding supports the concept that under physiological conditions, aggregates of CgB are the sorted units of cargo which have multiple loops on their surface leading to high membrane binding and sorting efficiency of CgB in the TGN.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Glombik</LastName>
            <ForeName>M M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurobiology, University of Heidelberg, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kr√∂mer</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salm</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huttner</LastName>
            <ForeName>W B</ForeName>
            <Initials>WB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerdes</LastName>
            <ForeName>H H</ForeName>
            <Initials>HH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>EMBO J</MedlineTA>
        <NlmUniqueID>8208664</NlmUniqueID>
        <ISSNLinking>0261-4189</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053378">Chromogranin B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002864">Chromogranins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004220">Disulfides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000515">alpha 1-Antitrypsin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C506140">chromogranin B, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053378" MajorTopicYN="N">Chromogranin B</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002864" MajorTopicYN="N">Chromogranins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004220" MajorTopicYN="N">Disulfides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000515" MajorTopicYN="N">alpha 1-Antitrypsin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024537</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0019-9567</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>67</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Infection and immunity</Title>
          <ISOAbbreviation>Infect Immun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Salmonella typhimurium and lipopolysaccharide stimulate extracellularly regulated kinase activation in macrophages by a mechanism involving phosphatidylinositol 3-kinase and phospholipase D as novel intermediates.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1011-7</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Activation of the extracellularly regulated kinase (ERK) pathway is part of the early biochemical events that follow lipopolysaccharide (LPS) treatment of macrophages or their infection by virulent and attenuated Salmonella strains. Phagocytosis as well as the secretion of invasion-associated proteins is dispensable for ERK activation by the pathogen. Furthermore, the pathways used by Salmonella and LPS to stimulate ERK are identical, suggesting that kinase activation might be solely mediated by LPS. Both stimuli activate ERK by a mechanism involving herbimycin-dependent tyrosine kinase(s) and phosphatidylinositol 3-kinase. Phospholipase D activation and stimulation of protein kinase C appear to be intermediates in this novel pathway of MEK/ERK activation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Procyk</LastName>
            <ForeName>K J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Microbiology, Institute of Microbiology and Genetics, Vienna Biocenter, 1030 Vienna, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovarik</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>von Gabain</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baccarini</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Infect Immun</MedlineTA>
        <NlmUniqueID>0246127</NlmUniqueID>
        <ISSNLinking>0019-9567</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016227">Benzoquinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047029">Lactams, Macrocyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011809">Quinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1W306TDA6S</RegistryNumber>
          <NameOfSubstance UI="D017828">Rifabutin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>70563-58-5</RegistryNumber>
          <NameOfSubstance UI="C020754">herbimycin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.17</RegistryNumber>
          <NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.4.4</RegistryNumber>
          <NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SJE1IO5E3I</RegistryNumber>
          <NameOfSubstance UI="C093973">2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XVA4O219QW</RegistryNumber>
          <NameOfSubstance UI="D000077191">Wortmannin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016227" MajorTopicYN="N">Benzoquinones</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047029" MajorTopicYN="N">Lactams, Macrocyclic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011809" MajorTopicYN="N">Quinones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017828" MajorTopicYN="N">Rifabutin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077191" MajorTopicYN="N">Wortmannin</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10029069</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0008-5472</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>59</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>hMSH5: a human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>816-22</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>MutS homologues have been identified in nearly all organisms examined to date. They play essential roles in maintaining mitotic genetic fidelity and meiotic segregation fidelity. MutS homologues appear to function as a molecular switch that signals genomic manipulation events. Here we describe the identification of the human homologue of the Saccharomyces cerevisiae MSH5, which is known to participate in meiotic segregation fidelity and crossing-over. The human MSH5 (hMSH5) was localized to chromosome 6p22-21 and appears to play a role in meiosis because expression is induced during spermatogenesis between the late primary spermatocytes and the elongated spermatid phase. hMSH5 interacts specifically with hMSH4, confirming the generality of functional heterodimeric interactions in the eukaryotic MutS homologue, which also includes hMSH2-hMSH3 and hMSH2-hMSH6.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bocker</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University and Medical College, Philadelphia, Pennsylvania 19107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barusevicius</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snowden</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rasio</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerrette</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robbins</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burczak</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Croce</LastName>
            <ForeName>C M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Copeland</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovatich</LastName>
            <ForeName>A J</ForeName>
            <Initials>AJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fishel</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF034759</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA067007</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA56542</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA67007</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005656">Fungal Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C091158">MSH4 protein, S cerevisiae</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C094801">MSH5 protein, S cerevisiae</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005656" MajorTopicYN="N">Fungal Proteins</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008540" MajorTopicYN="N">Meiosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029701" MajorTopicYN="Y">Saccharomyces cerevisiae Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013091" MajorTopicYN="Y">Spermatogenesis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10037723</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-9258</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>274</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.</ArticleTitle>
        <Pagination>
          <MedlinePgn>6336-41</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Germline mutations in two human mismatch repair (MMR) genes, hMSH2 and hMLH1, appear to account for approximately 70% of the common cancer susceptibility syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Although the hMLH1 protein has been found to copurify with another MMR protein hPMS2 as a heterodimer, their function in MMR is unknown. In this study, we have identified the physical interaction regions of both hMLH1 with hPMS2. We then examined the effects of hMLH1 missense alterations found in HNPCC kindreds for their interaction with hPMS2. Four of these missense alterations (L574P, K616Delta, R659P, and A681T) displayed &gt;95% reduction in binding to hPMS2. Two additional missense alterations (K618A and K618T) displayed a &gt;85% reduction in binding to hPMS2, whereas three missense alterations (S44F, V506A, and E578G) displayed 25-65% reduction in binding to hPMS2. Interestingly, two HNPCC missense alterations (Q542L and L582V) contained within the consensus interaction region displayed no effect on interaction with hPMS2, suggesting that they may affect other functions of hMLH1. These data confirm that functional deficiencies in the interaction of hMLH1 with hPMS2 are associated with HNPCC as well as suggest that other unknown functional alteration of the human MutL homologues may lead to tumorigenesis in HNPCC kindreds.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guerrette</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Genetics and Molecular Biology Program, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acharya</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fishel</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA067007</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA56542</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA67007</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C501486">MLH1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C074770">MutL protein, E coli</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.3</RegistryNumber>
          <NameOfSubstance UI="C497172">MSH2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.3</RegistryNumber>
          <NameOfSubstance UI="D000070957">MutL Protein Homolog 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.3</RegistryNumber>
          <NameOfSubstance UI="D000070956">MutL Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.3</RegistryNumber>
          <NameOfSubstance UI="D051718">MutS Homolog 2 Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="Y">Adenosine Triphosphatases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003123" MajorTopicYN="N">Colorectal Neoplasms, Hereditary Nonpolyposis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029968" MajorTopicYN="Y">Escherichia coli Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000070957" MajorTopicYN="N">MutL Protein Homolog 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000070956" MajorTopicYN="N">MutL Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051718" MajorTopicYN="N">MutS Homolog 2 Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051290</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1524-4539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>99</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation</Title>
          <ISOAbbreviation>Circulation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.</ArticleTitle>
        <Pagination>
          <MedlinePgn>993-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Macrophages in human atherosclerotic plaques produce a family of matrix metalloproteinases (MMPs), which may influence vascular remodeling and plaque disruption. Because oxidized LDL (ox-LDL) is implicated in many proatherogenic events, we hypothesized that ox-LDL would regulate expression of MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in monocyte-derived macrophages. MWRHOSA AND RESULTS: Mononuclear cells were isolated from normal human subjects with Ficoll-Paque density gradient centrifugation, and adherent cells were allowed to differentiate into macrophages during 7 days of culture in plastic dishes. On day 7, by use of serum-free medium, the macrophages were incubated with various concentrations of native LDL (n-LDL) and copper-oxidized LDL. Exposure to ox-LDL (10 to 50 microg/mL) increased MMP-9 mRNA expression as analyzed by Northern blot, protein expression as measured by ELISA and Western blot, and gelatinolytic activity as determined by zymography. The increase in MMP-9 expression was associated with increased nuclear binding of transcription factor NF-kappaB and AP-1 complex on electromobility shift assay. In contrast, ox-LDL (10 to 50 microg/mL) decreased TIMP-1 expression. Ox-LDL-induced increase in MMP-9 expression was abrogated by HDL (100 microg/mL). n-LDL had no significant effect on MMP-9 or TIMP-1 expression.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data demonstrate that unlike n-LDL, ox-LDL upregulates MMP-9 expression while reducing TIMP-1 expression in monocyte-derived macrophages. Furthermore, HDL abrogates ox-LDL-induced MMP-9 expression. Thus, ox-LDL may contribute to macrophage-mediated matrix breakdown in the atherosclerotic plaques, thereby predisposing them to plaque disruption and/or vascular remodeling.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>X P</ForeName>
            <Initials>XP</Initials>
            <AffiliationInfo>
              <Affiliation>Atherosclerosis Research Center, Division of Cardiology, and the Burns and Allen Research Institute, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meisel</LastName>
            <ForeName>S R</ForeName>
            <Initials>SR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ong</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaul</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cercek</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajavashisth</LastName>
            <ForeName>T B</ForeName>
            <Initials>TB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharifi</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>P K</ForeName>
            <Initials>PK</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circulation</MedlineTA>
        <NlmUniqueID>0147763</NlmUniqueID>
        <ISSNLinking>0009-7322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019715">Tissue Inhibitor of Metalloproteinase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C099252">oxidized low density lipoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.-</RegistryNumber>
          <NameOfSubstance UI="D017364">Collagenases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.35</RegistryNumber>
          <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017364" MajorTopicYN="N">Collagenases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019715" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018808" MajorTopicYN="N">Transcription Factor AP-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051289</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1524-4539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>99</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation</Title>
          <ISOAbbreviation>Circulation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure.</ArticleTitle>
        <Pagination>
          <MedlinePgn>990-2</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Incomplete suppression of the renin-angiotensin system during long-term ACE inhibition may contribute to symptomatic deterioration in patients with severe congestive heart failure (CHF). Combined angiotensin II type I (AT1) receptor blockade and ACE inhibition more completely suppresses the activated renin-angiotensin system than either intervention alone in sodium-depleted normal individuals. Whether AT1 receptor blockade with losartan improves exercise capacity in patients with severe CHF already treated with ACE inhibitors is unknown.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Thirty-three patients with severe CHF despite treatment with maximally recommended or tolerated doses of ACE inhibitors were randomized 1:1 to receive 50 mg/d losartan or placebo for 6 months in addition to standard therapy in a multicenter, double-blind trial. Peak aerobic capacity (V(O2)) during symptom-limited treadmill exercise and NYHA functional class were determined at baseline and after 3 and 6 months of double-blind therapy. Peak V(O2) at baseline and after 3 and 6 months were 13.5+/-0.6, 15.1+/-1.0, and 15.7+/-1.1 mL. kg-1. min-1, respectively, in patients receiving losartan and 14.1+/-0.6, 14.3+/-0.9, and 13.6+/-1.1 mL. kg-1. min-1, respectively, in patients receiving placebo (P&lt;0.02 for treatment group-by-time interaction). Functional class improved by at least one NYHA class in 9 of 16 patients receiving losartan and 1 of 17 patients receiving placebo.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Losartan enhances peak exercise capacity and alleviates symptoms in patients with CHF who are severely symptomatic despite treatment with maximally recommended or tolerated doses of ACE inhibitors.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hamroff</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Medicine, Divisions of Cardiology, The Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katz</LastName>
            <ForeName>S D</ForeName>
            <Initials>SD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mancini</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blaufarb</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bijou</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jondeau</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olivari</LastName>
            <ForeName>M T</ForeName>
            <Initials>MT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le Jemtel</LastName>
            <ForeName>T H</ForeName>
            <Initials>TH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circulation</MedlineTA>
        <NlmUniqueID>0147763</NlmUniqueID>
        <ISSNLinking>0009-7322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JMS50MPO89</RegistryNumber>
          <NameOfSubstance UI="D019808">Losartan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057911" MajorTopicYN="Y">Angiotensin Receptor Antagonists</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019808" MajorTopicYN="N">Losartan</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051665</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Growth factor-mediated Fyn signaling regulates alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression in rodent neocortical neurons.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2461-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Src-family protein tyrosine kinases (PTKs) transduce signals to regulate neuronal development and synaptic plasticity. However, the nature of their activators and molecular mechanisms underlying these neural processes are unknown. Here, we show that brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor enhance expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor 1 and 2/3 proteins in rodent neocortical neurons via the Src-family PTK(s). The increase in AMPA receptor levels was blocked in cultured neocortical neurons by addition of a Src-family-selective PTK inhibitor. Accordingly, neocortical cultures from Fyn-knockout mice failed to respond to BDNF whereas those from wild-type mice responded. Moreover, the neocortex of young Fyn mutants exhibited a significant in vivo reduction in these AMPA receptor proteins but not in their mRNA levels. In vitro kinase assay revealed that BDNF can indeed activate the Fyn kinase: It enhanced tyrosine phosphorylation of Fyn as well as that of enolase supplemented exogenously. All of these results suggest that the Src-family kinase Fyn, activated by the growth factors, plays a crucial role in modulating AMPA receptor expression during brain development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Narisawa-Saito</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Neurobiology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>A J</ForeName>
            <Initials>AJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamaguchi</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nawa</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006133">Growth Substances</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010982">Platelet-Derived Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>103107-01-3</RegistryNumber>
          <NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>62229-50-9</RegistryNumber>
          <NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C494960">Fyn protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C494961">Fyn protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D051076">Proto-Oncogene Proteins c-fyn</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Proc Natl Acad Sci U S A 1999 May 11;96(10):5890</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016222" MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006133" MajorTopicYN="N">Growth Substances</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010982" MajorTopicYN="N">Platelet-Derived Growth Factor</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051076" MajorTopicYN="N">Proto-Oncogene Proteins c-fyn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019061" MajorTopicYN="N">src-Family Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051661</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ectopic bone morphogenetic proteins 5 and 4 in the chicken forebrain lead to cyclopia and holoprosencephaly.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2439-44</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Proper dorsal-ventral patterning in the developing central nervous system requires signals from both the dorsal and ventral portions of the neural tube. Data from multiple studies have demonstrated that bone morphogenetic proteins (BMPs) and Sonic hedgehog protein are secreted factors that regulate dorsal and ventral specification, respectively, within the caudal neural tube. In the developing rostral central nervous system Sonic hedgehog protein also participates in ventral regionalization; however, the roles of BMPs in the developing brain are less clear. We hypothesized that BMPs also play a role in dorsal specification of the vertebrate forebrain. To test our hypothesis we implanted beads soaked in recombinant BMP5 or BMP4 into the neural tube of the chicken forebrain. Experimental embryos showed a loss of the basal telencephalon that resulted in holoprosencephaly (a single cerebral hemisphere), cyclopia (a single midline eye), and loss of ventral midline structures. In situ hybridization using a panel of probes to genes expressed in the dorsal and ventral forebrain revealed the loss of ventral markers with the maintenance of dorsal markers. Furthermore, we found that the loss of the basal telencephalon was the result of excessive cell death and not a change in cell fates. These data provide evidence that BMP signaling participates in dorsal-ventral patterning of the developing brain in vivo, and disturbances in dorsal-ventral signaling result in specific malformations of the forebrain.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Golden</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Children's Hospital of Philadelphia, and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. goldenj@mail.med.upenn.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bracilovic</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McFadden</LastName>
            <ForeName>K A</ForeName>
            <Initials>KA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beesley</LastName>
            <ForeName>J S</ForeName>
            <Initials>JS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubenstein</LastName>
            <ForeName>J L</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grinspan</LastName>
            <ForeName>J B</ForeName>
            <Initials>JB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055415">Bone Morphogenetic Protein 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055417">Bone Morphogenetic Protein 5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004343">Drug Implants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051762">PAX2 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071841">PAX6 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051761">Paired Box Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060528">Wnt4 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C525813">bmp4 protein, zebrafish</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019521" MajorTopicYN="N">Body Patterning</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055415" MajorTopicYN="N">Bone Morphogenetic Protein 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055417" MajorTopicYN="N">Bone Morphogenetic Protein 5</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019485" MajorTopicYN="N">Bone Morphogenetic Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002642" MajorTopicYN="N">Chick Embryo</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004343" MajorTopicYN="N">Drug Implants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005124" MajorTopicYN="N">Eye Abnormalities</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005136" MajorTopicYN="N">Eye Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016142" MajorTopicYN="N">Holoprosencephaly</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018398" MajorTopicYN="Y">Homeodomain Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051762" MajorTopicYN="N">PAX2 Transcription Factor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071841" MajorTopicYN="N">PAX6 Transcription Factor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051761" MajorTopicYN="N">Paired Box Transcription Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000196" MajorTopicYN="Y">embryology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013687" MajorTopicYN="N">Telencephalon</DescriptorName>
          <QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015534" MajorTopicYN="Y">Trans-Activators</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060528" MajorTopicYN="N">Wnt4 Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029961" MajorTopicYN="Y">Zebrafish Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064062</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2980</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>02</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of immunology</Title>
          <ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of protein kinase C alpha expression by antisense RNA in transfected Jurkat cells.</ArticleTitle>
        <Pagination>
          <MedlinePgn>466-76</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Taking the antisense approach to inhibit the expression of specific protein kinase C (PKC) isoforms, we investigated the function of PKC alpha in T cell activation by transfecting Jurkat cells with an episomal vector (pREP3) containing a copy of the corresponding gene in the antisense orientation. Transfected Jurkat cells were selected with hygromycin and cloned by limiting dilution. Two (as1/as2) stably transfected antisense PKC alpha-pREP3 clones (as PKC alpha-pREP3) exhibited consistently reductions (76% and 85%, respectively) of PKC alpha levels when analyzed by immunoblotting and immunoprecipitation and also of PKC alpha mRNA (75%, as determined by Northern blotting) when compared to control clones (C1/C2) containing the pREP3 vector alone. The ability of the as-PKC alpha-pREP3 construct to specifically reduce PKC alpha levels in both clones was demonstrated by Western blots probed with antibodies against the PKC beta isozyme (the form structurally more similar to PKC alpha) and other representative isoenzymes expressed in Jurkat cells (PKC delta, epsilon, theta, and mu). Stimulation of transfected Jurkat clones with phorbol-12-myristate-13 alone or in the presence of ionomycin resulted in significant reduction of IL-2R alpha expression, TNF-alpha production, and the induction of transcriptional activity of a pIL-2/Luc construct in both as PKC alpha-reduced clones. The magnitude of these decrements paralleled the reductions of PKC alpha expression. The loss of the effects in clone as1 after a high number of passages correlated with the recovery of normal levels of PKC alpha protein, suggesting a link between these processes. Thus, the findings of this study demonstrate the essential role that PKC alpha plays in major events of the T lymphocyte activation process.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>L√≥pez-Lago</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioquimica y Biologia Molecular, Facultad de Biologia, Universidad de Santiago de Compostela, Espa√±a.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freire-Moar</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barja</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur J Immunol</MedlineTA>
        <NlmUniqueID>1273201</NlmUniqueID>
        <ISSNLinking>0014-2980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="C496628">PRKCA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D051571">Protein Kinase C-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051571" MajorTopicYN="N">Protein Kinase C-alpha</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064085</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2980</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>02</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of immunology</Title>
          <ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and interferon-gamma reveals MCP-3 heterogeneity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>678-85</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Monocyte chemotactic protein-3 (MCP-3) is a pluripotent CC chemokine, attracting most leukocytic cell types. With the use of a sensitive and specific ELISA, MCP-3 was found to be inducible in fibroblasts and peripheral blood mononuclear cells (PBMC) by cytokines and cytokine inducers. MCP-3 production levels (1-10 ng/ml) were tenfold lower compared to those of MCP-1. In diploid fibroblasts, synergistic induction of MCP-3, but not of MCP-1, mRNA and protein was observed by combined treatment with IL-1beta and IFN-gamma. In PBMC, IFN-alpha and IFN-beta (but not IFN-gamma), as well as measles virus and double-stranded RNA, were potent inducers of MCP-3, which suggests a role for this chemokine in an early stage of viral infections. In contrast, endotoxin failed to induce MCP-3 production in fibroblasts and PBMC. Purification of MCP-3 from PBMC revealed biochemical heterogeneity. In monocyte chemotaxis and calcium mobilization assays, pure 11-kDa MCP-3 from PBMC showed similar potencies as MCP-3 from tumor cells. It was concluded that the induction of MCP-3 by IFN is regulated differently in fibroblasts and PBMC. In view of the multiple target cells for MCP-3, local and strictly regulated chemokine production might be important to conduct selectively the immune response in infection or inflammation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Menten</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Rega Institute, Laboratory of Molecular Immunology, University of Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Proost</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Struyf</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van Coillie</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Put</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lenaerts</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conings</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaspar</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Groote</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Billiau</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Opdenakker</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van Damme</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur J Immunol</MedlineTA>
        <NlmUniqueID>1273201</NlmUniqueID>
        <ISSNLinking>0014-2980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515450">CCL7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054410">Chemokine CCL7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018945">Monocyte Chemoattractant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>77238-31-4</RegistryNumber>
          <NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054410" MajorTopicYN="N">Chemokine CCL7</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018945" MajorTopicYN="N">Monocyte Chemoattractant Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10065632</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0165-2478</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>65</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology letters</Title>
          <ISOAbbreviation>Immunol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Uptake and processing of glycosylated mycolates for presentation to CD1b-restricted T cells.</ArticleTitle>
        <Pagination>
          <MedlinePgn>85-91</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Antigen presenting cells (APCs) expressing CD1b mediate the specific T cell recognition of mycobacterial lipid antigens. These lipid antigens require internalization by APCs prior to presentation, but the detailed mechanisms of uptake and intracellular processing are not known. Here we have examined several steps in the presentation of two related classes of CD1b-presented antigens, free and glycosylated mycolates. T cell recognition of glucose monomycolate (GMM) was blocked by agents that fix APC membranes or neutralize the pH of endosomes, indicating a requirement for GMM uptake into an acidic compartment prior to recognition. Different T cell lines responded to free mycolate or GMM without crossreactivity, yet both antigens were taken up by APCs at the same rate. This demonstrated that differential recognition of these antigens resulted from T cell specificity for their hydrophilic caps and that APCs were unable to interconvert these antigens by enzymatic or chemical deglycosylation or glycosylation. APCs were also unable to cleave mycobacterial trehalose dimycolate (TDM) at its most chemically labile linkages to yield antigenic free mycolates or GMM. Our results indicate that these mycolate-containing antigens are resistant to chemical or enzymatic cleavage by APCs, suggesting that molecular trimming is not a universal feature of lipid antigen processing.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Moody</LastName>
            <ForeName>D B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reinhold</LastName>
            <ForeName>B B</ForeName>
            <Initials>BB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reinhold</LastName>
            <ForeName>V N</ForeName>
            <Initials>VN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Besra</LastName>
            <ForeName>G S</ForeName>
            <Initials>GS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Porcelli</LastName>
            <ForeName>S A</ForeName>
            <Initials>SA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>AI40135</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ARO1988</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Immunol Lett</MedlineTA>
        <NlmUniqueID>7910006</NlmUniqueID>
        <ISSNLinking>0165-2478</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018949">Antigens, CD1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006017">Glycolipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009171">Mycolic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C048938">glucose mycolate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017951" MajorTopicYN="Y">Antigen Presentation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018949" MajorTopicYN="N">Antigens, CD1</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006017" MajorTopicYN="N">Glycolipids</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009161" MajorTopicYN="N">Mycobacterium</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009171" MajorTopicYN="N">Mycolic Acids</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064868</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0165-3806</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>113</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain research. Developmental brain research</Title>
          <ISOAbbreviation>Brain Res Dev Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cholinergic receptors in heart and brainstem of rats exposed to nicotine during development: implications for hypoxia tolerance and perinatal mortality.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1-12</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Cigarette smoking during pregnancy increases the incidence of perinatal mortality and Sudden Infant Death Syndrome (SIDS). We have evaluated prenatal or postnatal nicotine exposure in developing rats to examine the potential role of altered neurotransmitter receptor expression in these processes. Pregnant rats received continuous infusions of nicotine throughout gestation, at doses mimicking the plasma levels found in smokers. After birth, cardiac M2-muscarinic cholinergic receptors, which are responsible for inhibitory autonomic actions, were enhanced in the nicotine group, coincidentally with decreases in stimulatory beta-adrenergic receptors that have been demonstrated previously. Studies of adenylyl cyclase activity confirmed that the changes in receptor binding represented functional alterations: the stimulatory response to isoproterenol was obtunded by prenatal nicotine exposure, whereas the inhibitory response to carbachol was enhanced. Elevations of M2-muscarinic receptor binding were not generalized to all tissues, as the same prenatal nicotine treatment elicited a reduction in these receptors in the brainstem, an effect that has also been noted in infants who died of SIDS; we found no effects of prenatal nicotine on brainstem M1-receptor binding. Postnatal administration of nicotine produced similar brainstem receptor effects when treatment was conducted during the first postnatal week but not thereafter; postnatal nicotine treatment did not affect cardiac M2-receptor binding. Thus, during a critical developmental period, nicotine exposure produces cardiac and brainstem receptor imbalances that favor inhibitory responses, effects that can contribute to morbidity and mortality evoked by hypoxic episodes, such as those experienced during parturition, sleep apnea or airway obstruction.</AbstractText>
          <CopyrightInformation>Copyright 1999 Elsevier Science B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Slotkin</LastName>
            <ForeName>T A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA. t.slotkin@duke.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Epps</LastName>
            <ForeName>T A</ForeName>
            <Initials>TA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stenger</LastName>
            <ForeName>M L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sawyer</LastName>
            <ForeName>K J</ForeName>
            <Initials>KJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seidler</LastName>
            <ForeName>F J</ForeName>
            <Initials>FJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HD09713</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Brain Res Dev Brain Res</MedlineTA>
        <NlmUniqueID>8908639</NlmUniqueID>
        <ISSNLinking>0165-3806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043585">Receptor, Muscarinic M2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>10028-17-8</RegistryNumber>
          <NameOfSubstance UI="D014316">Tritium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6M3C89ZY6R</RegistryNumber>
          <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.6.1.1</RegistryNumber>
          <NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011297" MajorTopicYN="Y">Prenatal Exposure Delayed Effects</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043585" MajorTopicYN="N">Receptor, Muscarinic M2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023739</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0032-5791</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Poultry science</Title>
          <ISOAbbreviation>Poult. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Direct and correlated response to divergent selection for serum immunoglobulin M and G levels in chickens.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1-7</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Two pairs of chicken lines were divergently selected for serum immunoglobulin M and G levels at 10 wk of age to examine the effect of selection on direct and correlated traits. After three generations of selection, the lines were tested for their ability of antibody production against SRBC, a T cell dependent antigen. At 14 and 17 wk of age, the lines were immunized intravenously with 1 mL of 5% SRBC solution. Blood samples were collected at 7 and 14 d of post primary immunization (PPI) and post secondary immunization (PSI). Selection was effective (P &lt; 0.01) in changing the serum immunoglobulin M levels. The G levels were changed in a downward direction initially in the high line. The differences between the high immunoglobulin M (HIM) and low immunoglobulin M (LIM) lines as well as high immunoglobulin G (HIG) and low immunoglobulin G (LIG) lines became larger during the course of selection. Selection differentials varied considerably during the selection, but the selection response was almost constant. Realized heritability was relatively high, ranging from 0.58 to 0.66 and from 0.40 to 0.60 for the IgM and IgG selected lines, respectively. Total antibody titers to SRBC differed significantly (P &lt; 0.01) between the HIM and LIM lines at 7 and 14 d PPI, and 7 d PSI. The HIM line also produced significantly higher mercaptoethanol resistant antibody titers to SRBC than the LIM line at 7 and 14 d PPI and PSI. The LIG line had significantly higher total antibody titers to SRBC than the HIG line at both 7 and 14 d of PPI and PSI. From these results, it is suggested that selection of chickens on the basis of serum immunoglobulin isotypes may change antibody producing cells as well as other immunocompetent cells that modulate the immune response of the selected lines.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sarker</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Animal Breeding and Genetics, Faculty of Applied Biological Science, Hiroshima University, Kagamiyama, Higashi-Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsudzuki</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishibori</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Poult Sci</MedlineTA>
        <NlmUniqueID>0401150</NlmUniqueID>
        <ISSNLinking>0032-5791</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001947" MajorTopicYN="Y">Breeding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012641" MajorTopicYN="Y">Selection, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012756" MajorTopicYN="N">Sheep</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023757</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0032-5791</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Poultry science</Title>
          <ISOAbbreviation>Poult. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification of an androgen receptor within the uterus of the domestic fowl.</ArticleTitle>
        <Pagination>
          <MedlinePgn>107-13</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Cytosolic and nuclear fractions of the uterus (shell gland) of the hen's oviduct were found to contain a specific [17alpha-methyl-3H]-methyltrienolone ([3H]R1881; a synthetic androgen) binding component having properties of an androgen receptor; i.e., binding specificity, high affinity, and limited capacity. The value of the equilibrium dissociation constant (Kd) was of the order of 10(-9), and did not differ between laying and nonlaying hens. The maximum binding capacity (Bmax) per gram of tissue of both fractions was greater in laying hens than in nonlaying hens. When 5alpha-dihydrotestosterone was administered exogenously, the Bmax of the cytosolic fraction decreased and that of the nuclear fraction increased without any change in Kd. The specific binding in both fractions was at an increased level from 4 to 11 h before oviposition, suggesting that androgen binding may be related to certain events during an early stage of shell formation in the uterus of laying hens.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kawashima</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Diversity and Resources, Gifu University, Yanagido, Japan. kawasima@cc.gifu-u.ac.jp</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kondo</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yasuoka</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Poult Sci</MedlineTA>
        <NlmUniqueID>0401150</NlmUniqueID>
        <ISSNLinking>0032-5791</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>08J2K08A3Y</RegistryNumber>
          <NameOfSubstance UI="D013196">Dihydrotestosterone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>10028-17-8</RegistryNumber>
          <NameOfSubstance UI="D014316">Tritium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2C323EGI97</RegistryNumber>
          <NameOfSubstance UI="D015741">Metribolone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3XMK78S47O</RegistryNumber>
          <NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="Y">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013196" MajorTopicYN="N">Dihydrotestosterone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015741" MajorTopicYN="N">Metribolone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010057" MajorTopicYN="N">Oviducts</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010058" MajorTopicYN="N">Oviposition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023750</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0032-5791</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Poultry science</Title>
          <ISOAbbreviation>Poult. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Calcium dependency of interleukin-1 secretion by a chicken macrophage cell line.</ArticleTitle>
        <Pagination>
          <MedlinePgn>70-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The role of calcium in transducing the signal for interleukin-1 (IL-1) secretion was examined in the MQ-NCSU chicken macrophage cell line. Cells were maintained in RPMI 1640 medium supplemented with 5% chicken serum and antibiotic-antimycotic solution at 40 C and 5% CO2. The effects of stimulation with lipopolysaccharide (LPS), calcium ionophore A23187, or a combination of both on IL-1 secretion were examined. Calcium ionophore A23187 did not replace LPS in MQ-NCSU stimulation but the LPS + A23187 combination stimulated more IL-1 than ionophore alone in these cells. The combination of LPS and ionophore did not increase IL-1 secretion above the levels observed with LPS alone. No synergistic effects between LPS and A23187 were evident. In order to demonstrate that IL-1 secretion by the MQ-NCSU cells is a calcium-dependent process, ethylene glycol bis(beta-aminoethyl ether)N,N,N',N'-tetraacetic acid (EGTA) was used to chelate free calcium in the cultures. Incorporation of 5 mM EGTA in the cultures lowered IL-1 stimulated by LPS + A23187 to control levels. Addition of 5 mM CaC12 to EGTA-suppressed cultures restored IL-1 secretion. These results indicate that the calcium ionophore, A23187, augments IL-1 secretion by LPS-stimulated MQ-NCSU macrophages and that IL-1 secretion by these cells is a calcium-dependent process.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cieszynski</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Animal and Nutritional Sciences, University of New Hampshire, Durham 03824, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qureshi</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taylor</LastName>
            <ForeName>R L</ForeName>
            <Initials>RL</Initials>
            <Suffix>Jr</Suffix>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Poult Sci</MedlineTA>
        <NlmUniqueID>0401150</NlmUniqueID>
        <ISSNLinking>0032-5791</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002614">Chelating Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007476">Ionophores</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37H9VM9WZL</RegistryNumber>
          <NameOfSubstance UI="D000001">Calcimycin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>526U7A2651</RegistryNumber>
          <NameOfSubstance UI="D004533">Egtazic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000001" MajorTopicYN="N">Calcimycin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002614" MajorTopicYN="N">Chelating Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="Y">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004533" MajorTopicYN="N">Egtazic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007476" MajorTopicYN="N">Ionophores</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024543</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0019-9567</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>67</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Infection and immunity</Title>
          <ISOAbbreviation>Infect. Immun.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1056-62</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>During colonization of the respiratory tract by Bordetella pertussis, virulence factors contribute to adherence of the bacterium to the respiratory tract epithelium. In the present study, we examined the roles of the virulence factors filamentous hemagglutinin (FHA), fimbriae, pertactin (Prn), and pertussis toxin (PT) in the adherence of B. pertussis to cells of the human bronchial epithelial cell line NCI-H292 and of the laryngeal epithelial cell line HEp-2. Using B. pertussis mutant strains and purified FHA, fimbriae, Prn, and PT, we demonstrated that both fimbriae and FHA are involved in the adhesion of B. pertussis to laryngeal epithelial cells, whereas only FHA is involved in the adherence to bronchial epithelial cells. For PT and Prn, no role as adhesion factor was found. However, purified PT bound to both bronchial and laryngeal cells and as such reduced the adherence of B. pertussis to these cells. These data may imply that fimbriae play a role in infection of only the laryngeal mucosa, while FHA is the major factor in colonization of the entire respiratory tract.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van den Berg</LastName>
            <ForeName>B M</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. bvdberg@stad.dsl.nl</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beekhuizen</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Willems</LastName>
            <ForeName>R J</ForeName>
            <Initials>RJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mooi</LastName>
            <ForeName>F R</ForeName>
            <Initials>FR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Furth</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Infect Immun</MedlineTA>
        <NlmUniqueID>0246127</NlmUniqueID>
        <ISSNLinking>0019-9567</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018829">Adhesins, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001425">Bacterial Outer Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006388">Hemagglutinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010566">Virulence Factors, Bordetella</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C065273">filamentous hemagglutinin adhesin, Bordetella pertussis</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63GD90PP8X</RegistryNumber>
          <NameOfSubstance UI="C068929">pertactin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.31</RegistryNumber>
          <NameOfSubstance UI="D037342">Pertussis Toxin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018829" MajorTopicYN="N">Adhesins, Bacterial</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001422" MajorTopicYN="Y">Bacterial Adhesion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001425" MajorTopicYN="N">Bacterial Outer Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001886" MajorTopicYN="N">Bordetella pertussis</DescriptorName>
          <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010861" MajorTopicYN="N">Fimbriae, Bacterial</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006388" MajorTopicYN="N">Hemagglutinins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037342" MajorTopicYN="N">Pertussis Toxin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010566" MajorTopicYN="N">Virulence Factors, Bordetella</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024518</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0264-6021</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>338 ( Pt 2)</Volume>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Biochemical journal</Title>
          <ISOAbbreviation>Biochem J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein.</ArticleTitle>
        <Pagination>
          <MedlinePgn>417-25</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Complement receptor 2 (CR2) is important in the regulation of the B lymphocyte response; the regulation of its expression is therefore of central importance. We recently reported that a 42 kDa heterogeneous nuclear ribonucleoprotein (hnRNP) is involved in the transcriptional regulation of the human CR2 gene [Tolnay, Lambris and Tsokos (1997) J. Immunol. 159, 5492-5501]. We cloned the cDNA encoding this protein and found it to be identical with hnRNP D0B, a sequence-specific RNA-binding protein. By using a set of mutated oligonucleotides, we demonstrated that the recombinant hnRNP D0B displays sequence specificity for double-stranded oligonucleotide defined by the CR2 promoter. We conducted electrophoretic mobility-shift assays to estimate the apparent Kd of hnRNP D0B for the double-stranded DNA motif and found it to be 59 nM. Interestingly, hnRNP D0B displayed affinities of 28 and 18 nM for the sense and anti-sense strands of the CR2 promoter-defined oligonucleotide respectively. The significantly greater binding affinity of hnRNP D0B for single-stranded DNA than for double-stranded DNA suggests that the protein might melt the double helix. The intranuclear concentration of sequence-specific protein was estimated to be 250-400 nM, indicating that the protein binds to the CR2 promoter in vivo. Co-precipitation of a complex formed in vivo between hnRNP D0B and the TATA-binding protein demonstrates that hnRNP D0B interacts with the basal transcription apparatus. Our results suggest a new physiological role for hnRNP D0B that involves binding to double- and single-stranded DNA sequences in a specific manner and functioning as a transcription factor.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tolnay</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Physiology, Walter Reed Army Institute of Research, 14th and Dahlia Streets, Bldg. 40, Washington, DC 20307-5100, USA. mtolnay@hotmail.com</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vereshchagina</LastName>
            <ForeName>L A</ForeName>
            <Initials>LA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsokos</LastName>
            <ForeName>G C</ForeName>
            <Initials>GC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF039575</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>AI42782</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem J</MedlineTA>
        <NlmUniqueID>2984726R</NlmUniqueID>
        <ISSNLinking>0264-6021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000630986">HNRNPD protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081035">Heterogeneous Nuclear Ribonucleoprotein D0</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034502">Heterogeneous-Nuclear Ribonucleoprotein D</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034441">Heterogeneous-Nuclear Ribonucleoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081035" MajorTopicYN="N">Heterogeneous Nuclear Ribonucleoprotein D0</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034502" MajorTopicYN="Y">Heterogeneous-Nuclear Ribonucleoprotein D</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034441" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoproteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012261" MajorTopicYN="N">Ribonucleoproteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024535</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0264-6021</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>338 ( Pt 2)</Volume>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Biochemical journal</Title>
          <ISOAbbreviation>Biochem J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification and characterization of a recombinant metallothionein protein from a marine alga, Fucus vesiculosus.</ArticleTitle>
        <Pagination>
          <MedlinePgn>553-60</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>A cDNA library was constructed from macroalgae adapted to prolonged elevated environmental copper levels. To investigate the possible existence of a metallothionein (MT) gene, the library was screened with degenerate probes designed using plant MT cysteine-rich motifs. A gene was identified (1229 bp) with a putative open reading frame (204 bp) encoding a 67-amino-acid protein exhibiting several characteristic features of MT proteins, including 16 cysteine residues (24%) and only one aromatic residue. Although the protein sequence showed high identity with plant and invertebrate MTs, it contained a unique 'linker' region (14 amino acid residues) between the two putative metal-binding domains which contained no cysteine residues. This extended linker is larger than the tripeptide found in archetypal vertebrate MTs, but does not conform either with the 40-amino-acid linkers commonly found in plant MT sequences. An S-peptide Fucus MT fusion protein expressed in Escherichia coli exhibited a relative molecular mass of approximately 14 kDa. The recombinant fusion bound seven Cd ions, of which 50% were dissociated at pH 4.1. Under anaerobic conditions, the Cd ions were displaced by Cu(I), which associated with the protein at a ratio of 13:1. Laboratory exposure of F. vesiculosus to elevated copper resulted in induction of the MT gene. Thus this paper describes, for the first time, an MT gene identified from macroalgae which is induced by copper exposure and whose encoded protein product binds cadmium and copper.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Morris</LastName>
            <ForeName>C A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biosciences, University of Wales Cardiff, P.O. Box 911, Cardiff CF1 3US, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicolaus</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampson</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harwood</LastName>
            <ForeName>J L</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kille</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AJ005834</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem J</MedlineTA>
        <NlmUniqueID>2984726R</NlmUniqueID>
        <ISSNLinking>0264-6021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008670">Metals</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9038-94-2</RegistryNumber>
          <NameOfSubstance UI="D008668">Metallothionein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008668" MajorTopicYN="N">Metallothionein</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008670" MajorTopicYN="N">Metals</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000459" MajorTopicYN="N">Phaeophyta</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013054" MajorTopicYN="N">Spectrophotometry, Atomic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10028287</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0737-4038</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>16</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular biology and evolution</Title>
          <ISOAbbreviation>Mol Biol Evol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evolutionary analysis of TATA-less proximal promoter function.</ArticleTitle>
        <Pagination>
          <MedlinePgn>194-207</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Many molecular studies describe how components of the proximal promoter affect transcriptional processes. However, these studies do not account for the likely effects of distant enhancers or chromatin structure, and thus it is difficult to conclude that the sequence variation in proximal promoters acts to modulate transcription in the natural context of the whole genome. This problem, the biological importance of proximal promoter sequence variation, can be addressed using a combination of molecular and evolutionary analyses. Provided here are molecular and evolutionary analyses of the variation in promoter function and sequence within and between populations of Fundulus heteroclitus for the lactate dehydrogenase-B (Ldh-B) proximal promoter. Approximately one third of the Ldh-B proximal promoter contains interspersed regions that are functionally important: (1) they bind transcription factors in vivo, (2) they effect a change in transcription as assayed by transient transfection into two different fish cell lines, and (3) they bind purified transcription factors in vitro. Evolutionary analyses that compare sequence variation in these functional regions versus the nonfunctional regions indicate that the changes in the Ldh-B proximal promoter sequences are due to directional selection. Thus, the Ldh-B proximal promoter sequence variations that affect transcriptional processes constitute a phenotypic change that is subject to natural selection, suggesting that proximal promoter sequence variation affects transcription in the natural context of the whole genome.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Crawford</LastName>
            <ForeName>D L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Biology and Biochemistry, University of Missouri, Kansas City 64110, USA. crawd@cctr.umkc.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segal</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barnett</LastName>
            <ForeName>J L</ForeName>
            <Initials>JL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF082687</AccessionNumber>
              <AccessionNumber>AF082688</AccessionNumber>
              <AccessionNumber>AF082689</AccessionNumber>
              <AccessionNumber>AF082690</AccessionNumber>
              <AccessionNumber>AF082691</AccessionNumber>
              <AccessionNumber>AF082692</AccessionNumber>
              <AccessionNumber>AF082693</AccessionNumber>
              <AccessionNumber>AF082694</AccessionNumber>
              <AccessionNumber>AF082695</AccessionNumber>
              <AccessionNumber>AF082696</AccessionNumber>
              <AccessionNumber>AF082697</AccessionNumber>
              <AccessionNumber>AF082698</AccessionNumber>
              <AccessionNumber>AF082699</AccessionNumber>
              <AccessionNumber>AF082700</AccessionNumber>
              <AccessionNumber>AF082701</AccessionNumber>
              <AccessionNumber>AF082702</AccessionNumber>
              <AccessionNumber>AF082703</AccessionNumber>
              <AccessionNumber>AF082704</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>GM 07183</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Biol Evol</MedlineTA>
        <NlmUniqueID>8501455</NlmUniqueID>
        <ISSNLinking>0737-4038</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.1.27</RegistryNumber>
          <NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019143" MajorTopicYN="Y">Evolution, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005828" MajorTopicYN="N">Genetics, Population</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007695" MajorTopicYN="N">Killifishes</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007770" MajorTopicYN="N">L-Lactate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016385" MajorTopicYN="N">TATA Box</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024618</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-3166</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>129</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of nutrition</Title>
          <ISOAbbreviation>J Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations.</ArticleTitle>
        <Pagination>
          <MedlinePgn>399-405</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Daidzein and genistein glucuronides (DG and GG), major isoflavone metabolites, may be partly responsible for biological effects of isoflavones, such as estrogen receptor binding and natural killer cell (NK) activation or inhibition. DG and GG were synthesized using 3-methylcholanthrene-induced rat liver microsomes. The Km and Vmax for daidzein and genistein were 9.0 and 7.7 micromol/L, and 0.7 and 1.6 micromol/(mg protein. min), respectively. The absence of ultraviolet absorbance maxima shifts in the presence of sodium acetate confirmed that the synthesized products were 7-O-glucuronides. DG and GG were further purified by a Sephadex LH-20 column. DG and GG competed with the binding of 17beta-(3H) estradiol to estrogen receptors of B6D2F1 mouse uterine cytosol. The concentrations required for 50% displacement of 17beta-(3H) estradiol (CB50) were: 17beta-estradiol, 1.34 nmol/L; diethylstilbestrol, 1.46 nmol/L; daidzein, 1.6 micromol/L; DG, 14.7 micromol/L; genistein, 0.154 micromol/L; GG, 7.27 micromol/L. In human peripheral blood NK cells, genistein at &lt;0.5 micromol/L and DG and GG at 0.1-10 micromol/L enhanced NK cell-mediated K562 cancer cell killing significantly (P &lt; 0.05). At &gt; 0.5 micromol/L, genistein inhibited NK cytotoxicity significantly (P &lt; 0.05). The glucuronides only inhibited NK cytotoxicity at 50 micromol/L. Isoflavones, and especially the isoflavone glucuronides, enhanced activation of NK cells by interleukin-2 (IL-2), additively. At physiological concentrations, DG and GG were weakly estrogenic, and they activated human NK cells in nutritionally relevant concentrations in vitro, probably at a site different from IL-2 action.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food Science and Human Nutrition, Ames, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>T T</ForeName>
            <Initials>TT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cunnick</LastName>
            <ForeName>J E</ForeName>
            <Initials>JE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>P A</ForeName>
            <Initials>PA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hendrich</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nutr</MedlineTA>
        <NlmUniqueID>0404243</NlmUniqueID>
        <ISSNLinking>0022-3166</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004968">Estrogens, Non-Steroidal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005965">Glucuronates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6287WC5J2L</RegistryNumber>
          <NameOfSubstance UI="C004742">daidzein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DH2M523P0H</RegistryNumber>
          <NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004968" MajorTopicYN="N">Estrogens, Non-Steroidal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019833" MajorTopicYN="N">Genistein</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005965" MajorTopicYN="N">Glucuronates</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008862" MajorTopicYN="N">Microsomes, Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009747" MajorTopicYN="Y">Nutritional Physiological Phenomena</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051476</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model.</ArticleTitle>
        <Pagination>
          <MedlinePgn>746-55</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Oral tolerance is the induction of immunological hyporesponsiveness towards orally administered antigens. Tolerance initiation involves induction of anti-inflammatory (Th2) lymphocytes, with downregulation of pro-inflammatory (Th1) lymphocytes. The liver was previously shown to play a critical role in oral tolerance induction. The aim of the present study was to test whether liver-associated-lymphocytes expressing the NK1.1 marker (NK1.1+ LAL) are substantial for induction of oral tolerance in an experimental colitis model. Colitis was induced in C57 mice by intracolonic instillation of trinitrobenzensulfonic acid (TNBS). Mice received five oral doses of colonic proteins extracted from TNBS-colitis colonic wall. Anti-NK1.1 monoclonal antibodies were injected before tolerance induction. Colitis was assessed by standard clinical, macroscopic, and microscopic scores. Serum IFN-gamma, TGF-beta1, and IL4 levels were measured by enzyme-linked immunosorbent assay. To evaluate the role of NK1.1+ LAL in keeping the balance between immunogenic and tolerogenic subsets of cells, we tested whether peripheral lymphocytes harvested from tolerized and NK1.1-depleted nontolerized mice can adoptively transfer the tolerance into naive irradiated rats. Depletion of NK1.1+ LAL prevented immune tolerance induction in the experimental colitis model. NK1.1+ LAL-depleted nontolerized mice, disclosed severe clinical, macroscopic, and microscopic parameters of colitis. These mice had significantly lower TGF-beta1, IL4, and higher IFN-gamma serum levels, and their lymphocytes failed to transfer the tolerance into naive animals. In contrast, the feeding of colitis-extracted proteins, without NK1.1+ LAL depletion, markedly alleviated the disease. Tolerized mice had higher IL4 and TGF-beta1 and lower IFN-gamma serum levels, and adoptive transfer of their suppressor splenocytes markedly alleviated colitis in naive recipients. NK1.1+ LAL plays a critical role in oral tolerance induction. Depletion of this subset of LAL prevents a shift from Th1 to a Th2 type of immune response, hindering the ability to induce immune tolerance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Trop</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Unit, Division of Medicine, Hadassah University Hospital, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Samsonov</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gotsman</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alper</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diment</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ilan</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000941">Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>X</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051489</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Glucocorticoid receptor down-regulates c-Jun amino terminal kinases induced by tumor necrosis factor alpha in fetal rat hepatocyte primary cultures.</ArticleTitle>
        <Pagination>
          <MedlinePgn>849-57</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The effect of dexamethasone on Jun N-terminal kinase (JNK) activity was assayed by using fetal hepatocytes in primary culture. The addition of tumor necrosis factor alpha (TNF-alpha) caused an increase in JNK in a dose- and time-dependent manner. We show that activation of JNK by this extracellular signal is inhibited by dexamethasone in a dose-dependent fashion. This inhibitory effect was observed in cells treated for 10 minutes with dexamethasone in the presence of protein phosphatase inhibitors such as orthovanadate or okadaic acid, or in cells previously treated with actinomycin D. Glucocorticoid receptor (GR) can be precipitated with the fusion protein, GST-c-Jun (1-79), bound to agarose beads. However, the inhibitory effect of glucocorticoids on JNK activity was also observed using ATF-2 as substrate. In addition, dexamethasone inhibits JNK phosphorylation induced by TNF-alpha. Finally, we show that GR can also be phosphorylated in tyrosine residues in response to TNF-alpha and epidermal growth factor (EGF) upon ligand-binding. Our results suggest that the anti-inflammatory effect of glucocorticoids on the inflammatory pathways induced by TNF-alpha can be explained, at least in part, by modulating JNK activity through a direct protein-protein interaction; the JNK phosphorylation and tyrosine-phosphorylation state of GR may be regulatory steps also involved in that effect.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ventura</LastName>
            <ForeName>J J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Bioqu√≠mica y Biolog√≠a Molecular, Centro Mixto C.S. I.C./U.C.M., Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roncero</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fabregat</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benito</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016755">Proto-Oncogene Proteins c-jun</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1W21G5Q4N2</RegistryNumber>
          <NameOfSubstance UI="D019319">Okadaic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7S5I7G3JQL</RegistryNumber>
          <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.17</RegistryNumber>
          <NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.2</RegistryNumber>
          <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="Y">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004790" MajorTopicYN="N">Enzyme Induction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000196" MajorTopicYN="Y">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="Y">Mitogen-Activated Protein Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019319" MajorTopicYN="N">Okadaic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016755" MajorTopicYN="N">Proto-Oncogene Proteins c-jun</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011965" MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051501</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.</ArticleTitle>
        <Pagination>
          <MedlinePgn>939-45</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Recently, lamivudine used to treat patients with hepatitis B virus (HBV) infection was revealed to have potent antiviral activity. However, HBV resistance to lamivudine has been reported and shown to have amino acid substitutions in the methionine residue of the conserved tyrosine (Y), methionine (M), aspartate (D), aspartate (D) motif of RNA-dependent DNA polymerase. To explore the consequences of substitutions in this motif (YMDD), we made 7 variants by substituting the methionine of the YMDD motif with isoleucine (I), valine (V), alanine (A), leucine (L), lysine (K), arginine (R), and threonine (T). Replication ability of these variants was evaluated by transfection into human hepatoma cells. Sensitivity to lamivudine was tested for replication-competent variants. Four variants with hydrophobic substitutions (I, V, A, and L) remained replication-competent, whereas 3 others with hydrophilic substitutions (K, R, and T) exhibited impaired replication. Of the 4 replication-competent variants, 2 (I and V) were resistant, and 2 (A and L) were sensitive to lamivudine. Because the polymerase and the surface gene overlap, the introduction of these mutations affected the secretion of hepatitis B surface antigen (HBsAg), namely 4 variants (I, V, L, and R) secreted HBsAg, whereas 3 variants (A, K, and T) did not. Our study elucidated that only one amino acid substitution in the YMDD motif was sufficient to cause lamivudine resistance in vitro. As a result of replication competence and lamivudine sensitivity, only viruses having YIDD or YVDD sequences may appear during treatment with lamivudine. This in vitro system could be used to study HBV mutations, replication competence, and their susceptibility to antivirals.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ono-Nita</LastName>
            <ForeName>S K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shiratori</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masaki</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lan</LastName>
            <ForeName>K H</ForeName>
            <Initials>KH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carrilho</LastName>
            <ForeName>F J</ForeName>
            <Initials>FJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Omata</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2T8Q726O95</RegistryNumber>
          <NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30KYC7MIAI</RegistryNumber>
          <NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>42HK56048U</RegistryNumber>
          <NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AE28F7PNPL</RegistryNumber>
          <NameOfSubstance UI="D008715">Methionine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.7</RegistryNumber>
          <NameOfSubstance UI="D004259">DNA-Directed DNA Polymerase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>X</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004259" MajorTopicYN="N">DNA-Directed DNA Polymerase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051526</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0026-895X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>55</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pharmacology</Title>
          <ISOAbbreviation>Mol Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulation of alpha4beta2 nicotinic receptor desensitization by calcium and protein kinase C.</ArticleTitle>
        <Pagination>
          <MedlinePgn>432-43</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Neuronal nicotinic acetylcholine receptor (nAChR) desensitization is hypothesized to be a trigger for long-term changes in receptor number and function observed after chronic administration of nicotine at levels similar to those found in persons who use tobacco. Factors that regulate desensitization could potentially influence the outcome of long-lasting exposure to nicotine. The roles of Ca2+ and protein kinase C (PKC) on desensitization of alpha4beta2 nAChRs expressed in Xenopus laevis oocytes were investigated. Nicotine-induced (300 nM; 30 min) desensitization of alpha4beta2 receptors in the presence of Ca2+ developed in a biphasic manner with fast and slow exponential time constants of tauf = 1.4 min (65% relative amplitude) and taus = 17 min, respectively. Recovery from desensitization was reasonably well described by a single exponential with taurec = 43 min. Recovery was largely eliminated after replacement of external Ca2+ with Ba2+ and slowed by calphostin C (taurec = 48 min), an inhibitor of PKC. Conversely, the rate of recovery was enhanced by phorbol-12-myristate-13-acetate (taurec = 14 min), a PKC activator, or by cyclosporin A (with taurec = 8 min), a phosphatase inhibitor. alpha4beta2 receptors containing a mutant alpha4 subunit that lacks a consensus PKC phosphorylation site exhibited little recovery from desensitization. Based on a two-desensitized-state cyclical model, it is proposed that after prolonged nicotine treatment, alpha4beta2 nAChRs accumulate in a "deep" desensitized state, from which recovery is very slow. We suggest that PKC-dependent phosphorylation of alpha4 subunits changes the rates governing the transitions from "deep" to "shallow" desensitized conformations and effectively increases the overall rate of recovery from desensitization. Long-lasting dephosphorylation may underlie the "permanent" inactivation of alpha4beta2 receptors observed after chronic nicotine treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fenster</LastName>
            <ForeName>C P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurobiology, University of Alabama at Birmingham,USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beckman</LastName>
            <ForeName>M L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parker</LastName>
            <ForeName>J C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheffield</LastName>
            <ForeName>E B</ForeName>
            <Initials>EB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whitworth</LastName>
            <ForeName>T L</ForeName>
            <Initials>TL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quick</LastName>
            <ForeName>M W</ForeName>
            <Initials>MW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lester</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DA11940</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>NS31669</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Pharmacol</MedlineTA>
        <NlmUniqueID>0035623</NlmUniqueID>
        <ISSNLinking>0026-895X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105813">nicotinic acetylcholine receptor alpha4 subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.2</RegistryNumber>
          <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015290" MajorTopicYN="Y">Second Messenger Systems</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014982" MajorTopicYN="N">Xenopus laevis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051662</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2445-50</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Heme oxygenase (HO) catalyzes the conversion of heme to carbon monoxide, iron, and biliverdin, which is immediately reduced to bilirubin (BR). Two HO active isozymes exist: HO1, an inducible heat shock protein, and HO2, which is constitutive and highly concentrated in neurons. We demonstrate a neuroprotective role for BR formed from HO2. Neurotoxicity elicited by hydrogen peroxide in hippocampal and cortical neuronal cultures is prevented by the phorbol ester, phorbol 12-myristate 13-acetate (PMA) via stimulation of protein kinase C. We observe phosphorylation of HO2 through the protein kinase C pathway with enhancement of HO2 catalytic activity and accumulation of BR in neuronal cultures. The neuroprotective effects of PMA are prevented by the HO inhibitor tin protoporphyrin IX and in cultures from mice with deletion of HO2 gene. Moreover, BR, an antioxidant, is neuroprotective at nanomolar concentrations.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dor√©</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferris</LastName>
            <ForeName>C D</ForeName>
            <Initials>CD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zakhary</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hester</LastName>
            <ForeName>L D</ForeName>
            <Initials>LD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guastella</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snyder</LastName>
            <ForeName>S H</ForeName>
            <Initials>SH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K05 DA000074</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 DA000266</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DA-00074</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DA-00266</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D006419">Heme Oxygenase (Decyclizing)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C105245">heme oxygenase-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NI40JAQ945</RegistryNumber>
          <NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RFM9X3LJ49</RegistryNumber>
          <NameOfSubstance UI="D001663">Bilirubin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10944</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001663" MajorTopicYN="N">Bilirubin</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006419" MajorTopicYN="N">Heme Oxygenase (Decyclizing)</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10063323</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2006</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0391-1977</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Minerva endocrinologica</Title>
          <ISOAbbreviation>Minerva Endocrinol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Increased body mass index increase and insulin resistance parameters in dyslipidemia. Risk and positive correlation in essential obesity].</ArticleTitle>
        <Pagination>
          <MedlinePgn>65-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity is frequently characterized by hyperinsulinemia with insulin-resistance, tendency to impaired glucose tolerance and by impaired lipidic picture. The relationship existing between some obesity parameters i.e. BMI and weight excess (EP) regarding ideal weight calculated according Lorenz's formula and main parameters both of insulin-resistance and lipidic picture can be interesting.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">58 obese subject (10 M e 48 F) age 38 +/- 6.2 years (mean +/- DS) with BMI 34.3 +/- 5.3 and EP 33.7 +/- 15; they didn't suffer from hypertension and diabetes; they was subjected to an OGTT and evaluation of glycemia and insulinemia after 0', 60', 90', 120', 150', 180'. Moreover an assessment of lipidic state (cholesterol, triglyceride, HDL, LDL) was carried out. Glycemia and insulinemia with respective areas under curve (AUC glyc. e AUC ins.) and increases (AUCI glyc. e AUCI ins.) were compared with BMI and EP for searching relationship. The same was done for lipidic state.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">BMI was found positively related with glycemia after 0' (r = 0.3043, p &lt; 0.05) 60' (r = 0.3465, p &lt; 0.05) 120' (r = 0.2895, p &lt; 0.05) with AUC glyc. (r = 0411, p &lt; 0.01) and AUCI glyc. (r = 0.276, p &lt; 0.05), with insulinemia after 0' (r = 0.365, p &lt; 0.01) 60' (r = 0.350, p &lt; 0.01) and with AUC ins. (r = 0.272, p &lt; 0.05). HDL is negatively (r = -0.307, p &lt; 0.05) instead of triglyceride positive related (r = 0.338, p &lt; 0.05) with BMI. EP is positively related with glycemia after 0' (r = 0.376, p &lt; 0.01), 60' (r = 0.362, p &lt; 0.01), 120' (r = 0.290, p &lt; 0.05), with AUC glyc. (r = 0.422, p &lt; 0.01), with insulinemia after 0' (r = 0.512, p &lt; 0.01), 60' (r = 0.473, p &lt; 0.01) with AUC ins. (r = 0.420, p &lt; 0.01) and AUCI ins. (r = 0.354, p &lt; 0.01). Triglyceride was positively related (r = 0.365 p &lt; 0.01) with EP.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These relationships suggest that BMI and EP can be considered as indicators not only of obesity degree, but also of hyperinsulinemia and, to a lesser extent, dyslipidemia severity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Alberto</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Medicina Interna, Universit√† degli Studi, Torino.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Novi</LastName>
            <ForeName>R F</ForeName>
            <Initials>RF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maurino</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trombetta</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molinatti</LastName>
            <ForeName>G M</ForeName>
            <Initials>GM</Initials>
          </Author>
        </AuthorList>
        <Language>ita</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Aumento del BMI e parametri di insulino-resistenza e di dislipidemia. Riscontro di correlazioni positive nell'obesit√† essenziale.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Minerva Endocrinol</MedlineTA>
        <NlmUniqueID>8406505</NlmUniqueID>
        <ISSNLinking>0391-1977</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064818</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-8993</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>821</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain research</Title>
          <ISOAbbreviation>Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Distinct distribution and time-course changes in neuronal nitric oxide synthase and inducible NOS in the paraventricular nucleus following lipopolysaccharide injection.</ArticleTitle>
        <Pagination>
          <MedlinePgn>322-32</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Nitric oxide (NO) is known to be involved in the modulation of neuroendocrine function. To clarify the role of different isoforms of NO synthase (NOS) in the neuroendocrine response to immune challenge, the expressions of neuronal NOS (nNOS) and inducible NOS (iNOS) genes in the hypothalamus following lipopolysaccharide (LPS) injection were examined using in situ hybridization. NOS activity was also determined by NADPH-diaphorase (NADPH-d) histochemistry. LPS (25 mg/kg) or sterile saline was injected intraperitoneally to male Wistar rats and the rats sacrificed 30 min, or 1, 2, 3, 5, 12 or 24 h after injection. nNOS mRNA expression in the paraventricular nucleus (PVN) was significantly increased 2 h after LPS injection. iNOS mRNA, which was not detected until 2 h after LPS injection, was significantly increased in the PVN 3 h after LPS injection. Both RNA expressions had returned to basal levels by 12 h after LPS injection. The number of NADPH-d positive cells was significantly increased 5 h after LPS injection. iNOS expression was more robust in parvocellular PVN, while nNOS was distributed mainly in the magnocellular PVN. Double in situ hybridization histochemistry revealed that some of the iNOS- (48.4%) or nNOS-positive cells (34. 3%) in the parvocellular PVN expressed CRF mRNA. The results demonstrate that LPS-induced sepsis causes significant increases in nNOS and iNOS gene expression with different time-courses and distributions, and that iNOS mRNA was more frequently co-localized with CRF-producing parvocellular neurons in the PVN. Thus, NO produced by iNOS and nNOS may play an important role in the neuroendocrine response to an immune challenge. Distinct differences in the distribution and time-course changes of iNOS and nNOS suggest different roles for the hypothalamic-pituitary-adrenal axis and/or neurohypophyseal system.</AbstractText>
          <CopyrightInformation>Copyright 1999 Elsevier Science B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Harada</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imaki</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chikada</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naruse</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demura</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Brain Res</MedlineTA>
        <NlmUniqueID>0045503</NlmUniqueID>
        <ISSNLinking>0006-8993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006982">Hypertonic Solutions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>451W47IQ8X</RegistryNumber>
          <NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9015-71-8</RegistryNumber>
          <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D052248">Nitric Oxide Synthase Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="C496322">Nos1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="C496318">Nos2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.99.1</RegistryNumber>
          <NameOfSubstance UI="D009252">NADPH Dehydrogenase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006982" MajorTopicYN="N">Hypertonic Solutions</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009252" MajorTopicYN="N">NADPH Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052248" MajorTopicYN="N">Nitric Oxide Synthase Type I</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010286" MajorTopicYN="N">Paraventricular Hypothalamic Nucleus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012965" MajorTopicYN="N">Sodium Chloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10053</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>01</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-8993</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>116</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Nov</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain research</Title>
          <ISOAbbreviation>Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alterations of brain neurotransmitter receptor binding in Huntington's chorea.</ArticleTitle>
        <Pagination>
          <MedlinePgn>531-7</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Enna</LastName>
            <ForeName>S J</ForeName>
            <Initials>SJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bennett</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
            <Suffix>Jr</Suffix>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bylund</LastName>
            <ForeName>D B</ForeName>
            <Initials>DB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snyder</LastName>
            <ForeName>S H</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bird</LastName>
            <ForeName>E D</ForeName>
            <Initials>ED</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iversen</LastName>
            <ForeName>L L</ForeName>
            <Initials>LL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Brain Res</MedlineTA>
        <NlmUniqueID>0045503</NlmUniqueID>
        <ISSNLinking>0006-8993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.1.6</RegistryNumber>
          <NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.1.1.15</RegistryNumber>
          <NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011950" MajorTopicYN="N">Receptors, Cholinergic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">100141</PMID>
      <DateCompleted>
        <Year>1978</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-3002</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>530</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1978</Year>
              <Month>Sep</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta</Title>
          <ISOAbbreviation>Biochim Biophys Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development of glycogen and phospholipid metabolism in fetal and newborn rat lung.</ArticleTitle>
        <Pagination>
          <MedlinePgn>333-46</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Glucose, a major metabolic substrate for the mammalian fetus, probably makes significant contributions to surface active phospholipid synthesis in adult lung. We examined the developmental patterns of glycogen content, glycogen synthase activity, glycogen phosphorylase activity and glucose oxidation in fetal and newborn rat lung. These patterns were correlated with the development of phosphatidylcholine synthesis, content and the activities of enzymes involved in phosphatidylcholine synthesis. Fetal lung glycogen concentration increased until day 20 of gestation (term is 22 days) after which it declined to low levels. Activity of both glycogen synthase I and total glycogen synthase (I + D) in fetal lung increased late in gestation. Increased lung glycogen concentration preceded changes in enzyme activity. Glycogen phosphorylase a and total glycogen phosphorylase (a + b) activity in fetal lung increased during the period of prenatal glycogen depletion. The activity of the pentose phosphate pathway, as measured by the ratio of CO2 derived from oxidation of C1 and C6 of glucose, declined after birth. Fetal lung total phospholipid, phosphatidycholine and disaturated phosphatidylcholine content increased by 60, 90 and 180%, respectively, between day 19 of gestation and the first postnatal day. Incorporation of choline into phosphatidylcholine and disaturated phosphatidylcholine increased 10-fold during this time. No changes in phosphatidylcholine enzyme activities were noted during gestation, but both choline phosphate cytidylyltransferase and phosphatidate phosphatase activity increased after birth. The possible contributions of carbohydrate derived from fetal lung glycogen to phospholipid synthesis are discussed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maniscalco</LastName>
            <ForeName>W M</ForeName>
            <Initials>WM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>C M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gross</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gobran</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rooney</LastName>
            <ForeName>S A</ForeName>
            <Initials>SA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Warshaw</LastName>
            <ForeName>J B</ForeName>
            <Initials>JB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta</MedlineTA>
        <NlmUniqueID>0217513</NlmUniqueID>
        <ISSNLinking>0006-3002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-79-2</RegistryNumber>
          <NameOfSubstance UI="D006003">Glycogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.1.-</RegistryNumber>
          <NameOfSubstance UI="D006005">Phosphorylases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.1.11</RegistryNumber>
          <NameOfSubstance UI="D006006">Glycogen Synthase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N91BDP6H0X</RegistryNumber>
          <NameOfSubstance UI="D002794">Choline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006006" MajorTopicYN="N">Glycogen Synthase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010713" MajorTopicYN="N">Phosphatidylcholines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006005" MajorTopicYN="N">Phosphorylases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1000302</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-8993</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>118</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Dec</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain research</Title>
          <ISOAbbreviation>Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evidence on the cellular localization of adenyl cyclase in the neostriatum.</ArticleTitle>
        <Pagination>
          <MedlinePgn>356-8</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McGeer</LastName>
            <ForeName>E G</ForeName>
            <Initials>EG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Innanen</LastName>
            <ForeName>V T</ForeName>
            <Initials>VT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McGeer</LastName>
            <ForeName>P L</ForeName>
            <Initials>PL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Brain Res</MedlineTA>
        <NlmUniqueID>0045503</NlmUniqueID>
        <ISSNLinking>0006-8993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 4.6.1.1</RegistryNumber>
          <NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1001807</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0303-7207</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular and cellular endocrinology</Title>
          <ISOAbbreviation>Mol Cell Endocrinol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interactions of glucagon and fructose in the control of glycogenolysis in perfused rat liver.</ArticleTitle>
        <Pagination>
          <MedlinePgn>47-58</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>By measuring the specific radioactivity of glucose released from isolated perfused livers of normal, fed rats in the presence of [U-14C]fructose, the gluconeogenetic and glycogenolytic contributions to glucose production were estimated. After 20 min of perfusion with 4 mM fructose, glycogenolysis was inhibited by 40% in the absence and by 70% in the presence of glucagon (3 nM). Glucagon decreased the release of lactate plus pyruvate and enhanced glucose formation from fructose without affecting its uptake. Glycerol (4 mM) and xylitol (3 mM) had qualitatively similar, but smaller effects on glucagon-stimulated glycogenolysis. The glucagon-mediated phosphorylase b to a conversion was not altered by fructose, indicating that glycogenolysis was decreased as a consequence of an inhibition of phosphorylase a. During the first minutes after the addition of fructose, decreased ATP/AMP ratios and tissue Pi levels correlated with a transient increase of phosphorylase a activity. It was concluded that the effects of fructose on the control of hepatic glycogenolysis and glucose production were the result of a complex interplay between a transient b to a conversion of phosphorylase and an inhibition of the a-form of the enzyme, possibly by fructose 1-phosphate and other phosphorylated metabolites.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jakob</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Mol Cell Endocrinol</MedlineTA>
        <NlmUniqueID>7500844</NlmUniqueID>
        <ISSNLinking>0303-7207</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008112">Liver Glycogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30237-26-4</RegistryNumber>
          <NameOfSubstance UI="D005632">Fructose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-92-5</RegistryNumber>
          <NameOfSubstance UI="D005934">Glucagon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005632" MajorTopicYN="N">Fructose</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008112" MajorTopicYN="N">Liver Glycogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1001463</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-5793</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>72</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Dec</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>FEBS letters</Title>
          <ISOAbbreviation>FEBS Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Primary structure of the casein macropeptide of porcine and human kappa caseins].</ArticleTitle>
        <Pagination>
          <MedlinePgn>173-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The amino acid sequence of porcine and human caseinomacropeptides (CMP), the C-terminal glycopeptide released from kappa-casein by chymosin at the initial step of milk coagulation, have been investigated. The complete amino acid sequence of porcine CMP and that of the first 59 amino acid residues of human CMP have been determined. Porcine and human CMPs contain 71 and likely 65 amino acid residues respectively. The extra hexapeptide 38-43 found in porcine CMP arises obviously from the duplication of the DNA fragment coding for the 6 preceding amino acids.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chobert</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mercier</LastName>
            <ForeName>J C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bahy</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haz√©</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>fre</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Structure primaire du cas√©inomacropeptide des cas√©ines kappa porcine et humaine</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>FEBS Lett</MedlineTA>
        <NlmUniqueID>0155157</NlmUniqueID>
        <ISSNLinking>0014-5793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002364">Caseins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002364" MajorTopicYN="Y">Caseins</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008892" MajorTopicYN="N">Milk</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008895" MajorTopicYN="N">Milk, Human</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1002006</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0301-0147</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1976</Year>
            </PubDate>
          </JournalIssue>
          <Title>Haemostasis</Title>
          <ISOAbbreviation>Haemostasis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dose-dependent influence of acetylsalicyclic acid on platelet functions and plasmatic coagulation factors.</ArticleTitle>
        <Pagination>
          <MedlinePgn>239-49</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Lysine salt of acetylsalicylic acid (ASA) was given to ten patients by intravenous infusion. Blood samples taken at intervals during the infusion permitted the examination of the influence of the dose of ASA on platelet functions. Aggregation was significantly reduced when 50 mg ASA had entered circulation, while a diminution of PF3 and PF4 availability could only be demonstrated when the dose had reached 500 and 200 mg, respectively. In order to exclude a longer latency time for the diminution of PF3 and pf4 availability, a second series of ten patients received intravenous injections of 100 and 300 mg ASA, respectively. From these patients, blood was taken 1 h after the injection. The decrease of PF3 and PF4 availability in these cases was comparable to the results of the first group. In a third series of patients, a daily intravenous dose of 2,000 mg ASA was given. In these cases, a moderate decrease of factors II, VII, IX and X was observed. Since the appearance of a PIVKA effect could also be demonstrated, vitamin K antagonism was assumed when a high dose of AS</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Loew</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vinazzer</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Haemostasis</MedlineTA>
        <NlmUniqueID>0371574</NlmUniqueID>
        <ISSNLinking>0301-0147</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>37270-93-2</RegistryNumber>
          <NameOfSubstance UI="D010977">Platelet Factor 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37270-94-3</RegistryNumber>
          <NameOfSubstance UI="D010978">Platelet Factor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9001-25-6</RegistryNumber>
          <NameOfSubstance UI="D005167">Factor VII</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9001-26-7</RegistryNumber>
          <NameOfSubstance UI="D011516">Prothrombin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9001-28-9</RegistryNumber>
          <NameOfSubstance UI="D005164">Factor IX</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9001-29-0</RegistryNumber>
          <NameOfSubstance UI="D005170">Factor X</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R16CO5Y76E</RegistryNumber>
          <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005164" MajorTopicYN="N">Factor IX</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005167" MajorTopicYN="N">Factor VII</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005170" MajorTopicYN="N">Factor X</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010974" MajorTopicYN="N">Platelet Aggregation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010977" MajorTopicYN="N">Platelet Factor 3</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010978" MajorTopicYN="N">Platelet Factor 4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011516" MajorTopicYN="N">Prothrombin</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1000781</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0009-7330</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>39</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Circulation research</Title>
          <ISOAbbreviation>Circ Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Stimulation of renin release from rabbit renal cortex by arachidonic acid and prostaglandin endoperoxides.</ArticleTitle>
        <Pagination>
          <MedlinePgn>868-74</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The mechanism by which renal prostaglandins stimulate renin secretion in vivo is unknown. In this in vitro study we measured the effects of activation of the prostaglandin (PG) system on renin release from slices of rabbit renal cortex. The PG precursor arachidonic acid (C20:4), a natural PG endoperoxide (PGG2), two stable synthetic PG endoperoxide analogues (EPA I and II), PGE2, PGF2alpha, and two different PG synthesis inhibitors [indomethacin and 5,8,11,14-eicosatetraynoic acid (ETA)] were used to evaluate the possibility of a direct action of the cortical PG system on renin secretion. Renin release increased significantly with time after addition of C20:4, PGG2, EPA I, and EPA II to the incubation medium. Stimulation of renin release was se-related for C20:4 in concentrations of 0.6 to 4.5 X 10(-6) M, for EPA I in concentrations of 0.7 to 2.8 X 10(-6) M, and for EPA II in concentrations of 1.4 to 14.0 X 10(-6) M. Indomethacin (10(-4) M) and ETA (10(-4) M) significantly decreased basal renin release as well as the renin release stimulated by C20:4 and EPA I. PGE2(10(-12) to 10(-6) M) had no effect on renin release, whereas PGF2alpha (10(-12) to 10(-6) M) decreased renin release in a dose-dependent manner. These data raise the possibility of a direct action of the renal cortical PG system on renin secretion. The results further indicate that stimulation of renin release by C20:4 may depend more specifically on the action of PG endoperoxides than on the primary prostaglandins.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Webber</LastName>
            <ForeName>P C</ForeName>
            <Initials>PC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larsson</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anggard</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamberg</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corey</LastName>
            <ForeName>E J</ForeName>
            <Initials>EJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicolaou</LastName>
            <ForeName>K C</ForeName>
            <Initials>KC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Samuelsson</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circ Res</MedlineTA>
        <NlmUniqueID>0047103</NlmUniqueID>
        <ISSNLinking>0009-7330</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001095">Arachidonic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011453">Prostaglandins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011458">Prostaglandins E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011460">Prostaglandins F</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1191-85-1</RegistryNumber>
          <NameOfSubstance UI="D015117">5,8,11,14-Eicosatetraynoic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.-</RegistryNumber>
          <NameOfSubstance UI="D010544">Peroxidases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.23.15</RegistryNumber>
          <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XXE1CET956</RegistryNumber>
          <NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015117" MajorTopicYN="N">5,8,11,14-Eicosatetraynoic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001095" MajorTopicYN="N">Arachidonic Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007672" MajorTopicYN="N">Kidney Cortex</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010544" MajorTopicYN="N">Peroxidases</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011453" MajorTopicYN="N">Prostaglandins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011458" MajorTopicYN="N">Prostaglandins E</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011460" MajorTopicYN="N">Prostaglandins F</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1000779</PMID>
      <DateCompleted>
        <Year>1977</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0009-7330</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>39</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1976</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Circulation research</Title>
          <ISOAbbreviation>Circ Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intrarenal site of action of calcium on renin secretion in dogs.</ArticleTitle>
        <Pagination>
          <MedlinePgn>847-53</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We studied the effects of intrarenal calcium infusion on renin secretion in sodium-depleted dogs in an attempt to elucidate the major site of calcium-induced inhibition of renin release. Both calcium chloride and calcium gluconate reduced renal blood flow and renin secretion while renal perfusion pressure was unchanged. These data indicate that calcium inhibition of renin secretion did not occur primarily at the renal vascular receptor; decreased renal blood flow is usually associated with increased renin secretion. Calcium chloride infusion increased urinary chloride excretion without affecting sodium excretion, and calcium gluconate failed to increase either sodium or chloride excretion. Also, the filtered loads of sodium and chloride were unchanged during the calcium infusions. These results give no indication that calcium inhibited renin secretion by increasing the sodium or chloride load at the macula densa. The effects of intrarenal calcium infusion on renin release were also assessed in dogs with a nonfiltering kidney in which renal tubular mechanisms could not influence renin secretion. The observation that calcium still suppressed renin release in these dogs provides additional evidence that the the major effect of calcium involved nontubular mechanisms. Thus, it appears likely that calcium acted directly on the juxtaglomerular cells to inhibit renin secretion.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Watkins</LastName>
            <ForeName>B E</ForeName>
            <Initials>BE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davis</LastName>
            <ForeName>J O</ForeName>
            <Initials>JO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lohmeier</LastName>
            <ForeName>T E</ForeName>
            <Initials>TE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freeman</LastName>
            <ForeName>R H</ForeName>
            <Initials>RH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circ Res</MedlineTA>
        <NlmUniqueID>0047103</NlmUniqueID>
        <ISSNLinking>0009-7330</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002712">Chlorides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004573">Electrolytes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005942">Gluconates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NEZ333N27</RegistryNumber>
          <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.23.15</RegistryNumber>
          <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M4I0D6VV5M</RegistryNumber>
          <NameOfSubstance UI="D002122">Calcium Chloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002122" MajorTopicYN="N">Calcium Chloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002712" MajorTopicYN="N">Chlorides</DescriptorName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004573" MajorTopicYN="N">Electrolytes</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005942" MajorTopicYN="N">Gluconates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007606" MajorTopicYN="N">Juxtaglomerular Apparatus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">10016792</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0556-2821</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>49</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1994</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Physical review. D, Particles and fields</Title>
          <ISOAbbreviation>Phys Rev D Part Fields</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Production of chi charmonium via 300-GeV/c pion and proton interactions on a lithium target.</ArticleTitle>
        <Pagination>
          <MedlinePgn>543-546</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Antoniazzi</LastName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arenton</LastName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conetti</LastName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cox</LastName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delchamps</LastName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fortney</LastName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guffey</LastName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haire</LastName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ioannou</LastName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jenkins</LastName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Judd</LastName>
            <Initials>DJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kourkoumelis</LastName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manousakis-Katsikakis</LastName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuzminski</LastName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>LeCompte</LastName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchionni</LastName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazur</LastName>
            <Initials>PO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <Initials>CT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pramantiotis</LastName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rameika</LastName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Resvanis</LastName>
            <Initials>LK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosati</LastName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosen</LastName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simard</LastName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <Initials>RP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spiegel</LastName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stairs</LastName>
            <Initials>DG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tesarek</LastName>
            <Initials>RJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turkington</LastName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turnbull</LastName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turkot</LastName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tzamarias</LastName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voulgaris</LastName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wagoner</LastName>
            <Initials>DE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zioulas</LastName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <Initials>B</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Phys Rev D Part Fields</MedlineTA>
        <NlmUniqueID>0242621</NlmUniqueID>
        <ISSNLinking>0556-2821</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">10012221</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0556-2821</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>41</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1990</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Physical review. D, Particles and fields</Title>
          <ISOAbbreviation>Phys Rev D Part Fields</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signature for nu tau interactions in a high-energy proton-beam-dump experiment.</ArticleTitle>
        <Pagination>
          <MedlinePgn>322-324</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Loverre</LastName>
            <Initials>PF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Phys Rev D Part Fields</MedlineTA>
        <NlmUniqueID>0242621</NlmUniqueID>
        <ISSNLinking>0556-2821</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022128</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2008</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0950-9232</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncogene</Title>
          <ISOAbbreviation>Oncogene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1219-26</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The telomerase reverse transcriptase component (TERT) is not expressed in most primary somatic human cells and tissues, but is upregulated in the majority of immortalized cell lines and tumors. Here, we identify the c-Myc transcription factor as a direct mediator of telomerase activation in primary human fibroblasts through its ability to specifically induce TERT gene expression. Through the use of a hormone inducible form of c-Myc (c-Myc-ER), we demonstrate that Myc-induced activation of the hTERT promoter requires an evolutionarily conserved E-box and that c-Myc-ER-induced accumulation of hTERT mRNA takes place in the absence of de novo protein synthesis. These findings demonstrate that the TERT gene is a direct transcriptional target of c-Myc. Since telomerase activation frequently correlates with immortalization and telomerase functions to stabilize telomers in cycling cells, we tested whether Myc-induced activation of TERT gene expression represents an important mechanism through which c-Myc acts to immortalize cells. Employing the rat embryo fibroblast cooperation assay, we show that TERT is unable to substitute for c-Myc in the transformation of primary rodent fibroblasts, suggesting that the transforming activities of Myc extend beyond its ability to activate TERT gene expression and hence telomerase activity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Greenberg</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Hagan</LastName>
            <ForeName>R C</ForeName>
            <Initials>RC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Q</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hann</LastName>
            <ForeName>S R</ForeName>
            <Initials>SR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adams</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lichtsteiner</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chin</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morin</LastName>
            <ForeName>G B</ForeName>
            <Initials>GB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>DePinho</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF121948</AccessionNumber>
              <AccessionNumber>AF121949</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="N">
          <Grant>
            <GrantID>5T32GM07491</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01EY09300</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01HD28317</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Oncogene</MedlineTA>
        <NlmUniqueID>8711562</NlmUniqueID>
        <ISSNLinking>0950-9232</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C422952">telomerase RNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63231-63-0</RegistryNumber>
          <NameOfSubstance UI="D012313">RNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.49</RegistryNumber>
          <NameOfSubstance UI="D012194">RNA-Directed DNA Polymerase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.49</RegistryNumber>
          <NameOfSubstance UI="C509186">TERT protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.49</RegistryNumber>
          <NameOfSubstance UI="D019098">Telomerase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.49</RegistryNumber>
          <NameOfSubstance UI="C509187">Tert protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.8</RegistryNumber>
          <NameOfSubstance UI="C106400">ILPA protein, Aeromonas hydrophila</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.8</RegistryNumber>
          <NameOfSubstance UI="D019696">Peptidylprolyl Isomerase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="Y">Cell Transformation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019696" MajorTopicYN="Y">Peptidylprolyl Isomerase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016271" MajorTopicYN="N">Proto-Oncogene Proteins c-myc</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012313" MajorTopicYN="Y">RNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012194" MajorTopicYN="N">RNA-Directed DNA Polymerase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019098" MajorTopicYN="N">Telomerase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10028446</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1078-0998</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Inflammatory bowel diseases</Title>
          <ISOAbbreviation>Inflamm Bowel Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Abnormalities in mucin gene expression in Crohn's disease.</ArticleTitle>
        <Pagination>
          <MedlinePgn>24-32</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Alterations in the structure and/or quantity of mucins could alter the barrier function of mucus and play a role in initiating and maintaining mucosal inflammation in Crohn's disease. To investigate the hypothesis of a mucin gene defect in Crohn's disease, we analyzed the expression of the different mucin genes in the ileal mucosa of patients with Crohn's disease and controls. mRNA expression levels were assessed by a quantitative dot blot analysis and compared (i) between healthy and involved ileal mucosa of patients with Crohn's disease and (ii) between healthy mucosa of patients with Crohn's disease and controls. Expression of the different mucin genes was heterogeneous among controls and patients with Crohn's disease, except for MUC6 in controls. Nevertheless, MUC1 mRNA expression was significantly decreased in the involved ileal mucosa of patients with Crohn's disease when compared to the healthy mucosa (p = 0.02). Moreover, the expression levels of MUC3, MUC4, and MUC5B were significantly lower in both healthy and involved ileal mucosa of patients with Crohn's disease compared to controls (p &lt; or = 0.05). The decrease of expression levels of some mucin genes (more particularly MUC3, MUC4, and MUC5B) in both healthy and involved ileal mucosa suggests a primary or very early mucosal defect of these genes in CD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Buisine</LastName>
            <ForeName>M P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratoire de Biochimie et Biologie Mol√©culaire, H√¥pital C. Huriez, CH&amp;U Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desreumaux</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Debailleul</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gambiez</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geboes</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ectors</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delescaut</LastName>
            <ForeName>M P</ForeName>
            <Initials>MP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Degand</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aubert</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colombel</LastName>
            <ForeName>J F</ForeName>
            <Initials>JF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Porchet</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Inflamm Bowel Dis</MedlineTA>
        <NlmUniqueID>9508162</NlmUniqueID>
        <ISSNLinking>1078-0998</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009077">Mucins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001707" MajorTopicYN="N">Biopsy, Needle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007082" MajorTopicYN="N">Ileum</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009077" MajorTopicYN="N">Mucins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022233</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0378-4274</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>102-103</Volume>
            <PubDate>
              <Year>1998</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxicology letters</Title>
          <ISOAbbreviation>Toxicol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds.</ArticleTitle>
        <Pagination>
          <MedlinePgn>59-63</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Immune modulation by cannabinoids has been widely established over the past three decades. In spite of this, the mechanism of action responsible for immune modulation and other well described biological effects attributed to cannabinoid compounds has been elusive. The identification and cloning of two novel G protein coupled receptors, CB1 and CB2, both of which bind cannabimimetic agents has served as the basis for a putative mechanism of action. CB1, which is also referred to as the central cannabinoid receptor is the primary form expressed within the central nervous system (CNS). Conversely, the peripheral cannabinoid receptor, CB2, does not appear to be expressed within the CNS but is the predominant form of the receptor expressed within the immune system. Both CB1 and CB2 negatively regulate adenylate cyclase activity through a pertussis toxin sensitive GTP-binding protein. Recent investigations addressing the mechanism by which cannabinoids disrupt leukocyte function have demonstrated that in the presence of cannabinoids the cAMP signaling cascade is markedly inhibited as evidenced by decreased adenylate cyclase and protein kinase A activity and decreased DNA binding by cAMP response element binding proteins. The focus of this discussion will be on the effects cannabinoids elicit on events within the cAMP cascade and related signaling pathways critical to the regulation of cytokine genes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kaminski</LastName>
            <ForeName>N E</ForeName>
            <Initials>NE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DA07908</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Toxicol Lett</MedlineTA>
        <NlmUniqueID>7709027</NlmUniqueID>
        <ISSNLinking>0378-4274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043882">Receptors, Cannabinoid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002186" MajorTopicYN="N">Cannabinoids</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043882" MajorTopicYN="N">Receptors, Cannabinoid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011955" MajorTopicYN="N">Receptors, Drug</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>26</NumberOfReferences>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023669</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0950-9232</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncogene</Title>
          <ISOAbbreviation>Oncogene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.</ArticleTitle>
        <Pagination>
          <MedlinePgn>935-41</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The PML protein is associated to nuclear bodies (NBs) whose functions are as yet unknown. PML and two other NBs-associated proteins, Sp100 And ISG20 are directly induced by interferons (IFN). PML and Sp100 proteins are covalently linked to SUMO-1, and ubiquitin-like peptide. PML NBs are disorganized in acute promyelocytic leukemia and during several DNA virus infections. In particular, the HSV-1 ICP0 protein is known to delocalize PML from NBs. Thus, NBs could play an important role in oncogenesis, IFN response and viral infections. Here, we show that HSV-1 induced PML protein degradation without altering its mRNA level. This degradation was time- and multiplicity of infection-dependent. Sp100 protein was also degraded, while another SUMO-1 conjugated protein, RanGAP1 and the IFN-induced protein kinase PKR were not. The proteasome inhibitor MG132 abrogated the HSV-1-induced PML and Sp100 degradation and partially restored their NB-localization. HSV-1 induced PML and Sp100 degradation constitutes a new example of viral inactivation of IFN target gene products.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chelbi-Alix</LastName>
            <ForeName>M K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Centre National de la Recherche Scientifique Unit√© Propre de Recherche 9051, Laboratoire associ√© au Comit√© de Paris de la Ligue Contre le Cancer, Institut Universitaire d'H√©matologie de l'universit√© de Paris VII, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Th√©</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Oncogene</MedlineTA>
        <NlmUniqueID>8711562</NlmUniqueID>
        <ISSNLinking>0950-9232</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034961">Antigens, Nuclear</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007976">Leupeptins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071156">Promyelocytic Leukemia Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C092317">RANGAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025842">SUMO-1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>135844-47-2</RegistryNumber>
          <NameOfSubstance UI="C066642">Sp100 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>143220-95-5</RegistryNumber>
          <NameOfSubstance UI="C070576">PML protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9008-11-1</RegistryNumber>
          <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.-</RegistryNumber>
          <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RF1P63GW3K</RegistryNumber>
          <NameOfSubstance UI="C072553">benzyloxycarbonylleucyl-leucyl-leucine aldehyde</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D034961" MajorTopicYN="Y">Antigens, Nuclear</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020690" MajorTopicYN="Y">GTPase-Activating Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006561" MajorTopicYN="N">Herpes Simplex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018259" MajorTopicYN="Y">Herpesvirus 1, Human</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007976" MajorTopicYN="N">Leupeptins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071156" MajorTopicYN="N">Promyelocytic Leukemia Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025842" MajorTopicYN="N">SUMO-1 Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10023677</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2008</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0950-9232</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncogene</Title>
          <ISOAbbreviation>Oncogene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1015-22</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identified in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To define the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, a potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Uchida</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Aspects of Hematopoiesis, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Downing</LastName>
            <ForeName>J R</ForeName>
            <Initials>JR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyazaki</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frank</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nimer</LastName>
            <ForeName>S D</ForeName>
            <Initials>SD</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA 70388</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK 52208</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK43025</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Oncogene</MedlineTA>
        <NlmUniqueID>8711562</NlmUniqueID>
        <ISSNLinking>0950-9232</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050676">Core Binding Factor Alpha 2 Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007377">Interleukin-3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C102421">TEL-AML1 fusion protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050676" MajorTopicYN="N">Core Binding Factor Alpha 2 Subunit</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007377" MajorTopicYN="N">Interleukin-3</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015514" MajorTopicYN="Y">Oncogene Proteins, Fusion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014178" MajorTopicYN="Y">Translocation, Genetic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022458</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-972X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>84</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.</ArticleTitle>
        <Pagination>
          <MedlinePgn>805-10</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We have characterized two different mutations of the human androgen receptor (hAR) found in two unrelated subjects with androgen insensitivity syndrome (AIS): in one, the external genitalia were ambiguous (partial, PAIS); in the other, they were male, but small (mild, MAIS). Single base substitutions have been found in both individuals: E772A in the PAIS subject, and R871G in the MAIS patient. In COS-1 cells transfected with the E772A and R871G hARs, the apparent equilibrium dissociation constants (Kd) for mibolerone (MB) and methyltrienolone are normal. Nonetheless, the mutant hAR from the PAIS subject (E772A) has elevated nonequilibrium dissociation rate constants (k(diss)) for both androgens. In contrast, the MAIS subject's hAR (R871G) has k(diss) values that are apparently normal for MB and methyltrienolone; in addition, the R871G hAR's ability to bind MB resists thermal stress better than the hAR from the PAIS subject. The E772A and R871G hARs, therefore, confer the same pattern of discordant androgen-binding parameters in transfected COS-1 cells as observed previously in the subjects' genital skin fibroblasts. This proves their pathogenicity and correlates with the relative severity of the clinical phenotype. In COS-1 cells transfected with an androgen-responsive reporter gene, trans-activation was 50% of normal in cells containing either mutant hAR. However, mutant hAR-MB binding is unstable during prolonged incubation with MB, whereas normal hAR-MB binding increases. Thus, normal equilibrium dissociation constants alone, as determined by Scatchard analysis, may not be indicative of normal hAR function. An increased k(diss) despite a normal Kd for a given androgen suggests that it not only has increased egress from a mutant ligand-binding pocket, but also increased access to it. This hypothesis has certain implications in terms of the three-dimensional model of the ligand-binding domain of the nuclear receptor superfamily.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shkolny</LastName>
            <ForeName>D L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Lady Davis Institute for Medical Research, Sir M. B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beitel</LastName>
            <ForeName>L K</ForeName>
            <Initials>LK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ginsberg</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pekeles</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arbour</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinsky</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trifiro</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000728">Androgens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045165">Testosterone Congeners</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2C323EGI97</RegistryNumber>
          <NameOfSubstance UI="D015741">Metribolone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6PG9VR430D</RegistryNumber>
          <NameOfSubstance UI="D009277">Nandrolone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9OGY4BOR8D</RegistryNumber>
          <NameOfSubstance UI="C100075">mibolerone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013734" MajorTopicYN="N">Androgen-Insensitivity Syndrome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015741" MajorTopicYN="N">Metribolone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009277" MajorTopicYN="N">Nandrolone</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045165" MajorTopicYN="N">Testosterone Congeners</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022454</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-972X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>84</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors.</ArticleTitle>
        <Pagination>
          <MedlinePgn>786-94</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Pituitary adenomas cause clinical manifestations because of mass effects and excess hormone production. This group of tumors represents a tractable target for gene therapy because they are rarely metastatic and because reductions in tumor size and function, in addition to those achieved after surgery, may be of clinical benefit. In this report we describe a strategy for targeting the expression of toxic genes to pituitary cells using adenoviral vectors. Pituitary hormone promoters (human GH or glycoprotein hormone alpha-subunit) were used to express either a marker gene [beta-galactosidase (beta-gal)] or a toxic gene [herpes simplex virus thymidine kinase (TK)]. In GH-producing GH3 cells and in alpha-subunit-producing pituitary tumor cell lines, recombinant adenoviruses containing either the alpha-subunit promoter (Ad alpha Gal; AdaTK) or the GH promoter (AdGHGal; AdGHTK) were expressed at-high levels. Using histological studies and assays for beta-gal activity, expression was shown to persist for at least 21 days, and it was relatively selective for pituitary cell lines. Cytotoxicity studies were performed using the TK-containing vectors and treatment with ganciclovir. Both AdGHTK and AdaTK caused greater than 95% cytotoxicity of GH3 and alphaT3 cells, respectively, at a viral dose (multiplicity of infection, 5 plaque-forming units/cell) that induced minimal toxicity using control viruses. Little cellular toxicity was seen using a nonpituitary cell line (T47D breast tumor cells). The AdGHTK virus also caused marked reduction in the size of GH3 cell tumors that were propagated in nude mice. These studies suggest that adenoviral vectors carrying human pituitary gland specific promoters may be useful for developing gene therapy strategies for the treatment of pituitary adenomas.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>E J</ForeName>
            <Initials>EJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thimmapaya</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jameson</LastName>
            <ForeName>J L</ForeName>
            <Initials>JL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015292">Glycoprotein Hormones, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010907">Pituitary Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12629-01-5</RegistryNumber>
          <NameOfSubstance UI="D019382">Human Growth Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.21</RegistryNumber>
          <NameOfSubstance UI="D013937">Thymidine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.2.1.23</RegistryNumber>
          <NameOfSubstance UI="D001616">beta-Galactosidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P9G3CKZ4P5</RegistryNumber>
          <NameOfSubstance UI="D015774">Ganciclovir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000236" MajorTopicYN="N">Adenoma</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015774" MajorTopicYN="N">Ganciclovir</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018390" MajorTopicYN="Y">Gene Targeting</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015292" MajorTopicYN="N">Glycoprotein Hormones, alpha Subunit</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019382" MajorTopicYN="N">Human Growth Hormone</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010907" MajorTopicYN="N">Pituitary Hormones</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018139" MajorTopicYN="N">Simplexvirus</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013937" MajorTopicYN="N">Thymidine Kinase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001616" MajorTopicYN="N">beta-Galactosidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10021457</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-9738</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>103</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reduced water permeability and altered ultrastructure in thin descending limb of Henle in aquaporin-1 null mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>491-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>It has been controversial whether high water permeability in the thin descending limb of Henle (TDLH) is required for formation of a concentrated urine by the kidney. Freeze-fracture electron microscopy (FFEM) of rat TDLH has shown an exceptionally high density of intramembrane particles (IMPs), which were proposed to consist of tetramers of aquaporin-1 (AQP1) water channels. In this study, transepithelial osmotic water permeability (Pf) was measured in isolated perfused segments (0.5-1 mm) of TDLH in wild-type (+/+), AQP1 heterozygous (+/-), and AQP1 null (-/-) mice. Pf was measured at 37 degrees C using a 100 mM bath-to-lumen osmotic gradient of raffinose, and fluorescein isothiocyanate (FITC)-dextran as the luminal volume marker. Pf was (in cm/s): 0.26 +/- 0.02 ([+/+]; SE, n = 9 tubules), 0.21 +/- 0.01 ([+/-]; n = 12), and 0.031 +/- 0.007 ([-/-]; n = 6) (P &lt; 0.02, [+/+] vs. [+/-]; P &lt; 0.0001, [+/+] vs. [-/-]). FFEM of kidney medulla showed remarkably fewer IMPs in TDLH from (-/-) vs. (+/+) and (+/-) mice. IMP densities were (in microm-2, SD, 5-12 micrographs): 5,880 +/- 238 (+/+); 5,780 +/- 450 (+/-); and 877 +/- 420 (-/-). IMP size distribution analysis revealed mean IMP diameters of 8.4 nm ([+/+] and [+/-]) and 5.2 nm ([-/-]). These results demonstrate that AQP1 is the principal water channel in TDLH and support the view that osmotic equilibration along TDLH by water transport plays a key role in the renal countercurrent concentrating mechanism. The similar Pf and AQP1 expression in TDLH of (+/+) and (+/-) mice was an unexpected finding that probably accounts for the unimpaired urinary concentrating ability in (+/-) mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chou</LastName>
            <ForeName>C L</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Kidney and Electrolyte Metabolism, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Knepper</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoek</LastName>
            <ForeName>A N</ForeName>
            <Initials>AN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verkman</LastName>
            <ForeName>A S</ForeName>
            <Initials>AS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK035124</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL059198</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK-35124</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>Z99 HL999999</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 DK038452</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL-59198</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 DK035124</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK055864</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL-60288</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>Z01 HL001285-21</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C496021">Aqp1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C496022">Aqp1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020346">Aquaporins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>059QF0KO0R</RegistryNumber>
          <NameOfSubstance UI="D014867">Water</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>146410-94-8</RegistryNumber>
          <NameOfSubstance UI="D051398">Aquaporin 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051398" MajorTopicYN="N">Aquaporin 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020346" MajorTopicYN="N">Aquaporins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007672" MajorTopicYN="N">Kidney Cortex</DescriptorName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007679" MajorTopicYN="N">Kidney Medulla</DescriptorName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008138" MajorTopicYN="N">Loop of Henle</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009994" MajorTopicYN="N">Osmolar Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10022835</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0261-4189</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>The EMBO journal</Title>
          <ISOAbbreviation>EMBO J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4.</ArticleTitle>
        <Pagination>
          <MedlinePgn>926-33</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Proliferating myoblasts express the muscle determination factor, MyoD, throughout the cell cycle in the absence of differentiation. Here we show that a mitogen-sensitive mechanism, involving the direct interaction between MyoD and cdk4, restricts myoblast differentiation to cells that have entered into the G0 phase of the cell cycle under mitogen withdrawal. Interaction between MyoD and cdk4 disrupts MyoD DNA-binding, muscle-specific gene activation and myogenic conversion of 10T1/2 cells independently of cyclin D1 and the CAK activation of cdk4. Forced induction of cyclin D1 in myotubes results in the cytoplasmic to nuclear translocation of cdk4. The specific MyoD-cdk4 interaction in dividing myoblasts, coupled with the cyclin D1-dependent nuclear targeting of cdk4, suggests a mitogen-sensitive mechanism whereby cyclin D1 can regulate MyoD function and the onset of myogenesis by controlling the cellular location of cdk4 rather than the phosphorylation status of MyoD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biochemistry, NCI, National Institutes of Health, Building 37 Room 4A21, 9000 Rockville Pike, Bethesda, MD 20892, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Q</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>X</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paterson</LastName>
            <ForeName>B M</ForeName>
            <Initials>BM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>EMBO J</MedlineTA>
        <NlmUniqueID>8208664</NlmUniqueID>
        <ISSNLinking>0261-4189</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017570">MyoD Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>136601-57-5</RegistryNumber>
          <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024510" MajorTopicYN="Y">Muscle Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017570" MajorTopicYN="N">MyoD Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="Y">Proto-Oncogene Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018411" MajorTopicYN="N">Spodoptera</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10027785</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0198-8859</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>60</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Human immunology</Title>
          <ISOAbbreviation>Hum Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparative analysis of HLA-B 8101 by serology, isoelectric focusing, and sequence-based typing.</ArticleTitle>
        <Pagination>
          <MedlinePgn>168-70</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We describe a bone marrow donor evaluation on a twenty-four-year-old patient from Honduras, Central America. The patient's phenotype included a HLA-B7v, with serologic reactivity to HLA- B7, 8101, and 48, and was consistent with, HLA-B*8101. One-dimensional isoelectric focusing (IEF) identified HLA-B 7.1, a low frequency isotype that has previously been associated with the HLA-B7 variant, B*0705. To further classify this allele, sequence based typing (SBT) was performed, confirming HLA-B*8101 sequence homology. The diagnostic evaluation of this case illustrates the correlation of sequenced based typing and isoelectric focusing in defining HLA Class I antigen characteristics and the use of IEF in screening for rare and novel alleles.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Skerrett</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Mount Sinai Medical Center, New York, New York 10029-6574, USA. D.Skerrett@smtplink.mssm.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosina</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gudzowaty</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isola</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scigliano</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fruchtman</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hum Immunol</MedlineTA>
        <NlmUniqueID>8010936</NlmUniqueID>
        <ISSNLinking>0198-8859</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007525" MajorTopicYN="N">Isoelectric Focusing</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10025139</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0029-0831</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>31</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>No to hattatsu = Brain and development</Title>
          <ISOAbbreviation>No To Hattatsu</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[A case of myasthenia gravis with transient remission after influenza A virus infection].</ArticleTitle>
        <Pagination>
          <MedlinePgn>70-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>A boy with ocular type myasthenia gravis was reported. The therapeutic effect of pyridostigmine bromide and corticosteroid was insufficient. However, clinical symptoms disappeared rapidly after an influenza A virus infection. On a peripheral lymphocytes subsets analysis, the CD 3, CD 4 and CD 4/CD 45 RA positive lymphocytes increased with the therapy and decreased after the infection. By contrast, CD 19 positive lymphocytes decreased with the therapy and increased after the infection. These results suggested that influenza A may improve the clinical signs of myasthenia gravis, as is the improved case with measles.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamada</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Nagaoka Central Hospital, Niigata.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gunji</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsui</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>jpn</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>No To Hattatsu</MedlineTA>
        <NlmUniqueID>0215224</NlmUniqueID>
        <ISSNLinking>0029-0831</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016131" MajorTopicYN="N">Lymphocyte Subsets</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10025572</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0304-3940</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>259</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neuroscience letters</Title>
          <ISOAbbreviation>Neurosci Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Smooth muscle cells are the site of neurokinin-1 receptor localization in the arterial supply of the rat sciatic nerve.</ArticleTitle>
        <Pagination>
          <MedlinePgn>119-22</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The occurrence and distribution of the preferred receptor for the neuropeptide, substance P (SP), the neurokinin-1 receptor (NK1R) was investigated in the vascular supply of the rat sciatic nerve. Messenger RNA for NK1R was demonstrated by RT-PCR in the epineurial layer where the majority of small arteries and arterioles feeding the endoneurial vasculature are located. Immunoreactivity to NK1 R-protein was localized on the smooth muscle cells of these arterial vessels by means of immunofluorescence using a polyclonal NK1R antiserum. This muscular localization of NK1R explains the previously reported [Zochodne, D.W. and Ho, L.T., J. Physiol., 444 (1991) 615-630] moderate vasoconstrictor rather than vasodilator effects of SP in this vascular bed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kummer</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Anatomy and Cell Biology, Justus-Liebig University, Giessen, Germany. wolfgang.kummer@anatomie.med.uni-giessen.de</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shigemoto</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haberberger</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Neurosci Lett</MedlineTA>
        <NlmUniqueID>7600130</NlmUniqueID>
        <ISSNLinking>0304-3940</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018040">Receptors, Neurokinin-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018040" MajorTopicYN="N">Receptors, Neurokinin-1</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10025733</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0887-8013</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical laboratory analysis</Title>
          <ISOAbbreviation>J Clin Lab Anal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings.</ArticleTitle>
        <Pagination>
          <MedlinePgn>19-26</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>This study reports findings from a retrospective, comprehensive review of 80 cases of adult AML in regard to cytomorphology, enzyme cytochemistry (EC), flow cytometric immunophenotyping (FCI), and chromosomal analysis. From this review, we conclude that diagnostically challenging cases can only be subtyped by combining the cytomorphology with EC, FCI, and subsequent cytogenetic results. This is particularly true in recognizing the hypogranular variant of AML,M3 (AML, M3m) and distinguishing it from other subtypes. Nonlineage expression of markers (CD1, CD2, CD4, CD5, CD7, and CD56) was nonspecific as to AML subtype. Of interest, CD2 coexpression in acute myelomonocytic leukemia with eosinophilia (M4-Eo) was exclusively associated with inversion of chromosome 16 (inv 16) and was not observed in the other M4-Eo's without inv16. We also recognized a previously undescribed M3m with CD56 coexpression, heightening awareness of this entity which needs to be distinguished from the unique subtype of CD56+ AML with otherwise similar immunophenotypic and morphologic characteristics. In addition, nonlineage expression of CD19 alone was exclusively associated with the cytogenetic finding of t (8;21) (q22; q22) and thus may represent a favorable prognostic indicator by FCI.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dunphy</LastName>
            <ForeName>C H</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, St. Louis University Health Sciences Center, Missouri 63104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Lab Anal</MedlineTA>
        <NlmUniqueID>8801384</NlmUniqueID>
        <ISSNLinking>0887-8013</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004798">Enzymes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.7</RegistryNumber>
          <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.-</RegistryNumber>
          <NameOfSubstance UI="D009283">Naphthol AS D Esterase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.1.-</RegistryNumber>
          <NameOfSubstance UI="D002265">Carboxylic Ester Hydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.1.-</RegistryNumber>
          <NameOfSubstance UI="C019873">chloroacetate esterase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.1.-</RegistryNumber>
          <NameOfSubstance UI="C021855">naphthylbutyrate esterase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002265" MajorTopicYN="N">Carboxylic Ester Hydrolases</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002869" MajorTopicYN="Y">Chromosome Aberrations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004798" MajorTopicYN="N">Enzymes</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006651" MajorTopicYN="N">Histocytochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016130" MajorTopicYN="Y">Immunophenotyping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="Y">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009283" MajorTopicYN="N">Naphthol AS D Esterase</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009195" MajorTopicYN="N">Peroxidase</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10025797</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0028-3878</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>52</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurology</Title>
          <ISOAbbreviation>Neurology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adrenoleukodystrophy protein enhances association of very long-chain acyl-coenzyme A synthetase with the peroxisome.</ArticleTitle>
        <Pagination>
          <MedlinePgn>614-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To clarify the function of adrenoleukodystrophy protein (ALDP) using our ALDP-deficient mice established by gene targeting.</AbstractText>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">X-linked adrenoleukodystrophy (ALD) is characterized biochemically by the accumulation of very long-chain fatty acids (VLCFA) in tissues and body fluids, and is caused by impairment of peroxisomal beta-oxidation. In ALD, very long-chain acyl-coenzyme A synthetase (VLACS), which is necessary for peroxisomal beta-oxidation, does not function.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The ALDP-deficient mice and C57BL/6J mice were used. VLACS or ALDP were transiently expressed by lipofection in murine fibroblasts, and VLCFA beta-oxidation was assayed. Liver peroxisomes were purified by sequential centrifugations and a Nycodenz gradient centrifugation. The peroxisomal localization of VLACS was compared between the mutant and control mice using a Western blot analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Impairment of VLCFA beta-oxidation in ALDP-deficient fibroblasts was not corrected by the additional expression of VLACS alone but was by the coexpression of VLACS and ALDP. Although the tissue-specific expression of VLACS was similar in ALDP-deficient and normal mice, peroxisomal VLACS was clearly lower in ALDP-deficient than in normal mice.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ALDP plays a role in the peroxisomal localization of VLACS, and VLACS does not function unless localized in the peroxisome.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamada</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka, Japan. yamada@neuro.med.kyushu-u.ac.jp</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taniwaki</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shinnoh</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchiyama</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimozawa</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohyagi</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asahara</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kira</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurology</MedlineTA>
        <NlmUniqueID>0401060</NlmUniqueID>
        <ISSNLinking>0028-3878</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C115572">ABCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074063">ATP Binding Cassette Transporter, Subfamily D, Member 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D003066">Coenzyme A Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.3</RegistryNumber>
          <NameOfSubstance UI="C090799">FAA2 protein, S cerevisiae</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.3</RegistryNumber>
          <NameOfSubstance UI="C019143">long-chain-fatty-acid-CoA ligase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074063" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily D, Member 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003066" MajorTopicYN="N">Coenzyme A Ligases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008830" MajorTopicYN="N">Microbodies</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012097" MajorTopicYN="Y">Repressor Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029701" MajorTopicYN="Y">Saccharomyces cerevisiae Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024515</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0264-6021</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>338 ( Pt 2)</Volume>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Biochemical journal</Title>
          <ISOAbbreviation>Biochem J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.</ArticleTitle>
        <Pagination>
          <MedlinePgn>393-401</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The canalicular multispecific organic anion transporter (cMOAT), a member of the ATP-binding cassette transporter family, mediates the transport of a broad range of non-bile salt organic anions from liver into bile. cMOAT-deficient Wistar rats (TR-) are mutated in the gene encoding cMOAT, leading to defective hepatobiliary transport of a whole range of substrates, including bilirubin glucuronide. These mutants also have impaired hepatobiliary excretion of GSH and, as a result, the bile flow in these animals is reduced. In the present work we demonstrate a role for cMOAT in the excretion of GSH both in vivo and in vitro. Biliary GSH excretion in rats heterozygous for the cMOAT mutation (TR/tr) was decreased to 63% of controls (TR/TR) (114+/-24 versus 181+/-20 nmol/min per kg body weight). Madin-Darby canine kidney (MDCK) II cells stably expressing the human cMOAT protein displayed &gt;10-fold increase in apical GSH excretion compared with wild-type MDCKII cells (141+/-6.1 pmol/min per mg of protein versus 13.2+/-1.3 pmol/min per mg of protein in wild-type MDCKII cells). Similarly, MDCKII cells expressing the human multidrug resistance protein 1 showed a 4-fold increase in GSH excretion across the basolateral membrane. In several independent cMOAT-transfectants, the level of GSH excretion correlated with the expression level of the protein. Furthermore, we have shown, in cMOAT-transfected cells, that GSH is a low-affinity substrate for the transporter and that its excretion is reduced upon ATP depletion. In membrane vesicles isolated from cMOAT-expressing MDCKII cells, ATP-dependent S-(2,4-dinitrophenyl)glutathione uptake is competitively inhibited by high concentrations of GSH (Ki approximately 20 mM). We concluded that cMOAT mediates low-affinity transport of GSH. However, since hepatocellular GSH concentrations are high (5-10 mM), cMOAT might serve an important physiological function in maintenance of bile flow in addition to hepatic GSH turnover.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Paulusma</LastName>
            <ForeName>C C</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal and Liver Diseases, Academic Medical Center F0-116, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Geer</LastName>
            <ForeName>M A</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evers</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heijn</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ottenhoff</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borst</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oude Elferink</LastName>
            <ForeName>R P</ForeName>
            <Initials>RP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem J</MedlineTA>
        <NlmUniqueID>2984726R</NlmUniqueID>
        <ISSNLinking>0264-6021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027321">Anion Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027321" MajorTopicYN="N">Anion Transport Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001648" MajorTopicYN="N">Bile Canaliculi</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10024683</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1019-6439</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of oncology</Title>
          <ISOAbbreviation>Int J Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.</ArticleTitle>
        <Pagination>
          <MedlinePgn>501-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Phenylbutyrate (PB) is a potent differentiating agent and currently under investigation for the treatment of prostate cancer (CaP) and other malignancies. We have studied the impact of PB in vitro and in vivo on differentiation, proliferation and apoptosis in the LNCaP and LuCaP 23.1 prostate cancer xenograft models. In vitro we found that i) PB increased PSA secretion/cell, ii) inhibited cell proliferation in a time- and dose-dependent manner resulting in a cell cycle arrest in G1-phase and iii) induced apoptosis at concentrations of 2.5 mM after 3 days of treatment. In PB treated animals tumor growth stabilized or regressed. Combination of castration and PB treatment had a synergistic antiproliferative effect. The growth-inhibitory and differentiating properties and a low toxicity profile of PB provide rationale for further clinical studies in patients with CaP.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Melchior</LastName>
            <ForeName>S W</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Johannes Gutenberg-University Medical School, 55131 Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>L G</ForeName>
            <Initials>LG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Figg</LastName>
            <ForeName>W D</ForeName>
            <Initials>WD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quinn</LastName>
            <ForeName>J E</ForeName>
            <Initials>JE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santucci</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brunner</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Th√ºroff</LastName>
            <ForeName>J W</ForeName>
            <Initials>JW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lange</LastName>
            <ForeName>P H</ForeName>
            <Initials>PH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vessella</LastName>
            <ForeName>R L</ForeName>
            <Initials>RL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>1 P50 DK/CS4756-03</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Int J Oncol</MedlineTA>
        <NlmUniqueID>9306042</NlmUniqueID>
        <ISSNLinking>1019-6439</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000728">Androgens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10037161</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-5793</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>444</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>FEBS letters</Title>
          <ISOAbbreviation>FEBS Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulation of human hsp90alpha gene expression.</ArticleTitle>
        <Pagination>
          <MedlinePgn>130-5</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Mammalian HSP90alpha and HSP90beta are encoded by two individual genes. On the basis of the upstream sequences of the human hsp90alpha gene, GenBank accession number U25822, we have constructed CAT reporter plasmids driven by individual fragments of the hsp90alpha gene. We found that (1) the proximal heat shock element complex located at -96/-60 enhances hsp90alpha promoter expression; (2) heat shock induction depends upon the coexistence of distal heat shock element at -1031/-1022 and the proximal heat shock element complex of the hsp90alpha gene; (3) unlike hsp90beta, downstream sequences of the transcription start site inhibit hsp90alpha expression. We conclude that the regulatory mechanisms for the expression of hsp90alpha and hsp90beta genes are different.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>S L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>X K</ForeName>
            <Initials>XK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heng</LastName>
            <ForeName>F Y</ForeName>
            <Initials>FY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>N H</ForeName>
            <Initials>NH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Y F</ForeName>
            <Initials>YF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>U25822</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>FEBS Lett</MedlineTA>
        <NlmUniqueID>0155157</NlmUniqueID>
        <ISSNLinking>0014-5793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002457">Cell Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002457" MajorTopicYN="N">Cell Extracts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018869" MajorTopicYN="N">Heat-Shock Response</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020218" MajorTopicYN="N">Response Elements</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10036188</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0888-7543</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>56</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genomics</Title>
          <ISOAbbreviation>Genomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>M band proteins myomesin and skelemin are encoded by the same gene: analysis of its organization and expression.</ArticleTitle>
        <Pagination>
          <MedlinePgn>78-89</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The complete exon-intron organization of the murine gene encoding sarcomeric myomesin has been determined. The gene is composed of 38 exons and 37 introns, spanning approximately 105 kb of DNA. Intron positions and phases are essentially identical to those identified in M-protein. They are related to the modular structure of myomesin, which is composed almost entirely of immunoglobulin and fibronectin type III domains. Nearly all repeats follow a two exon-one domain structure. The start and end of each domain are defined by introns in phase I, while internal introns are more divergent in position and very rarely use phase I. Genomic Southern blotting and reverse transcription-polymerase chain reaction revealed that differential splicing of a single exon gives rise to two polypeptides, described in the literature as myomesin and skelemin, respectively. A single transcriptional start point was detected in both skeletal and cardiac muscle. Analysis of the presumptive promoter region revealed several potential regulatory elements. CAT expression assays using promoter deletion constructs identified three regions that seem to be important for the muscle-specific transcriptional activation of the myomesin gene. These results provide the basis for a comparative analysis of the regulation of myomesin and M-protein genes in vivo.</AbstractText>
          <CopyrightInformation>Copyright 1999 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Steiner</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, University of Potsdam, Lenn√©strasse 7a, Potsdam, D-14471, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>F√ºrst</LastName>
            <ForeName>D O</ForeName>
            <Initials>DO</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Genomics</MedlineTA>
        <NlmUniqueID>8800135</NlmUniqueID>
        <ISSNLinking>0888-7543</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064211">Connectin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C577299">MYOM1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009124">Muscle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C577300">Myom1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015139" MajorTopicYN="N">Blotting, Southern</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064211" MajorTopicYN="N">Connectin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009124" MajorTopicYN="N">Muscle Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10036187</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0888-7543</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>56</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genomics</Title>
          <ISOAbbreviation>Genomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Revised genomic organization of FBN1 and significance for regulated gene expression.</ArticleTitle>
        <Pagination>
          <MedlinePgn>70-7</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>FBN1 encodes fibrillin-1, an extracellular matrix protein that is defective in Marfan syndrome. This gene is divided into 65 exons and was previously reported to be approximately 110 kb in length. The existence of 3 exons upstream of the exon containing the putative initiating methionine left open the possibility of alternative fibrillin-1 isoforms that vary at their N-termini. Detailed examination of YACs containing human FBN1 reveal that the gene is 200 kb, almost twice as large as previously thought. Characterization of the porcine FBN1 cDNA and 5' flanking sequence demonstrates extreme conservation between the pig and the human predicted proteins and argues against the possibility of alternative amino-terminal coding sequence. These data further our understanding of the regulatory requirements for gene expression and establish a framework for recombinant expression of fibrillin-1.</AbstractText>
          <CopyrightInformation>Copyright 1999 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Biery</LastName>
            <ForeName>N J</ForeName>
            <Initials>NJ</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eldadah</LastName>
            <ForeName>Z A</ForeName>
            <Initials>ZA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moore</LastName>
            <ForeName>C S</ForeName>
            <Initials>CS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stetten</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spencer</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dietz</LastName>
            <ForeName>H C</ForeName>
            <Initials>HC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF073800</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01AR41135</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Genomics</MedlineTA>
        <NlmUniqueID>8800135</NlmUniqueID>
        <ISSNLinking>0888-7543</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000605722">FBN1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000605724">Fbn1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071838">Fibrillin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071837">Fibrillins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018244" MajorTopicYN="N">Chromosomes, Artificial, Yeast</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071838" MajorTopicYN="N">Fibrillin-1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071837" MajorTopicYN="N">Fibrillins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015698" MajorTopicYN="N">Genomic Library</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015183" MajorTopicYN="N">Restriction Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10036186</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2007</Year>
        <Month>11</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0888-7543</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>56</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genomics</Title>
          <ISOAbbreviation>Genomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A gene upregulated in the acoustically damaged chick basilar papilla encodes a novel WD40 repeat protein.</ArticleTitle>
        <Pagination>
          <MedlinePgn>59-69</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The chick WDR1 gene is expressed at higher levels in the chick basilar papilla after acoustic overstimulation. The 3.3-kb WDR1 cDNA encodes a novel 67-kDa protein containing nine WD40 repeats, motifs that mediate protein-protein interactions. The predicted WDR1 protein has high sequence identity to WD40-repeat proteins in budding yeast (Saccharomyces cerevisiae), two slime molds (Dictyostelium discoideum and Physarum polycephalum), and the roundworm (Caenorhabditis elegans). The yeast and P. polycephalum proteins bind actin, suggesting that the novel chick protein may be an actin-binding protein. Sequence database comparisons identified mouse and human cDNAs with high sequence identity to the chick WDR1 cDNA. The mouse Wdr1 and human WDR1 proteins showed 95% sequence identity to each other and 86% identity to the chick WDR1 protein. Northern blot analysis of total RNA from the chick basilar papilla after noise trauma revealed increased levels of a 3.1-kb transcript in the lesioned area. The WDR1 gene was mapped to human chromosome 4, between 22 and 24 cM from the telomere of 4p.</AbstractText>
          <CopyrightInformation>Copyright 1999 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Adler</LastName>
            <ForeName>H J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology/Head-Neck Surgery, University of Michigan, Ann Arbor, Michigan, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Winnicki</LastName>
            <ForeName>R S</ForeName>
            <Initials>RS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>T W</ForeName>
            <Initials>TW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lomax</LastName>
            <ForeName>M I</ForeName>
            <Initials>MI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF020054</AccessionNumber>
              <AccessionNumber>AF020055</AccessionNumber>
              <AccessionNumber>AF020056</AccessionNumber>
              <AccessionNumber>AF020260</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DC02492</GrantID>
            <Acronym>DC</Acronym>
            <Agency>NIDCD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 DC02982</GrantID>
            <Acronym>DC</Acronym>
            <Agency>NIDCD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DC02492</GrantID>
            <Acronym>DC</Acronym>
            <Agency>NIDCD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Genomics</MedlineTA>
        <NlmUniqueID>8800135</NlmUniqueID>
        <ISSNLinking>0888-7543</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118067">WDR1 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001489" MajorTopicYN="N">Basilar Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002894" MajorTopicYN="N">Chromosomes, Human, Pair 4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006317" MajorTopicYN="N">Hearing Loss, Noise-Induced</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015183" MajorTopicYN="N">Restriction Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10036185</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2006</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0888-7543</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>56</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genomics</Title>
          <ISOAbbreviation>Genomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2.</ArticleTitle>
        <Pagination>
          <MedlinePgn>51-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We cloned and functionally characterized the murine Bin1 gene as a first step to investigate its physiological roles in differentiation, apoptosis, and tumorigenesis. The exon-intron organization of the &gt;/=55-kb gene is similar to that of the human gene. Consistent with a role for Bin1 in apoptosis, the promoter included a functional consensus motif for activation by NF-kappaB, an important regulator of cell death. A muscle regulatory module defined in the human promoter that includes a consensus recognition site for myoD family proteins was not conserved in the mouse promoter. However, Bin1 is upregulated in embryonic development by E10.5 in myotomes, the progenitors of skeletal muscle, supporting a role in myogenesis and suggesting that the mouse and human genes may be controlled somewhat differently during development. In C2C12 myoblasts antisense Bin1 prevents induction of the cell cycle kinase inhibitor p21WAF1, suggesting that it acts at an early time during the muscle differentiation program. Interspecific mouse backcross mapping located the Bin1 locus between Mep1b and Apc on chromosome 18. Since the human gene was mapped previously to chromosome 2q14, the location of Bin1 defines a previously unrecognized region of synteny between human chromosome 2 and mouse chromosome 18.</AbstractText>
          <CopyrightInformation>Copyright 1999 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>N C</ForeName>
            <Initials>NC</Initials>
            <AffiliationInfo>
              <Affiliation>The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steingrimsson</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>DuHadaway</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wasserman</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruiz</LastName>
            <ForeName>J C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Copeland</LastName>
            <ForeName>N G</ForeName>
            <Initials>NG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jenkins</LastName>
            <ForeName>N A</ForeName>
            <Initials>NA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prendergast</LastName>
            <ForeName>G C</ForeName>
            <Initials>GC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Genomics</MedlineTA>
        <NlmUniqueID>8800135</NlmUniqueID>
        <ISSNLinking>0888-7543</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C109221">Bin1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="Y">Adaptor Proteins, Signal Transducing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002889" MajorTopicYN="N">Chromosomes, Human, Pair 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024510" MajorTopicYN="Y">Muscle Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
          <QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020161" MajorTopicYN="N">Physical Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015183" MajorTopicYN="N">Restriction Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="Y">Tumor Suppressor Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10029158</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0301-472X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>27</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental hematology</Title>
          <ISOAbbreviation>Exp Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>210-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Diethyldithiocarbamate (DDTC) exhibits chemoprotective effects via reduced myelosuppression in mice treated with various chemotherapeutic agents. The mechanism of DDTC-mediated chemoprotection is believed to involve the induction and release of several cytokines, including interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and granulocyte colony-stimulating factor (G-CSF). In the present study the roles of IL-1beta and TNF-alpha in DDTC-mediated G-CSF induction were examined using human long-term bone marrow cultures (hLTBMCs). Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis. IL-1beta mRNA levels were increased threefold over control following DDTC treatment of hLTBMCs, implying that DDTC induces IL-1beta at the level of transcription. Conversely, studies involving inhibition of DDTC-induced TNF-alpha synthesis, with the inhibitor MNX 160, had no effect on DDTC-induced G-CSF release or colony proliferation. These findings taken together strongly suggest that IL-1beta mediates the chemoprotective effects of DDTC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kennedy</LastName>
            <ForeName>S M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Physiology, University of Rochester, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borch</LastName>
            <ForeName>R F</ForeName>
            <Initials>RF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA34620</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>GM08427</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Exp Hematol</MedlineTA>
        <NlmUniqueID>0402313</NlmUniqueID>
        <ISSNLinking>0301-472X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507763">IL1RN protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507764">Il1rn protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>143011-72-7</RegistryNumber>
          <NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>99Z2744345</RegistryNumber>
          <NameOfSubstance UI="D004050">Ditiocarb</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004050" MajorTopicYN="N">Ditiocarb</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006410" MajorTopicYN="N">Hematopoiesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012795" MajorTopicYN="N">Sialoglycoproteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10029178</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0301-472X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>27</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental hematology</Title>
          <ISOAbbreviation>Exp Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Umbilical cord blood banking for unrelated transplantation: evaluation of cell separation and storage methods.</ArticleTitle>
        <Pagination>
          <MedlinePgn>380-5</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Cost-efficient umbilical cord blood (UCB) banking requires well-standardized methods of volume reduction and storage. To compare UCB fractionation using a technique of hydroxyethyl starch (HES) sedimentation with the Ficoll (double) and Percoll methods, 50 whole units was allocated randomly to each procedure. HES resulted in a significantly better recovery of mononuclear cells (87.5%), granulocyte/macrophage colony-forming units (CFU-GM) (88.4%), and CD34- cells (87.4%) and lesser volume reduction (85.5%). HES was the least laborious, time consuming, and expensive of the three procedures, costing 3.4- and 4.4-fold less than the Ficoll and Percoll methods, respectively. Five units processed by each method was frozen in 4.5-mL cryotubes under optimal conditions. After thawing, the greatest degree of recovery of viable nucleated cells and number of CFU-GM per unit were obtained using the HES procedure. Using 4.5-mL cryotubes, the calculated number of units that could be stored in 600-L containers was 3.8- and 2.2-fold higher for Ficoll- and Percoll-separated than for HES-separated units, respectively. Nevertheless, the higher direct costs of the density gradient separation procedures outweighed their lower storage cost. For long-term cryopreservation, we assessed the freezing of HES-processed units in 50-mL cryobags and their specifically designed canisters. We found cell recoveries similar to those obtained with cryotubes, but storage capacity was decreased. Special racks designed for these canisters resulted in a 5-fold increase over the number of units stored in standard cryobags. This system also is feasible for Percoll- and Ficoll-separated units, resulting in comparable storage costs for the three separation methods. We conclude that this HES procedure and the 50-mL cryobags constitute a cost-efficient system for large-scale UCB banking.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Regidor</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Cl√≠nica Puerta de Hierro, Universidad Aut√≥noma de Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Posada</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monteagudo</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garaulet</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Somolinos</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>For√©s</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briz</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fern√°ndez</LastName>
            <ForeName>M N</ForeName>
            <Initials>MN</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Exp Hematol</MedlineTA>
        <NlmUniqueID>0402313</NlmUniqueID>
        <ISSNLinking>0301-472X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019650" MajorTopicYN="N">Hematopoietic Stem Cell Mobilization</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10036338</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1050-1606</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of sport nutrition</Title>
          <ISOAbbreviation>Int J Sport Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of encapsulated soluble fiber on carohydrate metabolism during exercise.</ArticleTitle>
        <Pagination>
          <MedlinePgn>13-23</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Previous investigations have reported that soluble fiber reduces the plasma glucose and insulin changes after an oral glucose load. To improve the palatability of a soluble-fiber feeding, this study addressed how a combined, soluble fiber (delivered in capsule form) and a preexercise CHO feeding would affect metabolic responses during exercise. On 3 different days, participants ingested a placebo (CON), 75 g liquid CHO (GLU), or 75 g liquid CHO with 14.5 g encapsulated guar gum (FIB) 45 min before cycling for 60 min at 70% VO2 peak. Peak concentrations of plasma glucose and insulin were similar and significantly greater than CON preexercise (p &lt; 05). Similarities in carbohydrate reliance were observed in GLU and FIB. Muscle glycogen use did not differ significantly among trials. These results demonstrate that encapsulated soluble fiber delivered with liquid CHO feeding does not affect plasma glucose, insulin, or muscle glycogen utilization during exercise.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Parcell</LastName>
            <ForeName>A C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Human Performance Research Center, Department of Physical Education, Brigham Young University, 212 Richards Building, Provo, UT 84602, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ray</LastName>
            <ForeName>M L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moss</LastName>
            <ForeName>K A</ForeName>
            <Initials>KA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruden</LastName>
            <ForeName>T M</ForeName>
            <Initials>TM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharp</LastName>
            <ForeName>R L</ForeName>
            <Initials>RL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>King</LastName>
            <ForeName>D S</ForeName>
            <Initials>DS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Int J Sport Nutr</MedlineTA>
        <NlmUniqueID>9307702</NlmUniqueID>
        <ISSNLinking>1050-1606</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002214">Capsules</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005685">Galactans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008351">Mannans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053149">Plant Gums</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-79-2</RegistryNumber>
          <NameOfSubstance UI="D006003">Glycogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E89I1637KE</RegistryNumber>
          <NameOfSubstance UI="C007894">guar gum</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>S</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004043" MajorTopicYN="N">Dietary Fiber</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005230" MajorTopicYN="N">Fatty Acids, Nonesterified</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005685" MajorTopicYN="N">Galactans</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008351" MajorTopicYN="N">Mannans</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005082" MajorTopicYN="N">Physical Exertion</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053149" MajorTopicYN="N">Plant Gums</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012119" MajorTopicYN="N">Respiration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10029548</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-2960</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>38</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemistry</Title>
          <ISOAbbreviation>Biochemistry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2535-41</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The ferric form of the N-lobe of human serum transferrin (Fe(III)-hTF/2N) has been expressed at high levels in Pichia pastoris. The Fe(III)-hTF/2N was crystallized in the space group P41212, and X-ray crystallography was used to solve the structure of the recombinant protein at 2.5 A resolution. This represents only the second P. pastoris-derived protein structure determined to date, and allows the comparison of the structures of recombinant Fe(III)-hTF/2N expressed in P. pastoris and mammalian cells with serum-derived transferrin. The polypeptide folding pattern is essentially identical in all of the three proteins. Mass spectroscopic analyses of P. pastoris- hTF/2N and proteolytically derived fragments revealed glycosylation of Ser-32 with a single hexose. This represents the first localization of an O-linked glycan in a P. pastoris-derived protein. Because of its distance from the iron-binding site, glycosylation of Ser-32 should not affect the iron-binding properties of hTF/2N expressed in P. pastoris, making this an excellent expression system for the production of hTF/2N.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bewley</LastName>
            <ForeName>M C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Biosciences, College of Sciences, Massey University, Palmerston North, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tam</LastName>
            <ForeName>B M</ForeName>
            <Initials>BM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grewal</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shewry</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>M E</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mason</LastName>
            <ForeName>A B</ForeName>
            <Initials>AB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woodworth</LastName>
            <ForeName>R C</ForeName>
            <Initials>RC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baker</LastName>
            <ForeName>E N</ForeName>
            <Initials>EN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacGillivray</LastName>
            <ForeName>R T</ForeName>
            <Initials>RT</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>PDB</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>1B3E</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK 21739</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK 35533</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HD 20859</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochemistry</MedlineTA>
        <NlmUniqueID>0370623</NlmUniqueID>
        <ISSNLinking>0006-2960</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014168">Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>452VLY9402</RegistryNumber>
          <NameOfSubstance UI="D012694">Serine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010843" MajorTopicYN="N">Pichia</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014168" MajorTopicYN="N">Transferrin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10047537</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0952-7915</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in immunology</Title>
          <ISOAbbreviation>Curr Opin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antigen presentation by MHC class I and its regulation by interferon gamma.</ArticleTitle>
        <Pagination>
          <MedlinePgn>76-81</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Antigen processing by MHC class I molecules begins with the generation of peptides by proteolytic breakdown of proteins. IFN-gamma upregulates gene expression of several proteasomal subunits as well as the proteasome regulator PA28; this implicated their role in antigen degradation. Crystallographic, mutational and biochemical studies contributed to our understanding of the basic principles of proteasomal protein degradation and the consequences of IFN-gamma induction for proteasome function. In addition, nonproteasomal mechanisms seem to be involved in antigen degradation. Leucine aminopeptidase, which is also upregulated by IFN-gamma, was shown to collaborate with the proteasome for epitope production and unknown proteases seem to compensate for the loss of proteasomal degradation in the presence of proteasome inhibitors. Thus, a rather complex picture emerges for the rules governing peptide production in the presence or absence of IFN-gamma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fr√ºh</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>The R. W. Johnson Pharmaceutical Research Institute, General Atomics Court, San Diego, CA 92121, USA. kfrueh@prius.jnj.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Curr Opin Immunol</MedlineTA>
        <NlmUniqueID>8900118</NlmUniqueID>
        <ISSNLinking>0952-7915</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017951" MajorTopicYN="N">Antigen Presentation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>52</NumberOfReferences>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10048218</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-2720</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>193</Volume>
            <Issue>Pt 2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of microscopy</Title>
          <ISOAbbreviation>J Microsc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunogold localization of plant surface arabinogalactan-proteins using glycerol liquid substitution and scanning electron microscopy.</ArticleTitle>
        <Pagination>
          <MedlinePgn>150-7</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We have studied the spatial distributions of arabinogalactan-protein (AGP) epitopes on the surface of maize embryogenic calli and roots using monoclonal antibodies JIM4 and MAC207. For this purpose, a new immunogold-scanning electron microscopy (SEM) method was employed which is based on liquid substitution of samples with glycerol. Using this method, we were able to show that the AGP epitopes are distributed along callus and root surfaces and they decorate filamentous structures. In callus cells, the JIM4 epitope was specifically enriched in the outer extracellular layers covering compact clusters of embryogenic meristematic callus cells. In roots, the MAC207 epitope was abundant on the root epidermal surface corresponding to the outer root pellicle, but was only occasionally found on the mucilage layer covering the root cap cells. Silver-enhanced gold particles, indicating AGP epitopes, were often linearly arranged suggesting that AGPs associate with filamentous structures both on the surface of embryogenic calli and root epidermal cells. These results indicate that AGPs are components of the outer extracellular layers and networks that cover the surface of roots and cells undergoing somatic embryogenesis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Samaj</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Botanisches Institut, Universit√§t Bonn, Germany. unb15f@uni-bonn.de</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ensikat</LastName>
            <ForeName>H J</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baluska</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Knox</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barthlott</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volkmann</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Microsc</MedlineTA>
        <NlmUniqueID>0204522</NlmUniqueID>
        <ISSNLinking>0022-2720</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009088">Mucoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010940">Plant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C006619">arabinogalactan proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PDC6A3C0OX</RegistryNumber>
          <NameOfSubstance UI="D005990">Glycerol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>S</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005990" MajorTopicYN="N">Glycerol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009088" MajorTopicYN="N">Mucoproteins</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010940" MajorTopicYN="N">Plant Proteins</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010944" MajorTopicYN="N">Plants</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10048399</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2012</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1043-0342</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human gene therapy</Title>
          <ISOAbbreviation>Hum Gene Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.</ArticleTitle>
        <Pagination>
          <MedlinePgn>477-88</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dunbar</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Childrens Hospital Los Angeles, U.S.C. School of Medicine, CA 90027, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mullen</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramsey</LastName>
            <ForeName>W J</ForeName>
            <Initials>WJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carter</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kohn</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parkman</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lenarsky</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weinberg</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wara</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Culver</LastName>
            <ForeName>K W</ForeName>
            <Initials>KW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>W F</ForeName>
            <Initials>WF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leitman</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fleisher</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shearer</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clerici</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McGarrity</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bastian</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hershfield</LastName>
            <ForeName>M S</ForeName>
            <Initials>MS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hum Gene Ther</MedlineTA>
        <NlmUniqueID>9008950</NlmUniqueID>
        <ISSNLinking>1043-0342</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018952">Antigens, CD34</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.4.4</RegistryNumber>
          <NameOfSubstance UI="D000243">Adenosine Deaminase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000243" MajorTopicYN="N">Adenosine Deaminase</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018952" MajorTopicYN="N">Antigens, CD34</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015139" MajorTopicYN="N">Blotting, Southern</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007258" MajorTopicYN="N">Informed Consent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011296" MajorTopicYN="N">Prenatal Diagnosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012190" MajorTopicYN="N">Retroviridae</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016511" MajorTopicYN="N">Severe Combined Immunodeficiency</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10048316</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2007</Year>
        <Month>11</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0031-8655</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>69</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Photochemistry and photobiology</Title>
          <ISOAbbreviation>Photochem Photobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.</ArticleTitle>
        <Pagination>
          <MedlinePgn>236-41</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Photodynamic therapy (PDT) is a cancer treatment modality utilizing a photosensitizer, light and oxygen. Photodynamic therapy with Photofrin has been approved by the U.S. Food and Drug Administration for treatment of advanced esophageal and early lung cancer. Because of certain drawbacks associated with the use of Photofrin, there is a need to identify new photosensitizers for human use. The photosensitizer Pc 4 (HOSiPc-OSi[CH3]2[CH2]3N[CH3]2) has yielded promising PDT effects in many in vitro and in vivo systems. The aim of this study was to assess the usefulness of Pc 4 as a PDT photosensitizer for a human tumor grown as a xenograft in athymic nude mice. The ovarian epithelial carcinoma (OVCAR-3) was heterotransplanted subcutaneously in athymic nude mice. Sixty mice bearing OVCAR-3 tumors (approximately 80-130 mm3) were divided into six groups of 10 animals each, three for controls and three for treatment. The Pc 4 was given by tail vein injection, and 48 h later a 1 cm area encompassing the tumor was irradiated with light from a diode laser coupled to a fiberoptic terminating in a microlens (lambda = 672 nm, 150 J/cm2, 150 mW/cm2). Tumors of control animals receiving no treatment, light alone or Pc 4 alone continued to grow. Of animals receiving 0.4 mg/kg Pc 4 and light, one (10%) had a complete response and was cured (no regrowth up to 90 days post-PDT), while all others (90%) had a partial response and were delayed in regrowth. Of animals receiving 0.6 mg/kg Pc 4 and light, eight (80%) had a complete response, and two of these were cured. Of animals receiving 1.0 mg/kg Pc 4 and light, six (60%) had a complete response, and two of these were cured. In additional experiments, tumors from animals treated with Pc 4 (1 mg/kg) and light were removed 15, 30, 60 and 180 min post-PDT, and from these tumors DNA and protein were extracted. Agarose gel electrophoresis revealed the presence of apoptotic DNA fragmentation as early as 15 min post-PDT. Western blotting showed the cleavage of the 116 kDa native poly(ADP-ribose) polymerase (PARP) into fragments of approximately 90 kDa, another indication of apoptosis, and the presence of p21/WAF1/CIP1 (p21) in all PDT-treated tumors. These changes did not occur in control tumors. Pc 4 appears to be an effective photosensitizer for PDT of human tumors grown as xenografts in nude mice. Early apoptosis, as revealed by PARP cleavage, DNA fragmentation and p21 overexpression, may be responsible for the excellent Pc 4-PDT response. Clinical trials of Pc 4-PDT are warranted.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Colussi</LastName>
            <ForeName>V C</ForeName>
            <Initials>VC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106-5028, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feyes</LastName>
            <ForeName>D K</ForeName>
            <Initials>DK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mulvihill</LastName>
            <ForeName>J W</ForeName>
            <Initials>JW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Y S</ForeName>
            <Initials>YS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kenney</LastName>
            <ForeName>M E</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elmets</LastName>
            <ForeName>C A</ForeName>
            <Initials>CA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oleinick</LastName>
            <ForeName>N L</ForeName>
            <Initials>NL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mukhtar</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="N">
          <Grant>
            <GrantID>P01 CA48735</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA43703</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA51802</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Photochem Photobiol</MedlineTA>
        <NlmUniqueID>0376425</NlmUniqueID>
        <ISSNLinking>0031-8655</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493957">Cdkn1a protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016213">Cyclins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C107448">phthalocyanine Pc 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016213" MajorTopicYN="N">Cyclins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051160</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0148-7299</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>82</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics</Title>
          <ISOAbbreviation>Am J Med Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.</ArticleTitle>
        <Pagination>
          <MedlinePgn>290-3</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Germline mutations in the PTEN gene have recently been identified in some individuals with Cowden disease (CD), Lhermitte-Duclos disease (LDD), and Bannayan-Zonana syndrome. We report on a patient with CD and LDD in whom a unique de novo germline missense mutation is present in the PTEN gene. Direct sequence analysis detected a transitional change (T--&gt;C) at nucleotide 335, resulting in substitution of the amino acid proline for leucine. The mutation is in exon 5, which has been proposed as a "hot-spot" for germline mutations. Comparison of this patient's clinical course with the previously reported cases of CD and LDD shows more extensive and more severe clinical findings than reported previously. Findings in this patient contribute to the current understanding of germline PTEN mutations and clinical outcome.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sutphen</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of South Florida College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, Tampa 33612, USA. Rsutphen@com1.md.usf.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diamond</LastName>
            <ForeName>T M</ForeName>
            <Initials>TM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Minton</LastName>
            <ForeName>S E</ForeName>
            <Initials>SE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peacocke</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsou</LastName>
            <ForeName>H C</ForeName>
            <Initials>HC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Root</LastName>
            <ForeName>A W</ForeName>
            <Initials>AW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Genet</MedlineTA>
        <NlmUniqueID>7708900</NlmUniqueID>
        <ISSNLinking>0148-7299</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.2</RegistryNumber>
          <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.67</RegistryNumber>
          <NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.67</RegistryNumber>
          <NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002528" MajorTopicYN="N">Cerebellar Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005729" MajorTopicYN="N">Ganglioneuroma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018095" MajorTopicYN="N">Germ-Line Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006223" MajorTopicYN="N">Hamartoma Syndrome, Multiple</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="Y">Tumor Suppressor Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051167</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0148-7299</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>82</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics</Title>
          <ISOAbbreviation>Am J Med Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: avoiding pitfalls in the risk calculations.</ArticleTitle>
        <Pagination>
          <MedlinePgn>329-35</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We describe a general approach to derive fetal risk following two separate test results that each raise the likelihood of the same fetal abnormality without clearly determining whether the abnormality exists. Echogenic bowel observed on fetal ultrasonography may have multiple causes, including an a priori risk of approximately 1% of cystic fibrosis (CF). On numerous occasions our laboratory tests have detected only normal cystic fibrosis transmembrane regulator (CFTR) alleles in fetuses with echogenic bowel. This result indicates that another cause most likely explains the abnormal ultrasound finding. One of our tested fetuses was heterozygous for the deltaF508 CFTR mutation and had a normal karyotype. Over 770 CFTR mutations have been described, and a significant proportion of parental mutant alleles could not be detected by our 25-mutation test. Further mutation analysis demonstrated that the fetus' mother carried the deltaF508 mutation but the father (of different ethnic background than the mother) did not carry a detectable mutation. Thus, this test result substantially increased the risk of the fetus having CF, while still not giving a definitive answer to whether the fetus was affected. A rigorous mathematical analysis determined that the 1% risk of CF following ultrasound study was increased to slightly under 12% following DNA analysis. The case is described, and the mathematical formulas are explained and illustrated with examples, along with a review of conditional probability (Appendix 2).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hodge</LastName>
            <ForeName>S E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Columbia School of Physicians and Surgeons, New York State Psychiatric Institute, New York 10032, USA. seh2@columbia.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lebo</LastName>
            <ForeName>R V</ForeName>
            <Initials>RV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yesley</LastName>
            <ForeName>A R</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheney</LastName>
            <ForeName>S M</ForeName>
            <Initials>SM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angle</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Milunsky</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="N">
          <Grant>
            <GrantID>DK-31813</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>MH-28274</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>MH-48858</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Genet</MedlineTA>
        <NlmUniqueID>7708900</NlmUniqueID>
        <ISSNLinking>0148-7299</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505032">CFTR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126880-72-6</RegistryNumber>
          <NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003550" MajorTopicYN="N">Cystic Fibrosis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019005" MajorTopicYN="N">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016216" MajorTopicYN="N">Ultrasonography, Prenatal</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051171</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2006</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0148-7299</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>82</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics</Title>
          <ISOAbbreviation>Am J Med Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Monosomy 18q syndrome and atypical Rett syndrome in a girl with an interstitial deletion (18)(q21.1q22.3).</ArticleTitle>
        <Pagination>
          <MedlinePgn>348-51</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We describe a 6 1/2-year-old girl with an interstitial deletion of chromosome arm 18q (18q21.1q22.3). Her clinical manifestations are a combination of those found in monosomy 18q syndrome and those of Rett syndrome. Cytogenetic analysis demonstrated a deletion of the long arm of chromosome 18, defined by molecular analysis with polymorphic markers as a de novo interstitial deletion, paternally derived. The findings typical of the 18q- syndrome included mental retardation, midface hypoplasia, and hypoplasia of labia majora, and those typical of Rett syndrome were severe mental retardation, autistic behavior, inappropriate hand-washing movements, epilepsy, attacks of sighing and hyperventilation, and progressive scoliosis since the age of 5 years. She did not have microcephaly, and the mental delay was obvious from an early age without a period of normal development, which makes the diagnosis of Rett syndrome atypical. Previously, a girl with mosaicism for a monosomy 18q associated with Rett syndrome has been described. That girl had a terminal deletion of chromosome 18q, which seems to coincide in part with that in the present girl. It is possible that genes in the distal region of 18q are involved in the etiology of Rett syndrome.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gustavsson</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics and Pathology, Uppsala University, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimber</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wahlstr√∂m</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anner√©n</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Genet</MedlineTA>
        <NlmUniqueID>7708900</NlmUniqueID>
        <ISSNLinking>0148-7299</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002872" MajorTopicYN="Y">Chromosome Deletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002887" MajorTopicYN="N">Chromosomes, Human, Pair 18</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018900" MajorTopicYN="N">Dinucleotide Repeats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007621" MajorTopicYN="N">Karyotyping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009006" MajorTopicYN="Y">Monosomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015518" MajorTopicYN="N">Rett Syndrome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051474</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of macrophages with gadolinium chloride alters intercellular adhesion molecule-1 expression in the liver during acute endotoxemia in rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>728-36</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Cell adhesion molecules are important for localized accumulation of phagocytes at sites of tissue damage. In the present studies, we analyzed the effects of blocking hepatic macrophages on expression of beta2 integrins and intercellular adhesion molecule-1 (ICAM-1) adhesion molecules on liver cells during acute endotoxemia. Flow cytometric analysis revealed distinct subpopulations of macrophages from control animals that varied on the basis of their size and density. In contrast, hepatocytes and endothelial cells were relatively homogeneous. Treatment of rats with endotoxin (5 mg/kg, intravenously) resulted in a time-dependent increase in the percentage of small, dense macrophages and a progressive loss of larger, less-dense cells. In contrast, no major effects were observed on the physical properties of hepatocytes or endothelial cells. ICAM-1 was found to be constitutively expressed on endothelial cells and hepatocytes, as well as on macrophages. Induction of acute endotoxemia resulted in a time-dependent increase in ICAM-1 expression on hepatocytes, which was observed within 3 hours and reached a maximum after 24 hours. An increase in ICAM-1 expression was also observed on endothelial cells and on macrophages at 3 hours, followed by a decrease at 24 to 48 hours. Macrophages and endothelial cells also constitutively expressed beta2 integrins. Induction of acute endotoxemia had no effect on beta2 integrin expression by these cells. Pretreatment of rats with gadolinium chloride (GdCl3), a macrophage inhibitor known to block endotoxin-induced liver injury, abrogated the effects of endotoxin on ICAM-1 expression by hepatocytes and macrophages. In contrast, ICAM-1 expression on endothelial cells increased. Interestingly, treatment of rats with GdCl3 alone resulted in a marked increase in expression of ICAM-1 on endothelial cells and hepatocytes, and of beta2 integrins on macrophages and endothelial cells. Taken together, these data suggest that ICAM-1 is involved in mediating macrophage adherence and accumulation in the liver during endotoxemia. Furthermore, macrophages appear to regulate expression of this cell adhesion molecule on parenchymal cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ahmad</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ 08854-8020, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gardner</LastName>
            <ForeName>C R</ForeName>
            <Initials>CR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yurkow</LastName>
            <ForeName>E J</ForeName>
            <Initials>EJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laskin</LastName>
            <ForeName>D L</ForeName>
            <Initials>DL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ES05022</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>GM34310</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018821">CD18 Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126547-89-5</RegistryNumber>
          <NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AU0V1LM3JT</RegistryNumber>
          <NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P7082WY76D</RegistryNumber>
          <NameOfSubstance UI="C038958">gadolinium chloride</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018821" MajorTopicYN="N">CD18 Antigens</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019446" MajorTopicYN="N">Endotoxemia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005682" MajorTopicYN="N">Gadolinium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051473</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>719-27</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>As a model for the analysis of the fibrosuppressive role of estradiol, hepatic fibrosis was induced in male and female rats by the administration of a single dose of dimethylnitrosamine (DMN). The fibrotic response of the male liver after DMN treatment was significantly stronger than that of the female liver. In the male DMN model, estradiol reduced hepatic mRNA for type I and III procollagens and the tissue inhibitor of metalloproteinase-1 (TIMP-1), as well as deposition of type I and III collagen protein total hepatic collagen and malondialdehyde (MDA), a product of lipid peroxidation. Concomitant administration of a neutralizing antibody against rat estradiol enhanced fibrogenesis, as judged by the same parameters. Ovariectomy in the female model had a fibrogenic effect, inducing the hepatic expression of both types of procollagen and TIMP-1; in addition, the number of alpha-smooth muscle actin (alpha-SMA)-positive cells in the liver increased; estradiol replacement was fibrosuppressive in the castrated-female model. In rat hepatic stellate cells incubated in primary culture with estradiol, cell number, type I collagen production, and alpha-SMA expression were all reduced. These findings suggest that estradiol suppressed the induction of hepatic fibrosis, and may in part underlie the more rapid progression in males of hepatic fibrosis and its complications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yasuda</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, School of Medicine, University of Tokushima, Tokushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shiba</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ito</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>4TI98Z838E</RegistryNumber>
          <NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M43H21IO8R</RegistryNumber>
          <NameOfSubstance UI="D004128">Dimethylnitrosamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Hepatology. 1999 Mar;29(3):988-9</RefSource>
          <PMID Version="1">10051508</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004128" MajorTopicYN="N">Dimethylnitrosamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008106" MajorTopicYN="N">Liver Cirrhosis, Experimental</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051472</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2004</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endothelial cells lining transjugular intrahepatic portasystemic shunts originate in hepatic sinusoids: implications for pseudointimal hyperplasia.</ArticleTitle>
        <Pagination>
          <MedlinePgn>710-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The phenotype of the endothelial cells (ECs) in the pseudointima of transjugular intrahepatic portasystemic shunts (TIPS) and the mechanisms of pseudointima formation after TIPS were unknown. We hypothesized that TIPS were lined by hepatic sinusoidal ECs, which stimulated the migration of smooth muscle cells (SMCs) into the pseudointima and their proliferation. Studies were done with the following specific aims: (1) isolation of ECs from TIPS pseudointima and comparison of their phenotype with human cirrhotic sinusoidal and vascular ECs derived from hepatic and portal veins as well as aorta, and (2) testing of the effects of TIPS ECs on TIPS-derived SMC migration and proliferation. ECs were isolated from eight TIPS retrieved from liver explants by immunomagnetic separation using monodispersed magnetizable polystyrene beads (Dynabeads M-450) coated with Ulex Europeus 1. EC phenotypes were examined by transmission electron microscopy, factor VIII-related antigen, CD31, CD14, and CD34 expression, uptake of acetylated LDL and secretion of type IV collagen. The effects of EC-conditioned media on SMC migration and proliferation were tested in multiwell chemotaxis chambers and by cell counting, respectively. ECs were obtained from TIPS pseudointima with &gt;95% purity. The phenotype of TIPS-derived ECs matched that of cirrhotic sinusoidal endothelium (both expressed CD14) and differed from that of vascular endothelium (CD14 negative, Weibel-Palade positive). Conditioned media from both stenosed (n = 3) and nonstenosed (n = 3) TIPS-derived endothelial cells produced a marked (&gt;100%) P &lt;.001 increase in migration as well as (up to 88%) P &lt;.01 proliferation of SMCs from both stenosed (n = 3) as well as nonstenosed TIPS (n = 3). These data indicate that TIPS pseudointima are lined by hepatic sinusoidal endothelial cells, which stimulate pseudointima formation by increasing SMC migration and proliferation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sanyal</LastName>
            <ForeName>A J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Medical College of Virginia campus of Virginia Commonwealth University, Richmond, VA 23298-0711, USA. krrobert@hsc.vcu.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mirshahi</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006503" MajorTopicYN="N">Hepatic Veins</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006965" MajorTopicYN="N">Hyperplasia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011169" MajorTopicYN="N">Portal Vein</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019168" MajorTopicYN="N">Portasystemic Shunt, Transjugular Intrahepatic</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017539" MajorTopicYN="N">Tunica Intima</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051471</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2007</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>703-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>To examine the significance of aberrant DNA methylation in hepatocarcinogenesis, the DNA methylation status at the D17S5 locus and mRNA expression of a candidate tumor suppressor gene, HIC-1 (hypermethylated-in-cancer), which was identified at the D17S5 locus, in primary hepatocellular carcinomas (HCCs) and their corresponding noncancerous liver tissues were assessed. DNA hypermethylation at the D17S5 locus was detected in 44% of the noncancerous liver tissues showing chronic hepatitis or cirrhosis, which are widely considered to be precancerous conditions, but was not observed in noncancerous liver tissues showing no remarkable histological findings. The incidence of DNA hypermethylation at this locus was significantly higher in HCCs (90%) than noncancerous liver tissues (P &lt;.001). Loss of heterozygosity at the D17S5 locus, which was preceded by DNA hypermethylation at the same locus, was detected in 54% of HCCs. The HIC-1 mRNA expression level of noncancerous liver tissues showing chronic hepatitis or cirrhosis was significantly lower than that of noncancerous liver tissues showing no remarkable histological findings (P &lt;.01), and that of HCCs was even lower than that of noncancerous liver tissues (P &lt;.05). Poorly differentiated HCCs showed lower expression levels than well- to moderately differentiated HCCs. Mutation of the p53 gene may be involved in HIC-1 inactivation. Moreover, wild-type p53 did not overcome DNA hypermethylation at the D17S5 locus to activate HIC-1 in HCCs. These data suggest that aberrant DNA methylation at this locus and reduced HIC-1 mRNA expression participate in hepatocarcinogenesis during both early developmental stages and malignant progression of HCCs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kanai</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Division, National Cancer Center Research Institute, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hui</LastName>
            <ForeName>A M</ForeName>
            <Initials>AM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ushijima</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakamoto</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuda</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirohashi</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C096870">Hic1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="Y">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051741" MajorTopicYN="N">Kruppel-Like Transcription Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019656" MajorTopicYN="N">Loss of Heterozygosity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051468</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice [correction of rat] liver.</ArticleTitle>
        <Pagination>
          <MedlinePgn>677-87</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The growth-stimulatory actions of tumor necrosis factor alpha (TNF-alpha) after partial hepatectomy (PH) are difficult to reconcile with its well-established role in the genesis of liver injury. The lethal actions of TNF are thought to involve the induction of oxidant production by mitochondria. It is not known if TNF initiates mitochondrial oxidant production after PH. Furthermore, if this potentially toxic response follows PH, it is not clear how hepatocytes defend themselves sufficiently so that replication, rather than death, occurs. These studies test the hypothesis that TNF does increase mitochondrial oxidant production after PH but that these oxidants primarily promote the induction of antioxidant defenses in regenerating hepatocytes. Consistent with this concept, H2O2 production by liver mitochondria increases from 5 minutes to 3 hours after PH, beginning before the transient inductions of hepatic NF kB activity (which peaks at 30 minutes post-PH) and uncoupling protein-2 (UCP-2) (which begins around 30 minutes and peaks from 6-24 hours post-PH). Pretreatment with neutralizing anti-TNF antibodies, which inhibits hepatocyte DNA synthesis after PH, also reduces post-PH hepatic mitochondrial oxidant production by 80% and inhibits NF kappaB activation and UCP-2 induction by 50% and 80%, respectively. In contrast, pretreatment with D609, an agent that inhibits phosphatidylcholine-specific phospholipase C, neither inhibits regenerative induction of mitochondrial oxidant production, UCP-2 expression, nor hepatocyte DNA synthesis, although it inhibits NF kappaB activation by 50%. Given published evidence that NF kappaB is antiapoptotic and that UCP-2 may decrease mitochondrial oxidant production in some cells, these results suggest that TNF-dependent increases in oxidant production by liver mitochondria promote the induction of antioxidant defenses in the regenerating liver.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>F Y</ForeName>
            <Initials>FY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>H Z</ForeName>
            <Initials>HZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trush</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diehl</LastName>
            <ForeName>A M</ForeName>
            <Initials>AM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001952">Bridged-Ring Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009636">Norbornanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013859">Thiocarbamates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013871">Thiones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000604390">Ucp2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000604391">Ucp2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071246">Uncoupling Protein 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5QC1Z07M77</RegistryNumber>
          <NameOfSubstance UI="C046498">tricyclodecane-9-yl-xanthogenate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-79-2</RegistryNumber>
          <NameOfSubstance UI="D006003">Glycogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001952" MajorTopicYN="N">Bridged-Ring Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008115" MajorTopicYN="N">Liver Regeneration</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026901" MajorTopicYN="Y">Membrane Transport Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="Y">Mitochondrial Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009636" MajorTopicYN="N">Norbornanes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016877" MajorTopicYN="N">Oxidants</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013859" MajorTopicYN="N">Thiocarbamates</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013871" MajorTopicYN="N">Thiones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071246" MajorTopicYN="N">Uncoupling Protein 2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051483</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hepatoprotective effect of endogenous nitric oxide during ischemia-reperfusion in the rat.</ArticleTitle>
        <Pagination>
          <MedlinePgn>809-13</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The aim of this study was to evaluate the protective or deleterious effects of endogenous nitric oxide (NO) on liver cells during hepatic ischemia-reperfusion (IR) in the rat. Injury to hepatocytes and endothelial cells was evaluated by determining cytolysis-marker activity in plasma (alanine transaminase [ALT]; aspartate transaminase [AST]) and plasma hyaluronic acid (HA) concentration. Clamping the hepatic pedicle for 45 minutes caused a significant increase in plasma AST and ALT activity after 30 minutes of reperfusion, which reached a maximum (+270% and +740%, respectively) after 6 hours of reperfusion. Plasma HA concentration was significantly higher (+130%) only after 6 hours of reperfusion. Administration of a nonselective NO synthase (NOS) inhibitor, Nomega-nitro-L-arginine (L-NNA; 10 mg/kg iv), 30 minutes before IR, caused marked aggravation of postischemic liver injury, as shown by plasma ALT and AST activity and HA concentration. This deleterious effect was partially prevented by the simultaneous injection of L-arginine, the endogenous NO precursor (100 mg/kg iv). Interestingly, L-arginine alone limited postischemic damage (AST, -25%; ALT, -45%; HA, -21% vs. untreated IR rats at 6 hours reperfusion). Pretreatment with the Guanosine 3':5'-cyclic monophosphate-independent vasodilator, prazosin, partially reversed L-NNA effects, but it did not protect untreated IR animals. Pretreatment with aminoguanidine, a selective inhibitor of inducible NOS, did not aggravate hepatic IR injury. Thus, endogenous NO, probably produced by an early and transient activation of a constitutive NOS, protects both hepatocytes and endothelial cells against liver ischemia-reperfusion injury, and this effect is not entirely a result of vasorelaxation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cottart</LastName>
            <ForeName>C H</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, UFR des Sciences Pharmaceutiques et Biologiques, Universit√© Ren√© Descartes, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Do</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blanc</LastName>
            <ForeName>M C</ForeName>
            <Initials>MC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vaubourdolle</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Descamps</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durand</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galen</LastName>
            <ForeName>F X</ForeName>
            <Initials>FX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clot</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008102" MajorTopicYN="Y">Liver Circulation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015427" MajorTopicYN="N">Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">10057656</PMID>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1079-7114</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>73</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>1994</Year>
              <Month>Aug</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Physical review letters</Title>
          <ISOAbbreviation>Phys Rev Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Loss of spatial coherence by a single spontaneous emission.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1223-1226</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pfau</LastName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sp√§lter</LastName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurtsiefer</LastName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ekstrom</LastName>
            <Initials>CR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mlynek</LastName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Phys Rev Lett</MedlineTA>
        <NlmUniqueID>0401141</NlmUniqueID>
        <ISSNLinking>0031-9007</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051504</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells.</ArticleTitle>
        <Pagination>
          <MedlinePgn>960-70</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Oxidative stress plays a key role in liver fibrosis. Both inflammatory cells and activated Kupffer cells produce H2O2, an oxidant involved in the activation of hepatic stellate cells (HSC). Increased production of reactive oxygen intermediates (ROIs) in fibrotic livers is associated in part with the up-regulation of transforming growth factor beta (TGF-beta), and this cytokine enhances collagen production by cultured HSC. However, the possible link between oxidative stress and the molecular mechanisms by which TGF-beta induces collagen gene expression in HSC remains to be elucidated. To address this question, we investigated whether H2O2 is a mediator of TGF-beta-elicited alpha1(I) collagen gene (col1a1) up-regulation. We demonstrated that TGF-beta induces the accumulation of H2O2, and that this oxidant is, in turn, directly involved in up-regulating the expression of the col1a1 gene. While the addition of H2O2 to HSC induced the expression of alpha1(I) procollagen mRNA, catalase, an H2O2 enzyme scavenger, abrogated TGF-beta-mediated col1a1 gene up-regulation. We transfected HSC with chimeric plasmids driven by different segments of the mouse col1a1 promoter and mapped a cis-acting element (-370 to -344) essential for TGF-beta responsiveness. We further showed that TGF-beta induced the activation and binding of a C/EBPbeta-containing transcriptional complex to this sequence, an effect that was also mimicked by the addition of H2O2. Taken together, these data demonstrate a direct connection between TGF-beta-mediated accumulation of H2O2 and the up-regulation of col1a1 gene in HSC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Garc√≠a-Trevijano</LastName>
            <ForeName>E R</ForeName>
            <Initials>ER</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iraburu</LastName>
            <ForeName>M J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fontana</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dom√≠nguez-Rosales</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Auster</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covarrubias-Pinedo</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rojkind</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AA09231</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AA10541</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022762">CCAAT-Enhancer-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011347">Procollagen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013859">Thiocarbamates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>135467-92-4</RegistryNumber>
          <NameOfSubstance UI="C066229">prolinedithiocarbamate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-34-5</RegistryNumber>
          <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9DLQ4CIU6V</RegistryNumber>
          <NameOfSubstance UI="D011392">Proline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.6</RegistryNumber>
          <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022762" MajorTopicYN="N">CCAAT-Enhancer-Binding Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002374" MajorTopicYN="N">Catalase</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016877" MajorTopicYN="N">Oxidants</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011347" MajorTopicYN="N">Procollagen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020218" MajorTopicYN="N">Response Elements</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013859" MajorTopicYN="N">Thiocarbamates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051503</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2006</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0270-9139</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen.</ArticleTitle>
        <Pagination>
          <MedlinePgn>954-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Hepatitis B (HB) vaccine provides an uncertain duration of protection and the optimal timing of booster vaccine remains unclear. This study examined the immune response at 10 years of 118 children who had developed protective anti-HB surface (anti-HBs) levels after a primary series of HB immunizations in infancy. All of the children were born to hepatitis B e Antigen (HBeAg)-positive hepatitis B surface antigen (HBsAg) carrier mothers. HB markers in all subjects and cellular immune response in some were determined. A booster was given to all subjects after the collection of samples and another blood sample was collected 4 weeks later. The results showed that a total of 39 (33%) of the children were seronegative for anti-HBs. T-cell proliferative response to HBsAg was noted in 47% of children. On HBsAg stimulation, leukocyte samples from a significantly higher proportion of subjects produced cytokines (81% of T cells produced interleukin-2 [IL-2] and 100% produced IL-5). The booster dose of HB vaccine induced the production of a protective level of anti-HBs (&gt;/=10 mIU/mL) in all subjects. Cellular immunity was augmented with a positive rate of 58%, 90%, and 100% for HBsAg-induced T-cell proliferation, IL-2 production, and IL-5 production, respectively. Although 14 (11.9%) of the subjects were HB core antibody positive at 10 years of age, no new HBsAg carrier was detected. The results of this study show that protection afforded by HB vaccination persisted to the age of 10 years in all vaccinees. Immunologic memory was detected in all subjects including those who had lost their anti-HBs seropositivity. These results suggest that no booster vaccination is needed before 10 years of age. The most sensitive marker of immunologic memory is IL-5 production of T cells. (HEPATOLOGY 1999;29:954-959.)</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, National Taiwan University Hospital, Development Center for Biotechnology, Taipei, Taiwan. lmhuang@ha.mc.ntu.edu.tw</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiang</LastName>
            <ForeName>B L</ForeName>
            <Initials>BL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>C Y</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>P I</ForeName>
            <Initials>PI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chi</LastName>
            <ForeName>W K</ForeName>
            <Initials>WK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>M H</ForeName>
            <Initials>MH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006513">Hepatitis B e Antigens</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006513" MajorTopicYN="N">Hepatitis B e Antigens</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051530</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0026-895X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>55</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pharmacology</Title>
          <ISOAbbreviation>Mol Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.</ArticleTitle>
        <Pagination>
          <MedlinePgn>473-80</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The peripheral cannabinoid receptor (CB2) is a G protein-coupled receptor that is both positively and negatively coupled to the mitogen-activated protein kinase (MAPK) and cAMP pathways, respectively, through a Bordetella pertussis toxin-sensitive G protein. CB2 receptor-transfected Chinese hamster ovary cells exhibit high constitutive activity blocked by the CB2-selective ligand, SR 144528, working as an inverse agonist. We showed here that in addition to the inhibition of autoactivated CB2 in this model, we found that SR 144528 inhibited the MAPK activation induced by Gi-dependent receptors such as receptor-tyrosine kinase (insulin, insulin-like growth factor 1) or G protein-coupled receptors (lysophosphatidic acid), but not by Gi-independent receptors such as the fibroblast growth factor receptor. We showed that this SR 144528 inhibitory effect on Gi-dependent receptors was mediated by a direct Gi protein inhibition through CB2 receptors. Indeed, we found that through binding to the CB2 receptors, SR 144528 blocked the direct activation of the Gi protein by mastoparan analog in Chinese hamster ovary CB2 cell membranes. Furthermore, we described that sustained treatment with SR 144528 induced an up-regulation of the cellular Gi protein level as shown in Western blotting as well as in confocal microscopic experiments. This up-regulation occurred with a concomitant loss of SR 144528 ability to inhibit the insulin or lysophosphatidic acid-induced MAPK activation. This inverse agonist-induced modulation of the Gi strongly suggests that the modulated protein is functionally associated with the complex SR 144528/CB2 receptors, and that the Gi level may account for the heterologous desensitization phenomena.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bouaboula</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Sanofi Recherche, Montpellier cedex 04, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desnoyer</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carayon</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Combes</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Casellas</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Pharmacol</MedlineTA>
        <NlmUniqueID>0035623</NlmUniqueID>
        <ISSNLinking>0026-895X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001892">Camphanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043882">Receptors, Cannabinoid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C110630">SR 144528</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010566">Virulence Factors, Bordetella</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.31</RegistryNumber>
          <NameOfSubstance UI="D037342">Pertussis Toxin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001892" MajorTopicYN="N">Camphanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037342" MajorTopicYN="N">Pertussis Toxin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043882" MajorTopicYN="N">Receptors, Cannabinoid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011955" MajorTopicYN="N">Receptors, Drug</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010566" MajorTopicYN="N">Virulence Factors, Bordetella</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051660</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ca2+-induced inhibition of the cardiac Ca2+ channel depends on calmodulin.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2435-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Ca2+-induced inhibition of alpha1C voltage-gated Ca2+ channels is a physiologically important regulatory mechanism that shortens the mean open time of these otherwise long-lasting high-voltage-activated channels. The mechanism of action of Ca2+ has been a matter of some controversy, as previous studies have proposed the involvement of a putative Ca2+-binding EF hand in the C terminus of alpha1C and/or a sequence downstream from this EF-hand motif containing a putative calmodulin (CaM)-binding IQ motif. Previously, using site directed mutagenesis, we have shown that disruption of the EF-hand motif does not remove Ca2+ inhibition. We now show that the IQ motif binds CaM and that disruption of this binding activity prevents Ca2+ inhibition. We propose that Ca2+ entering through the voltage-gated pore binds to CaM and that the Ca/CaM complex is the mediator of Ca2+ inhibition.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, University of California, Los Angeles, CA 90095-1778, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olcese</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bransby</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birnbaumer</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>AR43411</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002147">Calmodulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.5.1.18</RegistryNumber>
          <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002147" MajorTopicYN="N">Calmodulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005982" MajorTopicYN="N">Glutathione Transferase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014982" MajorTopicYN="N">Xenopus laevis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051637</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2305-10</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The congenital nemaline myopathies are rare hereditary muscle disorders characterized by the presence in the muscle fibers of nemaline bodies consisting of proteins derived from the Z disc and thin filament. In a single large Australian family with an autosomal dominant form of nemaline myopathy, the disease is caused by a mutation in the alpha-tropomyosin gene TPM3. The typical form of nemaline myopathy is inherited as an autosomal recessive trait, the locus of which we previously assigned to chromosome 2q21.2-q22. We show here that mutations in the nebulin gene located within this region are associated with the disease. The nebulin protein is a giant protein found in the thin filaments of striated muscle. A variety of nebulin isoforms are thought to contribute to the molecular diversity of Z discs. We have studied the 3' end of the 20. 8-kb cDNA encoding the Z disc part of the 800-kDa protein and describe six disease-associated mutations in patients from five families of different ethnic origins. In two families with consanguineous parents, the patients were homozygous for point mutations. In one family with nonconsanguineous parents, the affected siblings were compound heterozygotes for two different mutations, and in two further families with one detected mutation each, haplotypes are compatible with compound heterozygosity. Immunofluorescence studies with antibodies specific to the C-terminal region of nebulin indicate that the mutations may cause protein truncation possibly associated with loss of fiber-type diversity, which may be relevant to disease pathogenesis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pelin</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Genetics, University of Helsinki, and the Folkh√§lsan Institute of Genetics, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hilpel√§</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Donner</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sewry</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akkari</LastName>
            <ForeName>P A</ForeName>
            <Initials>PA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilton</LastName>
            <ForeName>S D</ForeName>
            <Initials>SD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wattanasirichaigoon</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bang</LastName>
            <ForeName>M L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Centner</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hanefeld</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Odent</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fardeau</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Urtizberea</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muntoni</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dubowitz</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beggs</LastName>
            <ForeName>A H</ForeName>
            <Initials>AH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laing</LastName>
            <ForeName>N G</ForeName>
            <Initials>NG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Labeit</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de la Chapelle</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wallgren-Pettersson</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>GENBANK</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>AF117661</AccessionNumber>
              <AccessionNumber>AF117662</AccessionNumber>
              <AccessionNumber>AF117663</AccessionNumber>
              <AccessionNumber>AF117664</AccessionNumber>
              <AccessionNumber>AF117665</AccessionNumber>
              <AccessionNumber>AF117666</AccessionNumber>
              <AccessionNumber>AF117667</AccessionNumber>
              <AccessionNumber>AF117668</AccessionNumber>
              <AccessionNumber>AF117669</AccessionNumber>
              <AccessionNumber>AF117670</AccessionNumber>
              <AccessionNumber>AF117671</AccessionNumber>
              <AccessionNumber>AF117672</AccessionNumber>
              <AccessionNumber>AF117673</AccessionNumber>
              <AccessionNumber>AF117674</AccessionNumber>
              <AccessionNumber>AF117675</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA067941</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA067941</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA16058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AR044345</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA67941</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>AR44345</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018388">Codon, Terminator</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009124">Muscle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>02X6KNJ5EE</RegistryNumber>
          <NameOfSubstance UI="C035620">nebulin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002889" MajorTopicYN="Y">Chromosomes, Human, Pair 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018388" MajorTopicYN="N">Codon, Terminator</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016368" MajorTopicYN="Y">Frameshift Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018485" MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009124" MajorTopicYN="N">Muscle Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017696" MajorTopicYN="N">Myopathies, Nemaline</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051646</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0027-8424</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2356-60</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation caused by defective carnitine transport. This disease presents early in life with hypoketotic hypoglycemia or later in life with skeletal myopathy or cardiomyopathy. The gene for this condition maps to 5q31.2-32 and OCTN2, an organic cation/carnitine transporter, also maps to the same chromosomal region. Here we test the causative role of OCTN2 in primary carnitine deficiency by searching for mutations in this gene in affected patients. Fibroblasts from patients with primary carnitine deficiency lacked mediated carnitine transport. Transfection of patient's fibroblasts with the OCTN2 cDNA partially restored carnitine transport. Sequencing of the OCTN2 gene revealed different mutations in two unrelated patients. The first patient was homozygous (and both parents heterozygous) for a single base pair substitution converting the codon for Arg-282 to a STOP codon (R282X). The second patient was a compound heterozygote for a paternal 1-bp insertion producing a STOP codon (Y401X) and a maternal 1-bp deletion that produced a frameshift creating a subsequent STOP codon (458X). These mutations decreased the levels of mature OCTN2 mRNA and resulted in nonfunctional transporters, confirming that defects in the organic cation/carnitine transporter OCTN2 are responsible for primary carnitine deficiency.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Genetics, Department of Pediatrics, Emory University, 2040 Ridgewood Drive, Atlanta, GA 30322, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ganapathy</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Longo</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DA 10045</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK 48742</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018388">Codon, Terminator</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027701">Organic Cation Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492020">SLC22A5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074058">Solute Carrier Family 22 Member 5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S7UI8SM58A</RegistryNumber>
          <NameOfSubstance UI="D002331">Carnitine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002895" MajorTopicYN="N">Chromosomes, Human, Pair 5</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018388" MajorTopicYN="N">Codon, Terminator</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016368" MajorTopicYN="Y">Frameshift Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027701" MajorTopicYN="Y">Organic Cation Transport Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074058" MajorTopicYN="N">Solute Carrier Family 22 Member 5</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014804" MajorTopicYN="N">Vitamin B Deficiency</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051705</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0954-7894</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
          <ISOAbbreviation>Clin Exp Allergy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Expression of histidine decarboxylase messenger RNA and histamine N-methyltransferase messenger RNA in nasal allergy.</ArticleTitle>
        <Pagination>
          <MedlinePgn>76-83</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Histamine is an important chemical mediator in allergic rhinitis. Histamine is synthesized by L-histidine, catalysed by L-histidine decarboxylase (HDC) and metabolized mainly by histamine N-methyltransferase (HMT). The patients with allergic rhinitis may have altered histamine metabolism in the nasal tissue.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective was to compare the expression of HDC mRNA and HMT mRNA in nasal mucosa with normal individuals and patients with allergic rhinitis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We extracted RNA from scrapings of inferior turbinate mucosa of 11 patients with allergic rhinitis and from 11 normal subjects and from surgically dissected inferior turbinate mucosa of 11 patients. HDC, HMT and beta-actin mRNA were amplified by reverse transcription-polymerase chain reaction (RT-PCR).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean +/- SD of HDC/beta-actin ratios were 0.58 +/- 0.28 for the scrapings of normal subjects, 0.93 +/- 0.38 for the scrapings of the patients with allergic rhinitis and 1.41 +/- 0.26 for the inferior turbinates of the patients with allergic rhinitis. The mean +/- SD of HMT/beta-actin ratios were 1.66 +/- 0.27 for the scrapings of normal subjects, 0.93 +/- 0.20 for the scrapings of the patients with allergic rhinitis and 0.65 +/- 0.28 for the inferior turbinates of the patients with allergic rhinitis. The differences among the three groups were statistically significant.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased HDC mRNA expression and decreased HMT mRNA expression may be playing some role in the hyperresponsiveness of patients with allergic rhinitis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, Mie University School of Medicine, Tsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takeuchi</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ukai</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakakura</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Exp Allergy</MedlineTA>
        <NlmUniqueID>8906443</NlmUniqueID>
        <ISSNLinking>0954-7894</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.8</RegistryNumber>
          <NameOfSubstance UI="D006637">Histamine N-Methyltransferase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.1.1.22</RegistryNumber>
          <NameOfSubstance UI="D006640">Histidine Decarboxylase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Clin Exp Allergy. 1999 Jan;29(1):9-11</RefSource>
          <PMID Version="1">10051696</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006637" MajorTopicYN="N">Histamine N-Methyltransferase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006640" MajorTopicYN="N">Histidine Decarboxylase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012221" MajorTopicYN="N">Rhinitis, Allergic, Perennial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10051776</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0953-816X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The European journal of neuroscience</Title>
          <ISOAbbreviation>Eur J Neurosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Incorporation of a gephyrin-binding motif targets NMDA receptors to gephyrin-rich domains in HEK 293 cells.</ArticleTitle>
        <Pagination>
          <MedlinePgn>740-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The peripheral membrane protein gephyrin is essential for the postsynaptic localization of inhibitory glycine receptors (GlyRs). Binding of gephyrin to the GlyR beta subunit is mediated by a sequence motif located in the intracellular loop region connecting transmembrane segments 3 and 4. Here, insertion of this binding motif is shown to alter the subcellular distribution of an excitatory neurotransmitter receptor in transfected mammalian cells. Upon coexpression with gephyrin, a mutant N-methyl-D-aspartate (NMDA) receptor containing NMDA receptor 1 (NR1) subunits which harboured a gephyrin-binding motif within its cytoplasmic tail region, was targeted to intracellular gephyrin-rich domains, as previously observed for the GlyR beta subunit. Our data indicate that a gephyrin-binding motif located in a cytoplasmic domain of an integral membrane protein suffices for routing to gephyrin-rich domains.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kins</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurochemistry, Max-Planck-Institute for Brain Research, Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuhse</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laube</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Betz</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirsch</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Eur J Neurosci</MedlineTA>
        <NlmUniqueID>8918110</NlmUniqueID>
        <ISSNLinking>0953-816X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C073441">gephyrin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10049519</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2007</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1043-4666</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cytokine</Title>
          <ISOAbbreviation>Cytokine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo.</ArticleTitle>
        <Pagination>
          <MedlinePgn>956-63</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Levels of inflammatory cytokines tumour necrosis factor (TNF), interleukin 1 (IL-1), IL-6, and cytokine-induced neutrophil chemoattractant (CINC), which is a member of the alpha-chemokine family in rats, were measured in the pleural exudates during zymosan-induced pleurisy to examine the relationship between the local production of cytokines and the inflammatory reaction. All four cytokine levels in the pleural exudate began to increase after 1-2 h, preceding the influx of neutrophils, and peaked after 4-5 h. Thereafter, these cytokine levels declined after 24 h, whereas the exudate volume still continued to increase and leukocyte number reached a plateau. Concomitant injection of actinomycin D (10 microg) with zymosan markedly suppressed the neutrophil infiltration, parallel with CINC production in the pleural exudate at 4 h. A transient elevation of IL-6 level, peaking at 5 h, and subsequent rise in the level of an acute-phase protein, T-kininogen, were also observed in the plasma. When recombinant human TNF-alpha (rhTNF-alpha) (20 000 U) was intrapleurally injected a rapid increase in pleural CINC level, followed by neutrophil infiltration, and a sharp rise in IL-6 level in the plasma, followed by an increase in T-kininogen, were demonstrated. These results suggest that CINC produced in the pleural exudate may participate in neutrophil infiltration, that IL-6 induced in the plasma stimulates T-kininogen production, and that endogenous TNF may be partly involved in the induction of CINC and IL-6 in this zymosan inflammation.</AbstractText>
          <CopyrightInformation>Copyright 1998 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Utsunomiya</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ito</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oh-ishi</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cytokine</MedlineTA>
        <NlmUniqueID>9005353</NlmUniqueID>
        <ISSNLinking>1043-4666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C475829">CXCL1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054360">Chemokine CXCL1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019743">Chemokines, CXC</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002630">Chemotactic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C475895">Cxcl1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C513297">Cxcl1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006133">Growth Substances</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007704">Kininogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9010-72-4</RegistryNumber>
          <NameOfSubstance UI="D015054">Zymosan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054360" MajorTopicYN="N">Chemokine CXCL1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019743" MajorTopicYN="Y">Chemokines, CXC</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002630" MajorTopicYN="N">Chemotactic Factors</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006133" MajorTopicYN="N">Growth Substances</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036341" MajorTopicYN="Y">Intercellular Signaling Peptides and Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007704" MajorTopicYN="N">Kininogens</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010996" MajorTopicYN="N">Pleural Effusion</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010998" MajorTopicYN="N">Pleurisy</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015054" MajorTopicYN="N">Zymosan</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10049524</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1043-4666</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cytokine</Title>
          <ISOAbbreviation>Cytokine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The clinical value of assaying maternal serum and amniotic fluid intercellular adhesion molecule 1 (ICAM-1) in cases of premature rupture of membranes.</ArticleTitle>
        <Pagination>
          <MedlinePgn>989-92</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Intercellular adhesion molecule 1 (ICAM-1) expression and upregulation induced by pro-inflammatory cytokines may be of interest in defining human response to inflammation and infection. This study was initiated to determine the levels of ICAM-1 in sera and amniotic fluid of cases of premature rupture of membranes (PROM). Serum and amniotic fluid ICAM-1 levels were determined by ELISA in 33 cases of PROM and 10 cases of normal pregnancies of matched gestational age (controls). Both serum and amniotic fluid ICAM levels were significantly elevated in 76% and 85% of cases of PROM with mean fold increments of 3.13 and 3.95, respectively. This elevation was associated with intra-amniotic infection which was detected by microbiological culture and histopathological evidence of chorioamnionitis. Increased ICAM-1 in cases of PROM may be attributed to neutrophil activation and ICAM-1 expression on fetal membranes and mononuclear cells of amniotic fluid. These results demonstrate that determination of ICAM-1 may be a valuable biomarker for early detection of acute chorioamnionitis and the possibility of PROM.</AbstractText>
          <CopyrightInformation>Copyright 1998 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shaarawy</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, Faculty of Medicine, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Mallah</LastName>
            <ForeName>S Y</ForeName>
            <Initials>SY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Dawakhly</LastName>
            <ForeName>A S</ForeName>
            <Initials>AS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mosaad</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cytokine</MedlineTA>
        <NlmUniqueID>9005353</NlmUniqueID>
        <ISSNLinking>1043-4666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126547-89-5</RegistryNumber>
          <NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000653" MajorTopicYN="N">Amniotic Fluid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002821" MajorTopicYN="N">Chorioamnionitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005322" MajorTopicYN="N">Fetal Membranes, Premature Rupture</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10049743</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-291X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>255</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Possibility of the transformation of eEF-2 (100 kDa) to eEF-2 (65 kDa) in the peptide elongation process in vitro.</ArticleTitle>
        <Pagination>
          <MedlinePgn>535-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Two active eEF-2 polypeptides of approximately 100 and 65 kDa were copurified from rat liver cells and separated. The fate of eEF-2 (100 kDa) during its binding to ribosomes and in the translocation step of the peptide elongation process was investigated. It was shown that eEF-2 (100 kDa) did not change its form during the process of binding to the ribosomes. In the postribosomal supernatant, obtained from the postincubation mixture of the elongation process, only eEF-2 (65 kDa) was found. These results suggest that the form of eEF-2 (100 kDa), when bound to the ribosome during the elongation process, is transformed to eEF-2 (65 kDa).</AbstractText>
          <CopyrightInformation>Copyright 1999 Academic Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gajko</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Academy, Institute of Chemistry, Bialystok, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sredzi≈Ñska</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galasi≈Ñski</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gindzie≈Ñski</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020652">Peptide Elongation Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010445">Peptide Elongation Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GMW67QNF9C</RegistryNumber>
          <NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002474" MajorTopicYN="N">Cell-Free System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002848" MajorTopicYN="N">Chromatography, DEAE-Cellulose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010441" MajorTopicYN="Y">Peptide Chain Elongation, Translational</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020652" MajorTopicYN="N">Peptide Elongation Factor 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010445" MajorTopicYN="N">Peptide Elongation Factors</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011132" MajorTopicYN="N">Polyribosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10049952</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>06</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-1007</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>189</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of experimental medicine</Title>
          <ISOAbbreviation>J Exp Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Peripheral autoantigen induces regulatory T cells that prevent autoimmunity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>877-82</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Previous studies have shown that autoimmune thyroiditis can be induced in normal laboratory rats after thymectomy and split dose gamma-irradiation. Development of disease can be prevented by reconstitution of PVG rats shortly after their final irradiation with either peripheral CD4(+)CD45RC- T cells or CD4(+)CD8(-) thymocytes from syngeneic donors. Although the activity of both populations is known to depend on the activities of endogenously produced interleukin 4 and transforming growth factor beta, implying a common mechanism, the issue of antigen specificity of the cells involved has not yet been addressed. In this study, we show that the regulatory T cells that prevent autoimmune thyroiditis are generated in vivo only when the relevant autoantigen is also present. Peripheral CD4(+) T cells, from rats whose thyroids were ablated in utero by treatment with 131I, were unable to prevent disease development upon adoptive transfer into thymectomized and irradiated recipients. This regulatory deficit is specific for thyroid autoimmunity, since CD4(+) T cells from 131I-treated PVG.RT1(u) rats were as effective as those from normal donors at preventing diabetes in thymectomized and irradiated PVG.RT1(u) rats. Significantly, in contrast to the peripheral CD4(+) T cells, CD4(+)CD8(-) thymocytes from 131I-treated PVG donors were still able to prevent thyroiditis upon adoptive transfer. Taken together, these data indicate that it is the peripheral autoantigen itself that stimulates the generation of the appropriate regulatory cells from thymic emigrant precursors.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Seddon</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom. bseddon@nimr.mrc.ac.uk</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mason</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Exp Med</MedlineTA>
        <NlmUniqueID>2985109R</NlmUniqueID>
        <ISSNLinking>0022-1007</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>X</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018448" MajorTopicYN="N">Models, Immunological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054562" MajorTopicYN="N">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011828" MajorTopicYN="N">Radiation Chimera</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013934" MajorTopicYN="N">Thymectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064160</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2999</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>366</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmacology</Title>
          <ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate.</ArticleTitle>
        <Pagination>
          <MedlinePgn>119-26</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The alpha1-adrenoceptor subtypes of rat prostate were characterized in binding and functional experiments. In binding experiments, [3H]tamsulosin bound to a single class of binding sites with an affinity (pKD) of 10.79+/-0.04 and Bmax of 87+/-2 fmol mg(-1) protein. This binding was inhibited by prazosin, 2-(2,6-dimethoxy-phenoxyethyl)-aminomethyl-1,4-benzodioxane hydrochloride (WB4101), 5-methylurapidil, alpha-ethyl-3,4,5,-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)ethyl)-amin o)-propyl)benzeneacetonitrile fumarate (HV723) and oxymetazoline with high efficacy, resulting in a good correlation with the binding characteristics of cloned alpha1a but not alpha1b and alpha1d-adrenoceptor subtypes. In functional studies, noradrenaline and oxymetazoline produced concentration-dependent contractions. These contractions were antagonized by tamsulosin, prazosin, WB4101 and 5-methylurapidil with an efficacy lower than that exhibited by these agents for inhibition of [3H]tamsulosin binding. The relationship between receptor occupancy and contractile amplitude revealed the presence of receptor reserve for noradrenaline, but the contraction induced by oxymetazoline was not in parallel with receptor occupation and developed after predicted receptor saturation. From these results, it is suggested that alpha1A-adrenoceptors are the dominant subtype in the rat prostate which can be detected with [3H]tamsulosin, but that the functional subtype mediating adrenergic contractions has the characteristics of the alpha1L-adrenoceptor subtype, having a lower affinity for prazosin and some other drugs than the alpha1A-adrenoceptor subtype.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hiraoka</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Research and Development Division, Hokuriku Seiyaku, Katsuyama, Fukui, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohmura</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oshita</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watanabe</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morikawa</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagata</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taniguchi</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muramatsu</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharmacol</MedlineTA>
        <NlmUniqueID>1254354</NlmUniqueID>
        <ISSNLinking>0014-2999</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000097">Acetonitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058668">Adrenergic alpha-1 Receptor Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000317">Adrenergic alpha-Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004146">Dioxanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018340">Receptors, Adrenergic, alpha-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>10028-17-8</RegistryNumber>
          <NameOfSubstance UI="D014316">Tritium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>115787-31-0</RegistryNumber>
          <NameOfSubstance UI="C058562">HV 723</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1HLS600135</RegistryNumber>
          <NameOfSubstance UI="C057446">5-methylurapidil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8VLN5B44ZY</RegistryNumber>
          <NameOfSubstance UI="D010109">Oxymetazoline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E9H51OIT2B</RegistryNumber>
          <NameOfSubstance UI="C010654">(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G3P28OML5I</RegistryNumber>
          <NameOfSubstance UI="D000077409">Tamsulosin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>KC07KV8T5O</RegistryNumber>
          <NameOfSubstance UI="C053428">BMY 7378</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XM03YJ541D</RegistryNumber>
          <NameOfSubstance UI="D011224">Prazosin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000097" MajorTopicYN="N">Acetonitriles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058668" MajorTopicYN="N">Adrenergic alpha-1 Receptor Antagonists</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000316" MajorTopicYN="N">Adrenergic alpha-Agonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000317" MajorTopicYN="N">Adrenergic alpha-Antagonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004146" MajorTopicYN="N">Dioxanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010109" MajorTopicYN="N">Oxymetazoline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011224" MajorTopicYN="N">Prazosin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018340" MajorTopicYN="N">Receptors, Adrenergic, alpha-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077409" MajorTopicYN="N">Tamsulosin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10065634</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0165-2478</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>65</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology letters</Title>
          <ISOAbbreviation>Immunol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune effector mechanism in parasitic infections.</ArticleTitle>
        <Pagination>
          <MedlinePgn>101-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>In this article is a summary of our recent findings on the role of nitric oxide (NO) as an effector mechanism against the intracellular parasite, Leishmania major. NO is produced in large amounts in murine macrophages following activation by IFNgamma synthesized by Th1 cells. NO production is inhibited by IL-4, a product of Th2 cells. A set of stable cell surface markers has now been identified. ST2L and IL-18R are selectively expressed on Th2 and Th1 cells respectively. Antibody against ST2L can down-regulate Th2 cells in the highly susceptible BALB/c mice leading to control of otherwise fatal L. major infection. These results show directly the critical role of the balance between Th1 and Th2 cells in cutaneous leishmaniasis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liew</LastName>
            <ForeName>F Y</ForeName>
            <Initials>FY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, University of Glasgow, UK. fy11h@clinmed.gla.ac.uk</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>W L</ForeName>
            <Initials>WL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Immunol Lett</MedlineTA>
        <NlmUniqueID>7910006</NlmUniqueID>
        <ISSNLinking>0165-2478</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CitationSubset>X</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018320" MajorTopicYN="N">Leishmania major</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016773" MajorTopicYN="N">Leishmaniasis, Cutaneous</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>39</NumberOfReferences>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064392</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0309-0167</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>34</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cell density of adrenomedullin-immunoreactive cells in the gastric endocrine cells decreases in antral atrophic gastritis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>134-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Adrenomedullin (AM) is a novel hypotensive and vasorelaxing peptide recently isolated from human phaeochromocytoma tissue, and is widely distributed in various organs. In this study we examined the localization of AM-immunoreactive (IR) cells in the gastric mucosa and AM-IR cell density in antral atrophic gastritis.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Gastric mucosal tissues were taken from the gastric body and antral mucosa of 52 patients (27 men, 25 women; mean age 56.0 (range 20-86) years). Immunohistochemical analysis revealed that AM-IR cells were present in the pyloric glands, but not in the fundic glands, and that AM-IR cells were stained positively for chromogranin A and gastrin. The percentage of AM-IR cells vs chromogranin A- and gastrin-IR cells was 42 and 56%, respectively. The number of AM-IR cells decreased with the progression of severity of atrophic changes in the pyloric gland, and also of mononuclear cell infiltration. There was no correlation between the number of AM-IR cells and the degree of neutrophilic infiltration. Similar findings were also obtained for gastrin-IR cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AM-IR cells are present in the endocrine cells including gastrin-IR cells in the pyloric glands. These results suggest that AM may contribute to gastrin secretion in the pyloric glands.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kitani</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Internal Medicine, Kihara Kiyotake, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asada</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakata</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitamura</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sumiyoshi</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eto</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053379">Chromogranin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002864">Chromogranins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005755">Gastrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>148498-78-6</RegistryNumber>
          <NameOfSubstance UI="D053607">Adrenomedullin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D053607" MajorTopicYN="N">Adrenomedullin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053379" MajorTopicYN="N">Chromogranin A</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002864" MajorTopicYN="N">Chromogranins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019858" MajorTopicYN="N">Enteroendocrine Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005755" MajorTopicYN="N">Gastrins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005757" MajorTopicYN="N">Gastritis, Atrophic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064405</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0309-0167</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>34</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.</ArticleTitle>
        <Pagination>
          <MedlinePgn>184-6</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McCluggage</LastName>
            <ForeName>W G</ForeName>
            <Initials>WG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bharucha</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0F65R8P09N</RegistryNumber>
          <NameOfSubstance UI="D017273">Goserelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017273" MajorTopicYN="N">Goserelin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007889" MajorTopicYN="N">Leiomyoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014594" MajorTopicYN="N">Uterine Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10064621</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0892-6638</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
          <ISOAbbreviation>FASEB J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Activation of the adult mode of ovine growth hormone receptor gene expression by cortisol during late fetal development.</ArticleTitle>
        <Pagination>
          <MedlinePgn>545-52</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The developmental and tissue-specific regulation of growth hormone receptor (GHR) mRNA expression is complex and involves alternate leader exon usage. The transcript composition of hepatic GHR mRNA has therefore been determined in fetal sheep during late gestation and after experimental manipulation of fetal plasma cortisol levels by fetal adrenalectomy and exogenous cortisol infusion, using RNase protection assays and a riboprobe containing exons 1A, 2, and 3 of the ovine GHR gene. Expression of the adult liver-specific GHR mRNA transcript containing exon 1A was not detected earlier than 138 days of gestation (term 145 +/-2 days). Thereafter, expression of this leader exon increased and accounted for 25-30% of the total GHR mRNA in the fetal liver at term. Hepatic GHR mRNA derived from leader exons other than 1A was detectable at 97 days and increased in abundance toward term in parallel with the normal prepartum rise in fetal plasma cortisol. Abolition of this cortisol surge by fetal adrenalectomy prevented both the activation of exon 1A expression and the prepartum rise in GHR mRNA derived from the other leader exons in fetal ovine liver. Conversely, raising cortisol levels by exogenous infusion earlier in gestation prematurely activated exon 1A expression and enhanced the abundance of GHR mRNA transcripts derived from the other leader exons. Cortisol therefore appears to activate the adult mode of GHR gene expression in fetal ovine liver during late gestation. These observations have important implications for the maturation of the somatotrophic axis and for the onset of GH-dependent growth after birth.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, University of Cambridge, Cambridge CB2 3EG, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gilmour</LastName>
            <ForeName>R S</ForeName>
            <Initials>RS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saunders</LastName>
            <ForeName>J C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dauncey</LastName>
            <ForeName>M J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fowden</LastName>
            <ForeName>A L</ForeName>
            <Initials>AL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>FASEB J</MedlineTA>
        <NlmUniqueID>8804484</NlmUniqueID>
        <ISSNLinking>0892-6638</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011986">Receptors, Somatotropin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WI4X0X7BPJ</RegistryNumber>
          <NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000315" MajorTopicYN="N">Adrenalectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005314" MajorTopicYN="Y">Embryonic and Fetal Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018507" MajorTopicYN="Y">Gene Expression Regulation, Developmental</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011986" MajorTopicYN="N">Receptors, Somatotropin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012756" MajorTopicYN="N">Sheep</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="Y">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10063314</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1226-3303</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Korean journal of internal medicine</Title>
          <ISOAbbreviation>Korean J Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells.</ArticleTitle>
        <Pagination>
          <MedlinePgn>53-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">p16 is known to be an important tumor suppressor gene and is also called MTS1 (multiple tumor suppressive gene 1). Especially in the case of non-small cell lung cancer, it was not expressed in more than 70% of cell lines examined. To determine changes in cell-cycle related proteins and the tumorigenic effect, we, therefore, transfected p16INK4A gene into lung cancer cell lines.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We transfected p16INK4A gene into lung cancer cell lines which do not express p16 protein. We evaluated the effect by clonogenic assay and observed the changes of cell-cycle related proteins.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The newly-expressed p16 formed a complex with cdk4, and phosphorylated pRB was decreased, although cyclin D1 and pRB:cyclin D1 complex were unchanged. Clonogenic assay after selection with G418 showed that, in the cell lines transfected with p16, tumorigenicity was significantly less than in the control.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest that the p16INK4A gene can be a candidate for gene therapy in cases of NSCLC in which p16INK4A gene is inactivated.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>K Y</ForeName>
            <Initials>KY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, College of Medicine, Seoul National University, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoo</LastName>
            <ForeName>C G</ForeName>
            <Initials>CG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>S K</ForeName>
            <Initials>SK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shim</LastName>
            <ForeName>Y S</ForeName>
            <Initials>YS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Y W</ForeName>
            <Initials>YW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Korea (South)</Country>
        <MedlineTA>Korean J Intern Med</MedlineTA>
        <NlmUniqueID>8712418</NlmUniqueID>
        <ISSNLinking>1226-3303</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016213">Cyclins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016213" MajorTopicYN="N">Cyclins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019942" MajorTopicYN="Y">Genes, p16</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
</PubmedArticle>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">10063564</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0044-409X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>123 Suppl 5</Volume>
            <PubDate>
              <Year>1998</Year>
            </PubDate>
          </JournalIssue>
          <Title>Zentralblatt fur Chirurgie</Title>
          <ISOAbbreviation>Zentralbl Chir</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast].</ArticleTitle>
        <Pagination>
          <MedlinePgn>14-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>In addition to classical morphological prognosis factors of breast carcinoma (pTNM stage, tumor grading, histological typing), many other immunohistochemical markers of different prognostic value exist.--The comparative estrogen (ER) and progesterone receptor (PR) analysis of normal and pathological breast tissue showed a gradually inverse biological correlation between the decrease of ER+PR+ and the increase of ER-PR-frequency from benign breast changes to noninvasive and invasive breast carcinomas. In benign breast epithelium, ER+PR+ and ER-PR+ might be regarded as low-risk phenotype, whereas ER+PR- and ER-PR- could be estimated as high-risk phenotype in view of a later dedifferentiation and possible malignization.--During carcinogenesis, the initial loss of epithelial growth factor receptor (EGF-R) as well as its later neoexpression could be regarded as a progression maker.--The proliferation rate (Ki67) in breast cancer significantly correlates with increasing grading and apoptosis rate, whereas the expression of bcl-2-protooncogene is inverse to increasing grading. As for the prognostic value of the single factors, it is supposed that they mostly might represent "one piece of a larger puzzle" [13].</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nizze</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institut f√ºr Pathologie, Universit√§t Rostock.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>al-Thobhani</LastName>
            <ForeName>A K</ForeName>
            <Initials>AK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terpe</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>ger</Language>
        <PublicationTypeList>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Steroidhormonrezeptorstatus und andere immunhistochemische Prognosemarker bei gut- und b√∂sartigen Erkrankungen der Brustdr√ºse.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Zentralbl Chir</MedlineTA>
        <NlmUniqueID>0413645</NlmUniqueID>
        <ISSNLinking>0044-409X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009376" MajorTopicYN="N">Neoplasms, Hormone-Dependent</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011230" MajorTopicYN="N">Precancerous Conditions</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>46</NumberOfReferences>
    </MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
